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Abstract
Spatial models are a flexible tool for identifying spatial inequalities and demonstrating
spatial patterns or clusters within a given dataset. In epidemiological studies, spatial
analyses have been conducted on disease incidence and mortality to identify such
spatial variability. During recent decades, with increasing computational capability,
Bayesian statistical methodologies have been utilised in the epidemiology field. When
developed in the Bayesian framework, spatial models allow a description of local and
more global features of outcomes over space as well as accommodating data-specific
properties, such as sparseness of the data due to rare outcomes, potentially depen-
dent spatial patterns, noise from observations and heterogeneity in the underlying
population.
For the past decade, breast cancer has been one of the most common invasive cancers
among Australian women as well as one of the top leading causes of cancer death
among females in Australia. Breast cancer is usually diagnosed either by means
of screening, such as mammography, and/or symptoms. Mammographic screening
often detects breast cancers at an earlier stage and time than those detected symp-
tomatically. With earlier effective treatment, patients detected at screening can have
vii
improved long-term prognosis compared with those detected otherwise. In a climate
of continuing controversy about the value of mammographic screening for reducing
breast cancer mortality, there has been strong interest in assessing the efficacy of
screening programs to guide appropriate allocation of health care resources. This is
of particular interest for remote Australians whose access to screening programs and
treatment facilities may be limited by the barriers of distance and socio-economic
status.
This thesis aims to understand spatial effects on breast cancer outcomes associated
with screening, with a focus on women in Queensland, Australia. In order to meet
the overall aim, the thesis examines the spatial survival inequalities in health out-
comes among these women along with the influence of screening and presents the
spatial patterns across the state using thematic maps. In particular, various patient
demographic, clinical and geographic factors are considered. We also determine and
quantify spatial inequalities in the intended use of cancer treatment among women
with screen-diagnosed breast cancer. The associated treatments include radiotherapy,
chemotherapy and hormonal therapy. Finally, this thesis proposes and examines var-
ious hierarchical model structures in investigating spatially varying health outcomes.
To address the thesis aim and objectives, a large dataset is utilised with an unselected,
population-based cohort of Queensland females diagnosed with breast cancer, with
corresponding information about screening practices obtained from prospectively col-
lected administrative data. A Bayesian spatial model was adopted as the baseline
model to accommodate the sparse data in small population areas and provide bet-
ter quantification of parameter uncertainty. The model facilitates spatial smoothing
by borrowing information from neighbouring regions to adjust or smooth estimates.
This thesis also investigates and compares alternative model formulations as well as
different hierarchical structures to advance knowledge and understand the application
of Bayesian spatial hierarchical models in an epidemiological field.
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CHAPTER 1
Introduction
1.1 Background
Breast cancer is expected to be the most commonly diagnosed cancer in females and
was the second largest cause of cancer related deaths among females in Australia in
2014 (Australian Institute of Health and Welfare, 2014). Screening plays an important
role in reducing illness and death through early detection of cancer. While there
are standard reporting mechanisms for the key outcome measures of screening and
cancer outcomes, such as attendance, participation, patient and clinically detected
type and severity of cancer, time of detection, treatment, recurrence, and survival,
these data by themselves do not fully explain the associations between screening
and cancer outcomes. In particular, there is little current understanding about how
these associations between screening and cancer outcomes vary across geographical
locations and differ by socio-demographic subgroups. This is of particular interest for
2 Chapter 1. Introduction
socio-demographically disadvantaged Australians whose access to screening programs
and treatment facilities may be influenced by distance and socioeconomic status.
BreastScreen Queensland (BSQ) is an excellent example of a public health cancer
screening program that provides the only population-based publicly funded breast
cancer screening service in Queensland, Australia. BreastScreen Queensland is part of
the BreastScreen Australia Program which was established in 1991 by the Australian
Government and the State and Territory governments, with over 200,000 women
screened by BreastScreen Queensland during 2007, including 129,634 women within
the target age group of 50 to 69 years (Youlden et al, 2009). The BreastScreen
Australia participation rate among women aged 50−69 was between 52% and 57% in
the corresponding 2-year period of 1996−1997 to 2011−2012 in Australia (Australian
Institute of Health and Welfare, 2014).
In the past decade, various analyses of breast cancer data have been performed to
examine the influence of relevant characteristics on health outcomes (see Chapter
2). In particular, some studies have focused on the influence of various patient fac-
tors for female breast cancer incidence and survival outcomes. These patient factors
include demographic, clinical and geographic characteristics. While some of these
factors have a similar influence on health outcomes across the globe, there are also
complex associations between geographic factors and cancer outcomes. A subset of
studies has investigated the association between breast cancer outcomes, geographic
characteristics and/or mammography screening programs for eligible women. A re-
view of these studies, present in Chapter 2, showed that socioeconomic inequalities
in incidence and survival for breast cancer were generally present in symptomatic
or non-screen detected patients. However, there were contradictory findings for the
presence of survival difference by socioeconomic status within screen-detected breast
cancer patients. Since differences in socioeconomic status can be found between ur-
ban, regional and remote populations in many countries, these suggest socioeconomic
status is one plausible mechanism for geographic disparities to arise in breast cancer
incidence and survival.
1.2. Research Aim 3
These previous breast cancer studies have consistently shown a geographic influence
on cancer outcomes in different study regions. Therefore, it is useful and necessary
to analyse and verify the effect of socioeconomic status and geographic remoteness
on breast cancer outcomes for different regions of Australia. In addition, various
detection methods (i.e. screen-detected, interval-detected and symptomatic or non-
screen detected) for breast cancer have also been identified as an important prognostic
factor which can provide useful information beyond stage shift, but can still be subject
to changes in geographic location. An interval-detected breast cancer, sometimes
called interval breast cancer, is any invasive breast cancer diagnosed in the 12 or 24
months (depending on the screening program) interval following a negative screening
episode and before the next scheduled screening examination. This raises the need to
include both geographic characteristics and detection methods in a population-based
breast cancer study for Queensland, Australia, which has not been done before.
Another important factor that might influence the survival of breast cancer patients is
the type of treatment. Various adjuvant therapy studies have assessed patient utiliza-
tion after a diagnosis with breast cancer and found that the use of various treatments
may be influenced by a range of factors. These studies reveal that inequalities in
the use and receipt of various types of adjuvant therapies among breast cancer pa-
tients have been observed across the world. Besides the difference between various
breast cancer treatment guidelines (Zagouri et al, 2015), these studies have identified
that geographic characteristics may be an influential factor for breast cancer patients
receiving different types of adjuvant therapies. Very little is understood about the
utilization inequalities of adjuvant therapy for breast cancer patients in Queensland,
Australia and whether there are other common underlying factors that influence their
choice of adjuvant therapy.
1.2 Research Aim
Overall, this project aims to understand spatial effects on breast cancer outcomes
associated with screening, with a focus on women in Queensland, Australia.
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In order to meet the overall aim, the following objectives are investigated.
1. To evaluate health outcomes associated with demographic and geographical
factors among women with breast cancer in Queensland, Australia.
2. To examine the spatial inequalities among these women.
3. To investigate the influence of different detection methods among these women.
4. To determine and quantify spatial inequalities in intended cancer treatment
among these women.
5. To propose and examine various hierarchical model structures in investigating
spatially varying health outcomes for these women.
Bayesian hierarchical models are adopted for this project as they allow a description
of local (small-area) and more global features of outcomes over space as well as ac-
commodating data-specific properties that are more difficult to handle using more
traditional modelling approaches.
Through collaboration with Cancer Council Queensland (CCQ) this project utilises
the link between the BreastScreen Queensland Registry data, which has over a mil-
lion screening episodes that have not been analysed in detail before, and data from the
Queensland Cancer Registry (QCR), combined with other population-based databases.
This dataset is a large, unselected, population-based cohort of Queensland females di-
agnosed with breast cancer, with corresponding information about screening practices
obtained from prospectively collected administrative data, the collection of which was
designed independently of the study, thus removing information bias. Less than 1%
of data was excluded due to missing information about patients, including age at
diagnosis, geographic location, and those who were identified at autopsy or by death
certificate only, or who had a survival time of less than one day. The combined
dataset was linked by BSQ staff using a deterministic matching process with over
90% matching completeness.
1.3. Research Plan 5
The analysis of the combined dataset provides a unique opportunity to identify and
describe spatial cancer outcomes in women screened for breast cancer. This comple-
ments and extends the usual routine monitoring and surveillance activities, and takes
us closer to understanding why such associations, if any, exist.
This research will help to advance public health knowledge to understand the complex
associations between socioeconomic status, geographic locations and cancer outcomes
associated with screening, and it is hoped that this in turn will lead to more effective
and efficient interventions.
This thesis contributes to the applied field of statistical analysis in the epidemiology
field by applying several previously developed Bayesian spatial models to analyse
breast cancer data in Queensland, Australia.
1.3 Research Plan
To fulfill the objectives in Section 1.2, four research activities have been undertaken.
1. Investigation of the impact of spatial location on the effectiveness of population-
based breast screening in reducing breast cancer mortality compared to other
detection methods among Queensland women. This addresses Objectives 1, 2
and 3.
2. Examination of differences in survival between screen- and interval-detected
breast cancer patients who participated in a public population-based breast
screening program in Queensland, Australia. This addresses Objectives 1, 2
and 3.
3. Determination and quantification of spatial inequalities in intended adjuvant
(radio-, chemo- and hormonal) therapy usage among women with screen-detected
breast cancer in Queensland, Australia. This addresses Objectives 2 and 4.
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4. Analysis of various spatial hierarchical models to examine spatially varying
covariate effects and identify any unobserved spatial subgroups within a relative
survival study. This addresses Objectives 2 and 5.
1.4 Thesis Structure
This document have been presented as chapters of the thesis, following an overall
literature review in Chapter 2. Details of the journals in which the papers have
appeared or the manuscripts have been submitted, and the contributions of the co-
authors, are given in the preface to each chapter.
• Chapter 3 presents the paper with the title “Bayesian Spatial Analysis for the
Evaluation of Breast Cancer Detection Methods”, and corresponds to Activity
1.
• Chapter 4 presents the paper with the title “Does Geographic Location Impact
the Survival Differential Between Screen- and Interval-Detected Breast Can-
cers?”. This corresponds to Activity 2.
• Chapter 5 presents the paper with the title “Geographic Variation in the In-
tended Choice of Adjuvant Treatments for Women Diagnosed with Screen-
Detected Breast Cancer in Queensland”. This corresponds to Activity 3.
• Chapter 6 presents the paper with the title “Evaluation of Spatially Varying
Coefficient Inequalities for Breast Cancer Patient Characteristics”. This corre-
sponds to Activity 4.
Note that because of the structure of a thesis by publication, these chapters have
preserved the format and content of the journal articles with the exception that the
references have been gathered into a single bibliography that appears at the end of
the thesis. Thus there is some inevitable overlap in the chapters, particularly with
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respect to review of relevant literature, description of the data sources and model,
and some discussion about implications of the analyses.
The contributions of each publication can be addressed by considering two aspects,
application and method. Chapters 3, 4 and 5 contribute to application by applying
Bayesian spatial models to a large breast cancer dataset which will advance public
health knowledge about breast cancer, and will lead to more effective and efficient in-
terventions. Chapters 5 and 6 contribute to methods by investigating various Bayesian
spatial model formulations and alternatives which will extend statistical knowledge
in the epidemiological field.
The thesis concludes with a discussion that summarises the research results, critically
evaluates the contributions of the project, and identifies potential future research.

CHAPTER 2
Literature Review
This chapter reviews the literature for the relevant breast cancer studies, Bayesian
framework and various models that have been developed and applied to epidemio-
logical studies and spatial analyses. The chapter first reviews various breast cancer
related studies that motivated this project. This is followed by describing how the
Bayesian hierarchical model was constructed as well as the computational procedures
through Markov chain Monte Carlo algorithms. Later in the chapter we introduce
a number of models that will be used in this project. We introduce a model that is
commonly used in the epidemiology field to perform a survival analysis. The rest of
the chapter focuses on describing problems that will be faced when conducting spatial
analyses and reviewing the various spatial models used in this research.
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2.1 Analysis of Breast Cancer
For more than a decade there has been an international and national focus on ex-
amining factors that influence, or at least are associated with, female breast cancer
incidence and survival. While some of these factors have a similar influence on health
outcomes across the globe, there are also complex associations between cancer out-
comes and geographically related factors. In Australia, for example, there is mixed
reporting about the interplay between spatial factors and cancer. For instance, two
separate studies have found a similar relationship between spatial effects and cancer.
The report by Draper et al (2004) assessed the nature and magnitude of mortality
inequalities (i.e. life expectancy, age-standardised mortality rates, excess mortality
and etc.) among Australians of all age using data from 1998− 2000, which included
387,506 all-cause death records as provided by the Australian Bureau of Statistics.
The second study by Bentley et al (2008) used multilevel analysis to examine the re-
lationship between area and individual socioeconomic characteristics and premature
cancer mortality among 25− 64 year old men and women (n = 16, 340) between 1998
and 2000 in Australia. These two studies, with differing methodology, observed sig-
nificantly higher mortality rates in socioeconomically disadvantaged areas compared
with the most advantaged areas and also geographically remote locations compared
with those more accessible areas in Australia for all cancers overall and lung cancer,
but not for breast cancer. In contrast, Cramb et al (2011a,b) assessed potential geo-
graphical inequalities in cancer incidence and survival across Queensland, Australia
between 1998 to 2007 for a total of 187,523 diagnosed invasive cancer cases. The study
found that compared to the Queensland average, women living in more disadvantaged
or rural areas had a lower rate of diagnosis of breast cancer (4 − 6% and 10 − 15%,
respectively) but higher mortality within five years of diagnosis in more disadvan-
taged or rural areas (5% and 12 − 14%, respectively) from this disease. In a later
study, based on a Bayesian spatial model similar to the one adopted in this thesis,
Cramb et al (2012) examined 25,202 females diagnosed with breast cancer in Queens-
land during 1996 to 2007, and found that stage and area disadvantage explained a
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substantial proportion of spatial inequalities in cancer survival. Similarly, Yu et al
(2008) used a multivariable model to assess the impact of socioeconomic status on
relative survival for 13 major cancers in the state of New South Wales, Australia
between 1996 to 2001. There was a total of 150,567 diagnosed cancer cases among
those aged 15− 89 years, which included 28,751 breast cancer cases. These patients
were found to have significantly worse survival in lower socioeconomic status areas
compared with higher socioeconomic status areas (p ≤ 0.0001). It was suggested by
the authors that this may be due to poorer access to high-quality cancer care, which
is a problem widely experienced by rural and remote women in Australia.
Other studies have reported different findings on the influence of geographic and socio-
economic characteristics on breast cancer incidence and mortality. McLafferty et al
(2011) aimed to understand rural-urban inequalities in diagnosing late-stage breast
cancer and the impact of socioeconomic deprivation and access to health care during
1988 − 1992 (37,392 cases) and 1998 − 2002 (44,070 cases) in the state of Illinois,
United States. The results of multilevel logistic models indicated that rural-urban
inequalities were associated with demographic, social and spatial characteristics for
the overall population, while African-American patients had a distinct risk gradient
with 50% higher risks for those lived in rural areas compared to urban regions in
1988-1992 and 20% higher risks in 1998 − 2002 among patients living outside the
city of Chicago. A similar modelling approach was used by Dasgupta et al (2012) to
examine 18,568 breast cancer patients aged 30− 70 years between 1997 and 2006 in
Queensland, Australia. The study determined that geographic remoteness was not
related to lower breast cancer survival, and found that the survival of women with
breast cancer depended on the socio-economic characteristics. Women who resided
in one of the more disadvantaged quintiles (i.e. quintile 4,3,2 or 1) had significantly
worse survival (odds ratios: 1.23, 1.27, 1.30 and 1.37, respectively) compared to those
living in the least disadvantaged quintile. An Australian study that used proportional
hazards regression to compare survival for five different cancers by geographical re-
moteness for 107,060 cancer cases diagnosed between 2000− 2008 in the state of New
South Wales (Chen et al, 2015) found significantly worse breast cancer survival in
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outer regional residents with the likelihood of death of 1.22 (95% confidence interval:
1.001 − 1.48) in regionalised disease and 1.30 (95% confidence interval: 1.02 − 1.64)
in metastatic disease, compared with those residing in major cities. Another recent
population-based breast cancer study also found a similar pattern of inequality using
a Poisson regression model to calculate the relative excess risk of death for 63,757
women diagnosed between 1987 and 2007 in New South Wales, Australia. Yu et al
(2015) reported increasing relative survival over the second decade but a statistically
significant higher relative excess risk of death from 1.21 (95% confidence interval:
1.01− 1.44) to 1.31 (95% confidence interval: 1.11− 1.55) for breast cancer mortality
for residents in rural areas compared to major cities.
2.1.1 Analysis of Detection Method
A number of studies have investigated the association between breast cancer out-
comes, geographic characteristics and/or mammographic screening programs for eli-
gible women. Earlier studies found an apparent survival benefit beyond a stage shift
for screen-detected breast cancer patients compared with those detected otherwise,
even after adjusting for known tumour characteristics, using a Cox proportional haz-
ards model (Shen et al, 2005). Screening detection is subject to length and lead-time
biases, which lead to stage shift in cancer diagnosis. Stage shift is the phenomena
that a tumour detected by screening had a shift in tumour stage to earlier stages as it
would have been detected in the absence of screening. Length bias is when screening
detects disproportionately more slowly growing tumours, and lead-time bias is the
difference in time of tumour detection between mammography and in the absence of
screening. Mook et al (2011) also applied the Cox proportional hazards model and
showed that screen detection improved prognosis beyond a stage shift and was inde-
pendently associated with better overall and breast cancer-specific survival. In 2012,
McKenzie et al (2012) performed a population-based study in South West England
(2002 − 2007) to assess potential socioeconomic inequalities in survival from screen-
detected and symptomatic breast cancer by examining the relative survival ratio.
2.1. Analysis of Breast Cancer 13
Socioeconomic inequalities in survival were attenuated in screen-detected breast can-
cer compared to other groups, but the inequalities were still apparent. Davies et al
(2013) investigated the relationship between socioeconomic deprivation and incidence
and 5-year relative survival of screen-detected and non screen-detected breast can-
cer in London women aged 50 − 64 from 1998 to 2008 that were extracted from the
Thames Cancer Registry. The logistic regression analysis revealed that the incidence
of screen-detected breast cancer was lower in socioeconomically deprived women who
also had worse 5-year relative survival than aﬄuent women. In addition, the odds
ratios for screen-detected cancer differed between ethnic group, even after adjusting
for age and deprivation. An Ireland study (Walsh et al, 2014) using Cox regression
models showed that socioeconomic deprivation was a major predictor of breast cancer
mortality for patients diagnosed between 1999-2008 and did not diminish over time,
compared with the period 1994-1998. The study also found that a range of patient,
tumour, screening status and treatment factors varied by deprivation status. A re-
cent New Zealand study (Seneviratne et al, 2015) employed Cox proportional hazard
models and found significant survival differences in non-screen detected breast can-
cer patients by race and socioeconomic status, but the survival differences were not
present among patients diagnosed through screening.
In summary, various studies have demonstrated that socioeconomic inequalities of
incidence and survival for breast cancer are generally present in symptomatic or non-
screen detected patients. However, there were contradictory findings for the presence
of survival differences by socioeconomic status within screen-detected breast cancer
patients.
2.1.2 Analysis of Treatment Choices
Various adjuvant therapy studies have assessed patient utilization after diagnosis with
breast cancer and found that the usage of various treatments may be influenced by
other factors. In 2012, Martinez et al (2012a,b) conducted two studies to examine
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disparities in radiation therapy utilization by breast cancer patients across geographic
regions using the Surveillance, Epidemiology, and End Results (SEER) database for
Sacramento city in California, United States, between 2000 and 2006. The first
study (Martinez et al, 2012a) examined rural-urban disparities in the use of post-
lumpectomy radiation therapy by breast cancer patients, using multivariate logistic
regression analysis, and found that patients from near-metro and rural areas were less
likely to receive post-lumpectomy radiation therapy for breast cancer than those who
resided in urban areas. The second study (Martinez et al, 2012b) investigated urban
and non-urban disparities in the use of post-mastectomy radiation therapy for breast
cancer patients, using multivariate logistic regression and Cox proportional hazards
models, and found that non-urban residents with local-regionally advanced breast
cancer (i.e. tumours ≥ 5cm, skin or chest wall invasion and ≥ 4 axillary node metas-
tases) were less likely to receive post-mastectomy radiation therapy. However, the
association between a particular factor (geographic remoteness) and a therapy (radi-
ation) may not have the same relationship to other types of treatment. For instance,
Olson et al (2012) also carried out a population-based analysis using logistic regres-
sion modelling to investigate the utilization difference in breast cancer screening and
treatment across different geographic remoteness regions for all patients diagnosed
during 2002 in British Columbia. The study found that rural communities, compared
to urban patients, were less likely to attend mammography screening and undergo
breast-conserving surgery, but there was no significant difference in use of chemother-
apy or hormonal therapy. In addition, the treatment usage may also be different by
study regions, race and other factors. Bhargava and Du (2009) used multivariate
logistic regression to examine racial and socioeconomic disparities in receiving adju-
vant chemotherapy for women aged ≥ 65 years from 16 areas of Georgia, Atlanta and
California, United States, between 1991 and 2002. The results show racial disparities
in receiving adjuvant chemotherapy for women ages 65 years to 69 years but the in-
clusion of socioeconomic status mediated the association between chemotherapy and
race in this age group.
The implications of such disparities are also a matter of debate in the literature. For
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example, a recent review has indicated that low use of adjuvant endocrine therapy
among low-income breast cancer patients is a potentially important and modifiable
risk factor for poor outcomes (Ursem et al, 2015). However, a systematic review
published this year (2015) shows that there is conflicting evidence concerning the
cost-effectiveness of chemotherapy, hormone therapy and targeted therapy for breast
cancer (Diaby et al, 2015). Some of the barriers and enablers of medication-taking
behaviour of adjuvant hormonal therapy for women with stage I-III breast cancers
have been identified (Cahir et al, 2015), including beliefs about consequences (e.g.
recurrence and non-necessity), intentions and goals (e.g. high-priority and quality of
life) and behaviour regulation (e.g. managing medication and no routine). However,
these are not exhaustive.
It has been suggested that residents of socioeconomically disadvantaged areas are
more likely to be exposed to lower stocks of social capital, fewer health and com-
munity services, and poorer physical infrastructure, and that these features of the
environment might directly affect individual health status (Turrell et al, 2007b).
2.2 Bayesian Hierarchical Modelling
As indicated in the previous section, a variety of methods have been used to investi-
gate the relationship between the socioeconomic characteristics of area/geographical
environment, individual-level demographics and health related issues such as cancer
incidence and mortality.
Until the mid-1990s, researchers examined socioeconomic disadvantage area effects on
individual health primarily based on ecological studies. Ecological studies have found
higher mortality and poorer health in disadvantaged areas (Turrell et al, 2007a,b).
However ecological studies have some limitations as they typically compare the health
profile of socioeconomically advantaged and disadvantaged areas using data aggre-
gated to a single geographical scale and hence are not able to provide a quantification
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of the variation between areas, and more importantly, indicate whether the variation
is probably due to a composition effect (i.e. the clustering of socioeconomic character-
istics) or a context effect (i.e. the environmental characteristics of the areas) (Jackson
et al, 2008; Turrell et al, 2007a,b). Ecological studies leave open the possibility that
socioeconomic area or geographical variations in health are simply an artifact of vary-
ing population compositions (e.g. greater concentrations of poor people in poor areas),
which cause confounding of individual-level and area-level sources of variation that
cannot be taken into account by the aggregated (ecological) studies (Turrell et al,
2007a,b).
From about the mid-1990s, researchers have increasingly used multilevel models to
examine the relationship between socioeconomic area effects and health issues. Un-
like the ecological approaches, multilevel analysis allows the partitioning of area and
individual sources of variation (i.e. between contextual and composition effects) to
better and more accurately estimate the geographical variation in health (Turrell
et al, 2007b). Multilevel research conducted to date after taking account of the so-
cioeconomic characteristics of individuals residing in the area has shown that living
in a socioeconomically disadvantaged area is associated with:
• higher mortality and poorer self-rated health which may be due to varying access
to screening, diagnostic tests, services, and less general practitioner services in
disadvantaged areas of Australia, which may result in delayed diagnoses and
treatment (Bentley et al, 2008; Turrell et al, 2007b), and
• lower levels of physical activity, poorer diet, higher alcohol consumption, higher
smoking prevalence and higher body mass which may be due to a lifestyle that is
socially and geographically patterned (Bentley et al, 2008; Turrell et al, 2007b).
When it comes to disease mapping, it is necessary to perform a multilevel or hier-
archical analysis of a disease incidence or mortality dataset (i.e. breast cancer) with
the inclusion of variation due to space in order to accurately map outcomes and to
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study the spatial structure of the disease (Banerjee et al, 2003, 2004; Bernardinelli
et al, 1995; Best et al, 2005; Knorr-Held, 2000; Mather et al, 2004). However, when
analysing discrete outcomes, a number of properties of the data must be accounted
for, such as sparseness of the data, potentially dependent spatial patterns, noise from
observations, heterogeneity in the underlying population counts and so on (Bernar-
dinelli et al, 1995; MacNab and Dean, 2002; Richardson et al, 2006; Schmid and Held,
2004).
To overcome these issues, Bayesian hierarchical models are used to study the associ-
ation between cancer outcomes and screening by incorporating spatial features and
accommodating data-specific features such as sparse numbers due to rare outcomes,
missing values, known biases and misclassification and measurement error. Through
hierarchical constructions of both the likelihood and priors of these models, they can
capture features such as univariate and multivariate outcomes, population migration
and accumulation of risk, as well as the complex constellation of demographic, social,
economic, cultural and environmental factors associated with cancer incidence and
survival (Ghosh et al, 1999; Hegarty et al, 2010; Lawson et al, 2000; Lawson, 2001;
MacNab, 2004; MacNab and Dean, 2002; Militino et al, 2001; Osnes and Aalen, 1999;
Richardson et al, 2006; Saez et al, 2012; Waller et al, 1997; Wu et al, 2010).
A Bayesian model consists of three main components, the posterior, likelihood and
prior. Each of these components is a probability distribution, with the posterior being
the normalised product of the likelihood and prior distributions.
The Bayesian analysis process can be divided into three steps:
1. Setting up a joint probability distribution for all observable and unobservable
quantities in a problem.
2. Calculating and interpreting the appropriate posterior distribution using com-
putational methodology such as Markov Chain Monte Carlo (MCMC) algo-
rithms.
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3. Evaluating the fit of the model and making inferences based on the simulated
results from the posterior distribution. If necessary, the three steps are repeated
with a modified/updated model.
Suppose θ is some unknown quantity, i.e. a parameter of interest or unobserved data.
Bayesian statistical conclusions about θ are made in terms of probability statements
that are conditional on the observed value y and, in some cases, also implicitly con-
ditioned on the known values of other quantities. Ignoring the latter, this probability
statement is written as p(θ|y) and is termed the posterior distribution, or simply the
posterior.
The joint distribution between θ and y can be written as a product of two distribu-
tions, the prior distribution p(θ) and likelihood function p(y|θ), and can be expressed
as
p(θ, y) = p(θ)p(y|θ). (2.1)
Using Bayes’ rule, p(A|B) = p(B|A)p(A)
p(B)
, and Equation 2.1, the posterior distribution
is:
p(θ|y) =
p(θ, y)
p(y)
=
p(θ)p(y|θ)
p(y)
(2.2)
where p(y) =
∫
p(θ)p(y|θ)dθ for continuous θ or p(y) =
∑
θ p(θ)p(y|θ) for discrete θ.
As p(y) does not depend on θ and, with fixed y, can be considered as a constant, we
can write:
p(θ|y) ∝ p(y|θ)p(θ). (2.3)
Hence, the posterior p(θ|y) is proportional to the product of the likelihood p(y|θ) and
the prior p(θ), up to a multiplicative constant.
The assumptions and distributions in a Bayesian model should be consistent with
knowledge about the underlying scientific problem and the data collection process
(Gelman et al, 2004).
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The prior is the important component that separates Bayesian statistical modeling
from classical statistical modeling based on maximum likelihood. Prior distributions
are determined based on one’s prior belief of the problem and data as well as scientific
judgment concerning the form and behavior of the parameters of interest. These
prior beliefs may be based on data, previous trials or other studies, literature, expert
judgement and so on. There are many types of priors and many ways of categorising
them. Here we distinguish between the generically termed informative and non-
informative priors.
Informative priors can be objective or subjective and may have stronger influence
on posterior inference than non-informative priors reflect a lack of prior knowledge
about θ. Non-informative priors are used when little knowledge about the unknown
parameters of interest is available or when one would like the data to “speak for
themselves”. A non-informative prior is also often described as flat, diffuse or vague
(Thorlund et al, 2013).
Another category of prior is a “conjugate prior” which has mathematical convenience
as the posterior will have the same distribution as the prior (Arashi et al, 2014). For
example a Beta distribution is a conjugate prior for the binomial likelihood and hence
the product of this prior and likelihood gives a Beta posterior distribution.
The parameters in the prior distribution are often called “hyperparameters”. These
hyperparameters can also be assigned a distribution, termed the hyperprior distribu-
tion, or can have fixed values.
The likelihood function or distribution is determined based on the type and struc-
ture of the data set. For example, cancer counts are usually modeled by a Poisson
distribution.
The posterior distribution summarises the total knowledge about the unknown pa-
rameters of interest given the observed data combined with prior belief and assump-
tions about the parameters. The posterior distribution may be sensitive to the prior
distribution and hence a sensitivity analysis is usually required by using different
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hyperparamenter settings and different prior distributions. The term ‘hierarchical’
in statistical modelling describes a model written in multiple levels or hierarchical
form to estimate model parameters when information is available on different lev-
els of observational units (Gelman et al, 2004). A hierarchical model is one that
is formed by combining sub-models. Bayesian hierarchical models have at least 2
stages, where the first stage contains the likelihood and the prior distribution for the
data variables, and the second stage is often the hyperparameters with hyperprior
distributions. The hierarchical model is often used to fit hierarchical data that could
be spatially structured. The term spatial refers to locations in space that can be
referenced by coordinates (i.e. latitude and longitude).
2.2.1 Bayesian Computation
There are two general approaches to Bayesian estimation, empirical Bayes (EB) and
full Bayes (FB). EB methods typically use a point estimate, rather than a distribution,
for the hyperparameter, for instance by using the maximum likelihood estimator, and
hence approximate the posterior distribution of the FB analysis (Efron, 2013). Thus,
EB is often computationally convenient, but has the weakness of underestimating the
uncertainty in the outcome. In contrast, FB methods treat the hyperparameters as
unknown and assign distributions to them (Aguero-Valverde, 2013). This is believed
to allow the full Bayesian analysis to better account for uncertainty in the data than
empirical Bayes (Bernardinelli and Montomoli, 1992; Persaud et al, 2010). Often the
hyperprior distribution is given a non-informative but proper prior: non-informative
because this hyperprior distribution would not greatly affect the posterior distribu-
tion, and proper so that the posterior is proper. Bernardinelli and Montomoli (1992)
compared EB and FB methods for disease mapping using breast cancer and Hodgkin’s
disease mortality data. In general, the Bayesian approach allows a very fine geograph-
ical scale analysis by smoothing those portions of the map where the information is
unreliable while preserving statistically substantive patterns. The comparison pre-
ferred the FB model as it is more powerful with the degree of estimated precision
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limited only by the allocated computing time. Moreover, the uncertainty embodied
in the estimates of the full posterior distributions enables a variety of hypothesis tests
by calculating appropriate statistics. The use of the Gibbs sampler also allows co-
variates and their respective coefficients to be represented as additional nodes in the
graphical model. Thus, FB with the Gibbs sampling approach is preferable to EB,
by offering greater flexibility and more comprehensive estimation of uncertainty in
statistical analysis of geographical variation in disease risk.
Markov chain Monte Carlo (MCMC) methods are a set of algorithms which gener-
ally exploit modern computer capability to perform iterative simulation of parameter
values within a Markov chain. Bayesian analysis commonly utilizes MCMC algo-
rithms that generate samples from the posterior distribution (Banerjee et al, 2015;
Damien et al, 2013; Gelman et al, 2004; Robert and Casella, 2004, 2010, 2013). Con-
vergence assessment is required for the posterior distribution to verify that the sta-
tionary/invariant distribution has been obtained. Two MCMC algorithms that are
commonly used for Bayesian modeling are the Gibbs sampler and Metropolis-Hastings
sampler (Banerjee et al, 2015; Damien et al, 2013; Gelman et al, 2004; Geman et al,
1984; Hastings, 1970; Robert and Casella, 2010, 2013; Smith and Roberts, 1993).
Other MCMC algorithms include adaptive rejection sampling, reversible jump, slice
sampling, perfect sampling and particle filters. These are reviewed by Gelman et al
(2004) and Robert and Casella (2004, 2010, 2013). The convergence of the simula-
tion can be evaluated through several methods including visual assessment of multiple
chains or convergence statistics such as Gelman-Rubin statistics (Banerjee et al, 2015;
Gelman and Rubin, 1992; Robert and Casella, 2010).
The Gibbs sampler, also called alternating conditional sampling, is among the sim-
plest of the Markov chain simulation algorithms and is usually the first choice for con-
ditionally conjugate models (Banerjee et al, 2015; Damien et al, 2013; Gelman et al,
2004; Robert and Casella, 2010, 2013). The Gibbs sampler generates a sequence of
samples for the elements in the parameter vector θ from the derived conditional pos-
terior distribution p(θ|y) of each element of θ, where y represents the data. Suppose
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the parameter vector θ has d elements, then each iteration of the Gibbs sampler cycles
through these d elements to draw samples from their corresponding full conditional,
conditional on the value of all the others. At iteration t, each θ
(t)
j is sampled from the
full conditional distribution given all other components of θ and the observed data y:
p(θ
(t)
j |θ
(t−1)
−j , y).
Where θ
(t−1)
−j represent all the elements of parameter vector θ, except for θ
(t)
j , at their
current values:
θ
(t−1)
−j = (θ
(t)
1 , . . . , θ
(t)
j−1, θ
(t−1)
j+1 , . . . , θ
(t−1)
d ).
The Metropolis-Hastings algorithm is a generalization of the Metropolis algorithm
(Metropolis et al, 1953) and can be used for models with difficult-to-sample-from full
conditionals (Banerjee et al, 2015; Gelman et al, 2004; Robert and Casella, 2010,
2013). The Gibbs sampler is a special case of a Metropolis-Hastings algorithm (Chib
and Greenberg, 1995). The Metropolis-Hastings algorithm is an adaptation of a
random walk process that uses an acceptance/rejection rule to generate a sequence
of samples that converge to the stationary distribution.
To simulate the conditional posterior density p(θ|y), the Metropolis-Hastings algo-
rithm proceeds as follows (Banerjee et al, 2015; Chib and Greenberg, 1995; Gelman
et al, 2004; Robert and Casella, 2010, 2013):
1. Select initial values, θ0, for all components of vector θ.
2. For iteration t = 1, 2, . . . , generate a sample for each component in the vector
θ for each iteration as follows:
(a) select a proposal density, q(θ∗|θ(t−1)), which simulates a proposed value θ∗
at iteration t.
i. For the Metropolis algorithm a symmetric density is required so that
q(θ∗|θ(t−1)) = q(θ(t−1)|θ∗).
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ii. The Hastings algorithm allows for asymmetric densities.
(b) Generate random value u from a uniform distribution between 0 and 1,
U(0, 1).
(c) Compute the ratio r:
i. For symmetric proposal density, r = min
(
p(θ∗)p(y|θ∗)
p(θ(t−1))p(y|θ(t−1))
, 1
)
.
ii. For asymmetric proposal density, r = min
(
p(θ∗)p(y|θ∗)q(θ(t−1)|θ∗)
p(θ(t−1))p(y|θ(t−1))q(θ∗|θ(t−1))
, 1
)
.
(d) Test u ≤ r:
• If true, then set θ(t) = θ∗, number of accepted values of θ is increased
by 1;
• Else, set θ(t) = θ(t−1).
If θ(t) = θ(t−1), that is, the update is not accepted, this still counts as an iteration in
the simulation.
The number of accepted values for θ in step 2d can be used to calculate the acceptance
rate by dividing the total number of accepted values by the total number of iterations
for each component of θ.
The recommended acceptance rate for a Metropolis algorithm, with random walk
normal proposal density, is 45% for one or two parameters to 23% as the number
of parameters approaches infinity (Chib and Greenberg, 1995). The acceptance rate
can be calibrated during the burn-in period by tuning the variance parameter of the
proposal distribution. A very small variance will result in a high acceptance rate,
while a very large variance will have a very low acceptance rate.
For the Metropolis-Hastings algorithm, it is desirable to have a high acceptance rate
when the proposal density approximates the posterior density or the tails of the
proposal density dominate those of the posterior density and a low acceptance rate
(40-70% acceptance, or less for higher dimensions) is preferable if a random walk is
adopted.
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The convergence of an MCMC simulation can be evaluated by the visual assessment
of multiple chains, including trace plots, density plots and autocorrelation plots. An-
other assessment method is the convergence statistics such as the general approach
proposed by Gelman and Rubin (1992). The Gelman and Rubin (1992) convergence
statistic monitors many long chain runs that start at different initial values for θ and
assesses the chains via an “analysis of variance” between and within the chains, when
the chains have ‘forgotten’ their initial values with indistinguishable output from all
chains. This convergence test is readily available in R v2.14.1 and above (R Develop-
ment Core Team, 2011) statistical software by using the function ‘gelman.diag’ under
the ‘coda’ package.
Posterior predictive checks (PPC) (Gelman et al, 2004) compare observed data with
data replicated under the model and the model is adequately fitted to the data if
around 95% of the observed data are within the 95% credible interval of the posterior
predictive distribution. PPC is not a statistic in its own right. It is a general approach
to look for systematic discrepancies between simulated data and the real data (Gelman
et al, 2004). The method simulates new outcomes from the fitted model and compares
them with the observed data. However, it has been criticised that the method can
lead to optimistic conclusions about the performance of a model as the data used to
validate the model are the same as those used to fit the model (Vehtari and Ojanen,
2012).
Model comparison methods include Bayes factors, Deviance Information Criterion
(DIC), reversible jump MCMC and model averaging (Banerjee et al, 2015; Gelman
et al, 2004). The Bayes factor is sometimes used for model comparison by calculating
the ratio of the marginal probability density under one model to the marginal density
under another model to show which model describes the data well. The Bayes factor
is only defined when the marginal likelihood under each model is proper and works
well when the underlying model is truly discrete (i.e., the data are not inherently
continuous). The DIC differs from the Bayes factor both in form and aims with the
equation as
DIC = D(y|θ) + pD = D(y|θ¯) + 2pD,
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where D(y|θ) is the posterior mean of the deviance defined as −2× log(p(y|θ)), and
D(y|θ¯) = −2 × log(p(y|θ¯)) is the point estimate of the deviance by substituting in
the posterior means θ¯ of θ, and pD is the effective number of parameters given by
pD = D(y|θ)−D(y|θ¯). The deviance is the difference between the fitted values and the
data. The effective number of parameters represents a penalty for model complexity.
The DIC is calculated in WinBUGS v1.4.3 (Lunn et al, 2000). When comparing
models, the one with smaller DIC value indicating a better-fitting model (Banerjee
et al, 2015; Gelman et al, 2004).
The discussion in this section has focused on MCMC and related diagnostics since
this is the approach that is used in this thesis and since it was the dominant com-
putational method at the commencement of this research project. However, it is
acknowledged that there is a growing literature on alternative estimation and compu-
tation approaches to Bayesian analysis. These include other MCMC algorithms such
as slice sampling, which have been incorporated in the popular packages WinBUGS
(used in this thesis) and OpenBUGS, JAGS and STAN (Plummer, 2011; Spiegel-
halter et al, 2007; Stan Development Team, 2015), as well as other approximation
methods aimed at faster computation than MCMC, such as INLA and Variational
Bayes (Blangiardo and Cameletti, 2015; Logsdon et al, 2010). Indeed, computational
algorithms for Bayesian estimation is a fast-growing field with many advances on the
horizon.
2.3 Relative Survival Models
Cancer survival measures the percentage of patients expected to survive for a certain
amount of time after a diagnosis with cancer (Cramb et al, 2011b). Relative survival is
the preferred method of survival analysis to examine cancer survival from population-
based data (Cramb et al, 2011b; Fairley et al, 2008; Saez et al, 2012). Another method
of survival analysis is cause-specific survival which requires information on a patient’s
cause of death. However, this information is often unavailable or unreliably reported
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for all cancer patients as it is difficult to classify each individual’s death into categories
of ‘entirely unrelated to cancer of interest’ or ‘entirely due to cancer of interest’. Using
relative survival can avoid the possible unavailability or errors from cause of death
information as it does not require such information for analysis. Another advantage
is that it provides a measure of the excess mortality experienced by cancer patients,
irrespective of whether the excess mortality is indirectly or directly attributable to the
cancer of interest. Relative survival is the ratio of the observed proportion of patients
surviving (where all mortalities are considered events) to the expected proportion of
survival from the general population, that is in a comparable group of people by age,
sex, geographic area and, if applicable, race (Cramb et al, 2011b; Fairley et al, 2008;
Saez et al, 2012).
A relative survival model is also known as an additive hazards model, in which the
hazard function with covariate vector x is modelled as the sum of the expected hazard,
λ∗(x), and the excess hazard due to diagnosis of cancer, exp(xβ). The basic relative
survival model (Cramb et al, 2011b; Dickman et al, 2004; Fairley et al, 2008; Saez
et al, 2012) is written as
λ(x) = λ∗(x) + exp(xβ).
The expected hazard λ∗(x), also sometimes called the baseline hazard, is estimated
from external data, for example the general population mortality rate. This baseline
hazard is different to the baseline hazard in a Cox proportional hazards model, an
arbitrary function which is not estimated. The expected hazard does not depend on
tumour-specific covariates such as stage. The hazards are assumed to be constant
within a pre-specified interval of follow-up time, that is, piecewise constant hazards.
The covariate vector x contains variables (e.g. age, sex and lifestyle) that represent
the effect on the survival of a cancer patient as well as indicator variables representing
the intervals of follow-up time. The parameters of each follow-up time are estimated
using the same method as other parameters. The excess hazards are assumed to be
proportional for any two patient subgroups over the follow-up time. By incorporat-
ing time by covariate interaction terms into the equation, non-proportional excess
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hazards can also be modeled (Dickman et al, 2004). The estimate of the excess haz-
ard parameter has an interpretation as an excess hazard ratio and is also known as
relative excess risk (RER) (Cramb et al, 2011b; Dickman et al, 2004; Fairley et al,
2008; Saez et al, 2012). For example, an RER of 1.6 for females compared to males
represents a 60 per cent higher excess hazard associated with the diagnosed cancer
for females than males.
Following Cramb et al (2011b); Dickman et al (2004); Fairley et al (2008); Saez et al
(2012), let the number of deaths, di observed in interval i be modelled by a Poisson
distribution,
di ∼ Poisson(µi),
where µi = λiyi and yi is the person-time at risk (i.e. survival time), which is the total
amount of time in the specified time period that the study subjects are at risk of dying
from the cancer studied. Let d∗i denote the expected number of deaths due to causes
other than the cancer of interest (estimated from general population mortality rates
and treated as given data). Thus the basic relative survival model can be written as
µi
yi
=
d∗i
yi
+ exp(xβ).
Rearrangement gives
(µi − d
∗
i )
yi
= exp(xβ),
which can then be written as
log(µi − d
∗
i ) = log(yi) + xβ.
This gives a generalized linear model with mortality outcome di and a Poisson error
structure as well as a non-standard link function log(µi−d
∗
i ) and offset log(yi), which
avoid the need to acquire cause of death information for the analysis. This model
can then be implemented using Bayesian methods with prior distributions assigned
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to each covariate and uncertainties appended to the non-standard link function where
appropriate (Cramb et al, 2011b; Fairley et al, 2008).
2.4 Standardised Incidence Ratio
Incidence refers to the number of newly diagnosed cancer cases within a pre-specified
spatial region and time interval (Cramb et al, 2011a,b). Due to the nature of cancer, in
some geographical areas only low cancer incidence will be found, hence the traditional
standardisation method for small numbers of cases is the indirectly standardised
incidence ratio (SIR). The SIR does not provide a comparison between geographical
areas of the same level (i.e. between Statistical Local Area (SLA)) but it instead
compares, in terms of Queensland, the SLA-specific estimates against the Queensland
average estimate as a whole after adjusting for the population age-structure differences
(Cramb et al, 2011a,b). This is done to avoid possible bias in interpretation where
SLAs have different population age structures (i.e. younger age population in one
SLA and older age population in another SLA) and the resulting measure (e.g. cancer
incidence) varies by age. Therefore, the interpretation of area risk is in terms of which
area is higher or lower than the Queensland average. The SIR is calculated by dividing
the observed number of cancer cases by the expected number of cancer cases, based
on the population size. The expected number of cancer cases was calculated as the
Queensland number of cancer cases divided by the Queensland population with age
and sex structure adjustment and the outcome is multiplied by the SLA population
(Cramb et al, 2011a,b).
The crude SIR is calculated as (Cramb et al, 2011a):
SIR =
Observed number of cancers diagnosed in a region
Expected number of cancers diagnosed in a region
Where the expected number of cancers diagnosed in a region is given by
Queensland number of cancers diagnosed
Queensland population
× population of geographical region
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However, there are limitations associated with the use of SIR estimates. For example,
areas with no observed cancer cases will automatically receive an SIR of zero regard-
less of the expected cancer cases. Moreover, a relatively small change in incidence
will cause a large difference in the SIR estimates (Lawson et al, 2000, 2003).
2.5 Bayesian Spatial Models
Bayesian spatial models can be used to estimate relative risk (RR) that is an ap-
proximation of the smoothed SIR (see Section 2.4). Using Bayesian spatial models to
estimate the smoothed SIR can overcome many of problems in using crude SIR esti-
mates. The smoothed estimates can incorporate outliers from very small populations
in order to overcome the likely disproportionate influence that will compromise the
overall interpretation (Cramb et al, 2011b). The observed and expected numbers of
cancer diagnoses from the crude SIR is used in the Bayesian spatial model to generate
a smoothed estimate of SIR that can better represent the SIR of each geographical
area with respect to the Queensland average.
Bayesian spatial models have been increasingly common in studying diseases with spa-
tial characteristics (Best et al, 2005). These models use information from neighbour-
ing regions to adjust or smooth estimates. They are thus more capable of handling
outliers, small counts and missing data (Ghosh et al, 1999; Wakefield, 2007).
A widely used Bayesian spatial model to analyse data that incorporates spatial infor-
mation is the Besag, York & Mollie´ (BYM) model (Banerjee et al, 2015; Besag et al,
1991; Best et al, 2005; Cramb et al, 2011b). Best et al (2005) compared a number
of Bayesian spatial models that have been used for disease mapping, using simulated
data. They found that the BYM model is an appropriate tool for small area disease
mapping. Lawson et al (2000) reported an empirical evaluation of disease mapping
models and showed that the BYM model and the gamma-Poisson exchangeable model
are the most robust compared to other models to analyse small area disease incidence.
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Ghosh et al (1999) approached the estimation of cancer incidence rates for local areas
with a hierarchical Bayesian generalized linear model and modelled the spatial struc-
ture of leukemia in upstate New York via a random effect, using a pairwise difference
prior. Bilancia and Fedespina (2009) examined lung cancer data from 1981-2001 in
the province of Lecce, Italy, with a modified version of the BYM model that has an
additional dummy variable as a linear predictor with a cluster-specific effect as the
coefficient, which assumes value 1 if area is in a cluster and 0 otherwise, to detect ge-
ographical clusters of disease. Lawson et al (2000) presented some preliminary results
concerning the goodness-of-fit of disease mapping methods and showed that the BYM
model is one of the most robust models that is relatively insensitive to outliers. Cramb
et al (2011b) used the BYM model and a generalized linear model to develop an atlas
of cancer in Queensland. Militino et al (2001) compared a non-parametric mixture
model of Poisson distributions to a Poisson-normal mixture model with spatial au-
tocorrelation to three different datasets (infant mortality data of British Columbia,
Canada, period 1981-1985; breast cancer data from Sardinia, period 1983-1987; Scot-
tish lip cancer data, period 1975-1980). They found the Poisson-normal mixture
model using penalized quasi-likelihood and Bayesian methods performed substan-
tially better than non-parametric methods when spatial autocorrelation is present.
Lawson and Clark (2002) proposed a modified BYM model involving the use of spatial
mixtures that can provide a balance between smoothness and the maintenance of dis-
continuities. They applied their method to a sudden infant death incidence data set.
MacNab (2003) presented a Bayesian hierarchical spatial model with extra-binomial
variation to analyse chronic lung disease across Canada. Hossain and Lawson (2006)
developed a range of cluster detection diagnostics for small area count data. The
paper compares the local likelihood (LL) model, BYM model and Lawson and Clark
(2002) model and found that the LL model with a CAR prior performed well across a
range of criteria. Bell and Broemeling (2000) used a Bayesian analysis based on the
conditional autoregressive (CAR) model to examine the possible association between
risk factors and disease incidence of lip cancer rate in Scotland.
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2.5.1 BYM Model
The BYMmodel is a hierarchical Bayesian model with a Poisson likelihood and a prior
that explains an area-specific random effect, which decomposes into a spatially struc-
tured random effect (spatially correlated heterogeneity) and an unstructured random
effect (uncorrelated heterogeneity) to better estimate the distribution of relative risk
of each geographical area (SLA) with respect to the Queensland average. A simple
BYM model, ignoring covariates, is specified as (Banerjee et al, 2015; Besag et al,
1991; Best et al, 2005; Cramb et al, 2011b):
yi ∼ Poisson(eiθi)
log(eiθi) = log(ei) + α + ui + vi (2.4)
log(θi) = α + ui + vi
vi ∼ N(0, τ
2
v )
The likelihood is thus given by
L(y) =
n∏
i=1
exp(−eiθi)
yi!
{eiθi}
yi ∝
n∏
i=1
θyii exp
(
−
n∑
i=1
eiθi
)
,
and the log-likelihood is
l(y) = lnL(y) =
∑
yi ln θi −
∑
eiθi.
The definition of each variable in the BYM model is as follows:
• yi is the observed number of diagnosed cancers in the ith geographical area.
• ei is the expected number of diagnosed cancers in the ith geographical area.
• θi is the relative risk (RR) of the ith geographical area.
• α is an overall level of the relative risk.
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• vi is the uncorrelated heterogeneity that provides information about the overall
non-spatial variability (global smoothing) and is usually given a normal prior
distribution centered around zero.
• ui is the correlated heterogeneity that describes the variability of risk relative to
neighbouring regions (local smoothing) and is given a conditional autoregressive
(CAR) prior (Besag et al, 1991; Best et al, 2005).
Additional information such as socio-economic factors can be incorporated into the
BYM model via the covariate vector (βxi) such that log θi = α+βxi+ui+vi (Bilancia
and Fedespina, 2009).
The CAR prior is widely used in small area data analysis to account for spatial
information contributed by neighbouring regions (Banerjee et al, 2015; Besag et al,
1991; Best et al, 2005; Cramb et al, 2011b, 2012; Hegarty et al, 2010; Lee et al, 2014;
Song and Lawson, 2009; Wheeler et al, 2010). The prior requires a neighbourhood
weight matrix to control the amount of smoothing. There are two general types of
weight matrix which are the adjacency-based weight matrix and the distance-based
weight matrix (Earnest et al, 2007).
For the BYM model, the CAR prior has the following form for the correlated hetero-
geneity (ui) in Equation 2.4 (Banerjee et al, 2015; Besag et al, 1991; Best et al, 2005;
Lee et al, 2014; Song and Lawson, 2009; Wheeler et al, 2010)
ui|u−i ∼ Normal
(∑
j wijuj
wi+
,
σ2u
wi+
)
i = 1, . . . , n (2.5)
where u−i denotes the values of the correlated random effects in all areas except
the ith area. wij is the ijth element of a symmetric n × n ‘weight’ matrix W with
diagonal elements wii = 0. A common choice is to use adjacency-based weight matrix
that set wij = 1 if locations i and j are neighbours and wij = 0 otherwise, hence this
gives wi+ equal to the number of neighbours. The local spatial dependence between
location i and j is measured by
γwij
wi+
, where γ can be thought of as an autocorrelation
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parameter that reflects the overall strength of spatial dependence between locations
with nonzero weights, such that γ ∈ (−1, 1). The γ parameter was set to its (upper)
limiting value of 1 for the BYM model, so that ui follow an intrinsic autoregression.
Thus, this is also known as the intrinsic CAR model. The joint prior distribution for
u is now improper with undefined mean and infinite variance, but a proper posterior
distribution will nevertheless be obtained with the usual hierarchical formulation
requirement for proper hyperprior distributions on variance component.
The CAR model can be applied to cancer incidence and can also be implemented in
survival analysis to form a Bayesian spatial survival model. For relative survival anal-
ysis, the generalized linear model proposed by Dickman et al (2004) (see Section 2.3)
has been extended by Fairley et al (2008) to incorporate spatial (ui) and unstructured
(vi) random effects, so that the model becomes
yi ∼ Poisson(µi)
log(µi − d
∗
i ) = log(yi) + xβ + ui + vi.
Similar to the BYM model the unstructured random effect (vi) is given a normal
prior distribution centered around zero and the spatial random effect (ui) is given a
CAR prior distribution. This model was also used by Cramb et al (2011b) for spatial
analysis of cancer in Queensland.
2.5.2 Shared Component Models
The shared component model usually is used when more than one response variable
is to be analysed within a single model. For instance, Knorr-Held and Best (2001)
illustrated the use of a shared component model in identifying shared and disease-
specific spatially varying risk patterns of oral and oesophageal cancer in Germany.
Kazembe et al (2009) utilized the shared component model to investigate the joint
and disease-specific spatial clusters of childhood fever and diarrhoea morbidity in
Malawi.
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In the shared component model, the key idea is to decompose the underlying co-
variates for each response group into portions comprising a shared component, com-
mon to all response groups, and a response-specific component (Kazembe et al, 2009;
Knorr-Held and Best, 2001). In spatial modelling, the shared component can be inter-
preted as a surrogate for unobserved spatial factors that are common to all modelled
response variables and each response-specific component represents those spatially
varying variables which are specific to the respective response group.
Based on Kazembe et al (2009), assume binary (0/1) response variables yijk with k
different responses, e.g. k = 1, 2, for record j in location i, and suppose yijk follows a
Bernoulli distribution
yijk ∼ Bernoulli(pijk) (2.6)
where pijk is the probability of record j in location i being in response group k and
is fitted with a logistic regression model
logit(pijk) = αk +Xijβk + uik + ηik (2.7)
where αk is the response-specific intercept; βk is the vector of regression coefficients
for each response group (k) corresponding to the predictor variables Xij; and uik and
ηik represent the respective spatially unstructured and structured random effects.
The spatially structured random effects (ηik) are partitioned into the common spa-
tially shared component and response-specific spatial component for each response
group to identify spatial patterns in the residual variation. For example, the spatially
structured random effects for a model with 2 responses
ηi1 = δ1φi + si1, ηi2 = δ2φi + si2, δ2 =
1
δ1
where δ1, δ2 > 0, are the weights for the shared component φi; φi is a latent variable
with spatial structure that is shared among all response groups; and si1 and si2 are
the response-specific spatial components. The weight δ can be used to measure the
relative effect or contribution of the shared variation on one of the response groups
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compared to the other response group (Ancelet et al, 2012; Kazembe et al, 2009; Vilas
et al, 2011). When δ is close to 1 then it means the response groups are influenced
by the shared component at a similar level (Ancelet et al, 2012; Vilas et al, 2011).
For a hierarchical Bayesian model, the logistic regression components (Equation 2.7)
can be assigned a prior distribution to demonstrate prior knowledge about the study
case or a vague prior to represent no prior knowledge. For the spatially unstructured
random effect uik, a multivariate Gaussian prior distribution (Downing et al, 2008) is
usually assigned with a specified variance-covariance matrix or a Wishart hyperprior
distribution for the precision matrix. The logarithms of the relative weights can be
assigned a Gaussian prior distribution (Knorr-Held and Best, 2001), and the shared
and response-specific spatially structured components can be assigned a CAR prior
distribution (Besag et al, 1991).
2.6 Varying Coefficient Models
The usual spatial regression models, such as the BYM model (Besag et al, 1991),
typically assume constant regression coefficients that are consistent throughout the
study region. Although these types of models can provide estimates of overall spatial
variation on the response, they lack power to provide more insight into spatially
varying covariate effects across the geographic region. Hence, in order to estimate the
varying coefficient effects of predictive variables to the response a varying coefficient
model can be adopted.
Numerous papers have discussed the varying coefficient model and found that it
is flexible and appealing to investigate dynamic patterns in potentially spatial or
temporal varying data (Choi et al, 2012; Gelfand et al, 2003; Hastie and Tibshirani,
1993; Huang et al, 2014; Reich et al, 2010; Wang et al, 2014). The basic form of a
varying coefficient model for a response variable y is:
y = Xβ(S) (2.8)
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The (unspecified) varying coefficient function of β(), for predictor variable vector
X, gives the regression coefficient that changes depending on S, which may be an
indicator of time or space (Choi et al, 2012; Gelfand et al, 2003; Hastie and Tibshirani,
1993; Huang et al, 2014; Reich et al, 2010).
There are different ways to formulate the varying coefficient function β(S) based
on the varying specification of S. For example, Wang et al (2014) consider the
time varying coefficient function β(t) with quadratic, exponential and trigonometric
functions. Huang et al (2014) assumed an additive dependence structure with a
set of constant predictive variables and a separate set of varying covariates that were
assumed to be smooth functions with continuous second derivatives. Choi et al (2012)
accounted for spatio-temporal dependence in the varying coefficient with the covariate
effect changing over spatial clusters and with each cluster having their own temporal
pattern. Reich et al (2010) proposed a spatially-varying coefficient model that allows
the effect of a subset of regression parameters to vary over the spatial domain. Kernel
methods, penalization and stochastic Bayesian formulations have also been used to
model β(S) (Hastie and Tibshirani, 1993).
2.7 Finite Mixture of Regressions Models
In many fields such as agriculture, economic, biological, medical and environmental
sciences, it is very common to study a heterogeneous population that is composed
of several subpopulations (Dunstan et al, 2013; Lu and Song, 2012). Since pre-
determining and classifying all the subpopulations within heterogeneous data before
analysis is not always feasible, it is useful to consider a model that assigns the un-
certain subpopulation membership of each observation into different data groups. A
finite mixture of regressions model has this capability (Dunstan et al, 2013; Faria and
Soromenho, 2010; Lu and Song, 2012; McLachlan and Peel, 2004; Zou et al, 2013).
This property can be used to identify potential geographic clusters (components) to
address unobserved spatially changing covariate influences on the response. This leads
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to the estimation of different vectors of regression coefficients across spatial clusters
that have a common set of predictive variables (Zou et al, 2013).
A simple mixture of linear regressions model (Faria and Soromenho, 2010) has the
following structure:
yi =


xiβ1 + ǫi1 with probability π1,
xiβ2 + ǫi2 with probability π2,
...
xiβJ + ǫiJ with probability πJ
(2.9)
which is equivalent to the density f(yi) of yi formulated as follows (McLachlan and
Peel, 2004; Zou et al, 2013):
f(yi) =
J∑
j=1
πjfj(yi) (2.10)
where yi denotes the ith observed value of the response variable y1, . . . , yn of size n;
xi is a (p+ 1)-dimensional vector of predictive variables for the ith observation with
corresponding βj vector of regression coefficients for the jth mixture component;
and under normality assumptions ǫij ∼ N(0, σ
2) for the ith observation and jth
component. The quantities π1, . . . , πJ are called the mixing probabilities or weights
that correspond to each mixture components, which are nonnegative quantities that
sum to one, that is,
0 ≤ πj ≤ 1, for all j = 1,. . . ,J (2.11)
and
J∑
j=1
πj = 1 (2.12)
The weight parameter πj acts as a selection mechanism to probabilistically allocate
each observation into separate clusters. In a Bayesian framework, the weight parame-
ter is estimated by assigning a prior distribution to the weight. It is common to assign
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the weight a Dirichlet prior distribution with a concentration parameter ψ, and this
can be denoted as πj ∼ Dir(ψj) and ψj > 0. The concentration parameter controls
the level of variation about the expected weight and can simply be a constant such
that ψ1, . . . , ψJ = 1, or it can be a random value. As the concentration parameter ap-
proaches zero no clustering will be produced and, when the concentration approaches
infinity a singleton cluster is produced. The probability density function for Dirichlet
distribution is
1
B(ϕ)
∏
j
π
ϕj−1
j
where
B(ϕ) =
∏
j Γ(ϕj)
Γ(
∑
j ϕj)
is the multivariate Beta function.
Pitman (2002) has described another method to draw the weight sequentially as
πj ∼ GEM(ψ) with the constraint π1 > π2 > . . . > 0 and
∑
πj = 1 (Pitman, 1996),
that is named after Griffiths, Engen and McCloskey, which has the following form:
λj|ψ ∼ Beta(1, ψ)
π1 = λ1
πj = λj
j−1∏
c=1
(1− λc).
An important issue is to determine the number of mixture clusters/components J . In
the case of a known number of clusters, it is straightforward to estimate the model pa-
rameters by using maximum likelihood estimation with an expectation maximization
algorithm or a Bayesian approach with Markov chain Monte Carlo (Zou et al, 2013).
However, in other situations where the number of clusters is uncertain, a different
algorithm is required to determine the number of clusters. In a Bayesian framework,
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Best et al (2005) implemented the reversible jump Markov chain Monte Carlo (Green,
1995) algorithm that moves between parameter subspaces of differing dimensionality
to determine the number of clusters. Lee and Song (2003) used the Bayes factor
together with a path sampling method to select the number of mixture model compo-
nents. Cai et al (2010) used a deviance information criterion to determine the number
of mixture components. Lu and Song (2012) determined the number of components
using a modified deviance information criterion that gives more penalty to complex
models and can account for missing data models.

CHAPTER 3
Bayesian Spatial Analysis for the Evaluation
of Breast Cancer Detection Methods
Preamble
This Chapter considered the investigation of the impact of spatial location on the
effectiveness of a population-based breast screening service in reducing breast cancer
mortality compared to other detection methods among Queensland women. Regard-
ing its contribution to objectives outlined in Section 1.2, it focuses on the first, second
and third objectives of this thesis. In this Chapter, the modelling of population-based
Queensland breast cancer data is considered using a relative survival model to assess
the survival outcome associated with each patient’s demographic and geographical
characteristics. Further to this modelling, this Chapter also incorporates spatial ran-
dom effects to account for latent spatial variation, with Bayesian methodology to
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accommodate the sparse area-specific data by borrowing information from neigh-
bouring regions to smooth and quantify the estimation. As for the third objective,
the influence of breast cancer detection methods on patient survival was investigated
using the proposed Bayesian spatial relative survival model in addition to all other
variables.
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3.1 Abstract
This study investigated the impact of spatial location on the effectiveness of population-
based breast screening in reducing breast cancer mortality compared to other detec-
tion methods among Queensland women. The analysis was based on linked population-
based datasets from BreastScreen Queensland and the Queensland Cancer Registry
for the period of 1997 to 2008 for women aged less than 90 years at diagnosis. A
Bayesian hierarchical regression modelling approach was adopted and posterior esti-
mation was performed using Markov chain Monte Carlo techniques. This approach
accommodated sparse data resulting from rare outcomes in small geographic areas,
while allowing for spatial correlation and demographic influences to be included. A
relative survival model was chosen to evaluate the relative excess risk for each breast
cancer related factor. Several models were fitted to examine the influence of demo-
graphic information, cancer stage, geographic information and detection method on
women’s relative survival. Overall, the study demonstrated that including the de-
tection method and geographic information when assessing the relative survival of
breast cancer patients helped capture unexplained and spatial variability. The study
also found evidence of better survival among women with breast cancer diagnosed in
a screening program than those detected otherwise as well as lower risk for those re-
siding in a more urban or socio-economically advantaged regions, even after adjusting
for tumour stage, environmental factors and demographics. However, no evidence of
dependency between method of detection and geographic location was found. This
project provides a sophisticated approach to examining the benefit of a screening
program while considering the influence of geographic factors.
3.2 Introduction
Breast cancer is the most common invasive cancer among Australian women, ac-
counting for an estimated 27% (or 14,560) of all cancers diagnosed among women
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in 2012 and is the second leading cause of cancer death in Australia (2,840 deaths,
or 15% of cancer deaths in 2010) (Australian Institute of Health and Welfare and
Australasian Association of Cancer Registries, 2012). Due to the strong relationship
between breast cancer stage and survival (Australian Institute of Health and Welfare
and National Breast Cancer Centre, 2007; Baade et al, 2011b), detection of breast
cancer earlier in its disease pathway increases the opportunity for effective treatment
to reduce the morbidity associated with this disease, and thus improve long-term
prognosis. Mammography screening plays an important role in the early detection
of cancer, and has been shown to improve the chance of survival (Berry et al, 2005;
Shen et al, 2005).
In a climate of continuing controversy about the value of mammographic screening
for reducing breast cancer mortality (McPherson et al, 1997; Olsen and Gøtzsche,
2001; Wishart et al, 2008), there has been strong interest in assessing the efficacy of
screening programs to guide appropriate allocation of health care resources (Bordas
et al, 2007; Hegarty et al, 2010; Wu et al, 2010). Studies over the past decade have
examined the efficacy of breast cancer screening in relation to the prognosis, pathology
and survival of breast cancer patients, compared against other methods of detection,
and have found method of detection to be an important prognostic factor with women
participating in a screening program generally having more favourable tumour stage
and better survival than those detected otherwise (McPherson et al, 1997; Mook et al,
2011; Nagtegaal et al, 2011; Nickson et al, 2012; Shen et al, 2005).
Women whose breast cancer is diagnosed through a breast screening program tend
to have better prognosis than those diagnosed symptomatically primarily because
they are detected at an earlier, less advanced stage. Women with screen detected
tumours are more likely to live longer and have longer time to distant recurrence
than those detected otherwise (Albert et al, 1978; Bordas et al, 2007; Joensuu et al,
2004; Kramer et al, 1999; Mook et al, 2011; Morrison, 1985; Otto et al, 2003; Shen
et al, 2005; Tabar et al, 2003; Wishart et al, 2008). There is a suggestion that at
least some of this advantage is due to lead-time and length bias, in which earlier
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stage tumours and those less aggressive, slow growing tumours, are more likely to
be detected by screening programs (Chu et al, 1988; Connor et al, 1989; Shen et al,
2005).
Previous studies have provided strong evidence of geographical variation in female
breast cancer incidence and survival with women living in more disadvantaged or
rural areas tending to have lower survival (Baade et al, 2011b; Cramb et al, 2011a,
2012; Dasgupta et al, 2012; Huang et al, 2009; Robsahm and Tretli, 2008; Sariego,
2009), even after adjusting for spread of disease at diagnosis (Dasgupta et al, 2012).
However these analyses provide little understanding about how the impact of mam-
mography screening on breast cancer survival varies across geographical location and
by demographic sub-groups. This is of particular interest for remote Australians
whose access to screening programs and treatment facilities is often limited by the
barrier of distance.
A Swedish study (Bordas et al, 2007) investigating this topic was limited due to the
homogeneous socio-economic characteristics of the study area. Studies such as these
have also been constrained by the difficulty of dealing with sparse data typically
associated with spatial data. Recently, Bayesian models and Markov chain Monte
Carlo (MCMC) algorithms have been used to accommodate sparse spatial data and
to create disease maps to assess the spatial and possible temporal effects associated
with the disease of interest (Ghosh et al, 1999; Hegarty et al, 2010; Lawson et al,
2000; Lawson, 2001; MacNab, 2004; MacNab and Dean, 2002; Militino et al, 2001;
Osnes and Aalen, 1999; Richardson et al, 2006; Saez et al, 2012; Waller et al, 1997;
Wu et al, 2010).
The use of relative survival is generally preferred in survival analyses of population-
based disease registry data. Relative survival compares the observed mortality among
study subjects (in particular, cancer patients) to the expected mortality based on
mortality in their general population counterparts. While the theory of Bayesian
univariate spatial models has been extensively researched, there are few examples of
Bayesian relative survival spatial models in the literature. Only Fairley et al (2008),
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Cramb et al (2011a) and Saez et al (2012) have utilized additional spatial information
from the neighbouring regions, thus facilitating the description of possible spatial
correlation and improved estimates of relative survival cancer outcomes. To our
knowledge, ours is the first study to examine the impact of geographical location
on the effectiveness of breast cancer screening using a fully Bayesian spatial relative
survival framework.
This study applies Bayesian spatial hierarchical relative survival models to investi-
gate the impact of spatial location on the effectiveness of population-based breast
screening in reducing breast cancer mortality, after accounting for the influence of de-
mographics and clinical features. Specifically, this paper aims to answer the following
questions:
Q1: How do breast cancer patients’ demographics, tumour stage, socio-economic
status and geographic remoteness influence their relative survival?
Q2: How do the screening programs influence the relative survival of breast cancer pa-
tients, taking into account patients’ demographics, tumour stage, socio-economic
status and geographic remoteness?
Q3: Are there substantive interactions between the screening program and the pa-
tients’ socio-economic status and geographic remoteness?
3.3 Methods
3.3.1 Data sources
Data were extracted from the BreastScreen Queensland (BSQ) and Queensland Can-
cer Registry (QCR) datasets. BreastScreen Queensland is part of the BreastScreen
Australia Program which was established in 1991 by the Australian Government and
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the State and Territory governments. It is a public health cancer screening program
that provides the only population-based breast cancer screening service in Queens-
land. More than 202,000 women were screened by BSQ during 2007. The Queensland
Cancer Registry is a population-based registry for which notification of invasive can-
cers is required by law. Between 1997 and 2007, the QCR recorded over 24,000 cases
of invasive breast cancer among women. Data from the QCR were linked to the BSQ
data by BSQ staff using a deterministic matching process with over 90% completeness
of matching. All invasive breast cancers (ICD-O-3 code = C50) diagnosed between
1 January 1997 and 31 December 2007, among Queensland women aged less than 90
years at diagnosis, were eligible for inclusion in this study. Follow-up was up to 31
December 2008.
3.3.2 Explanation of variables
The data which were analyzed in the modelling process included observed mortality,
age group at diagnosis (0-39 years, 40-49, 50-59, 60-69 and 70-89 years), marital
status at time of diagnosis (married, never married, widowed/divorced/separated or
unknown), indigenous status (Indigenous, non-Indigenous and unknown), tumour
stage at diagnosis, detection method and geographic location and classification. As
the study includes individual-level and area-level variables, the deaths among breast
cancer patients living in each SLA were aggregated by each individual-level variable
categories. For example, the deaths among breast cancer patients living in a specific
Statistical Local Area (SLA), of a specific age group, with the tumour diagnosed at
certain stage and method etc. were aggregated together.
Stage at diagnosis was classified into groups of localised, advanced and unknown using
information on tumour diameter and lymph-node involvement collected by the QCR
(Baade et al, 2011b).
Standard BSQ definitions (provided by BSQ staff) were used to categorise the method
of detecting breast cancer into screen detected, interval detected and non-screen
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detected. Screen detected breast cancers are those diagnosed through a system-
atic method (e.g. mammography) during a regular BreastScreen Australia screening
episode. An interval breast cancer is any invasive breast cancer diagnosed in the 24-
month interval following a negative screening episode and before the next scheduled
screening examination (Kavanagh et al, 1999). A non-screen detected breast cancer is
defined as either (i) any invasive breast cancer diagnosed prior to the commencement
of screening or an invasive breast cancer diagnosed outside of the screening program
after 24 months have elapsed following a negative screening episode; (ii) an inva-
sive breast cancer diagnosed in a woman who had not participated in an organised
screening program.
Geographical location was defined by Statistical Local Areas (SLAs), which are spatial
units likely to be socially and economically relevant to their residents, using the 2006
version of the Australian Standard Geographical Classification (ASGC). In 2006, there
were 478 SLAs in Queensland with a median population of 5,810.
Geographic remoteness of residence was categorised by an Accessibility-Remoteness
Index of Australia Plus (ARIA+) classification, with the categories of Major City, In-
ner Regional, Outer Regional, Remote and Very Remote areas. Due to small numbers
Remote and Very Remote categories were combined. These classifications are based
on road distance from a locality to the closest service center (Australian Institute of
Health and Welfare, 2004).
Socio-economic status (SES) measured by Socio-Economic Indexes for Area (SEIFA)
is based on the Index of Relative Socio-economic Advantage and Disadvantage (IR-
SAD) calculated by the Australian Bureau of Statistics (Australian Bureau of Statis-
tics, 2008). This index was chosen because it does not include Indigenous status in
its derivation. It provides a general measure of socio-economic disadvantage, with its
scores collapsed into quintiles Q1 (Most disadvantaged) to Q5 (Most advantaged).
Population all-cause age-specific mortality rates were calculated from the unit record
mortality file for Queensland residents, and generated for each combination of SLA,
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gender and broad time period (1997–2002; 2003–2007). To provide greater stability,
mortality and population data for each SLA were combined with the relevant data
from the neighbouring SLAs, as defined by the adjacency matrix. The expected num-
ber of deaths due to any cause among the breast cancer cohort for each combination
of variables was generated from these population mortality rates. Although these
expected deaths include the effect of deaths due to breast cancer, this does not, in
practice, affect the estimated survival proportions (Dickman et al, 2004).
3.3.3 Model specification
Following others such as Dickman et al (2004) and Cramb et al (2011b), and consis-
tent with most modern survival analyses on population-based cancer data, a relative
survival model was used. This has the advantage of not requiring cause of death in-
formation among the breast cancer cohort (Cramb et al, 2011b; Dickman et al, 2004;
Fairley et al, 2008; Pohar and Stare, 2006).
To model the observed number of deaths a generalized linear model with a Poisson
assumption was used.
dǫ ∼ Poisson(µǫ),
where dǫ is the observed number of deaths due to any cause among the cohort of breast
cancer patients for each stratum (ǫ), and µǫ is the mean of the observed number of
deaths due to any cause.
For a relative survival model that measures the relative excess risk (RER), the mean
of the observed number of deaths (µǫ) can be modelled by
µǫ = d
∗
ǫ + yǫ × exp(ηǫ),
where d∗ǫ is the expected number of non-breast cancer deaths among the cohort of
breast cancer patients for each stratum (ǫ). The person-time at risk, yǫ, is the total
amount of time in each year that the study subjects are at risk of dying from breast
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cancer, and ηǫ represents the excess hazard. The subscript ǫ is the general indicator
for the partition of data including, as appropriate, time t, the spatial unit i, and the
covariates described in Section 3.3.2 (and shown in Table 3.1).
The exponentiated values of the individual ηǫ components provide the relative excess
risk for the corresponding model variables (e.g. exp(α), exp(β) and exp(ui+vi)). The
excess hazard (ηǫ) is estimated by
ηǫ = αt + βx+ ui + vi,
where β is the coefficient vector associated with the vector of predictor variables x
listed in Section 3.3.2 as well as interactions between detection method and geographic
location; αt is the t
th intercept that varies by follow-up interval (i.e. number of years
from diagnosis to death or censoring) for t = 1, 2, . . . , 12; and ui and vi represent
the ith SLA (i = 1, 2, . . . , 478) with spatially structured and unstructured random
effects, respectively. The prior distribution for all entries of β and all αt is a zero
mean Normal distribution with a Gamma(0.5, 0.005) hyperprior distribution for the
precision; vi is the geographic unstructured random effect and also has a zero mean
Normal prior distribution with a Gamma(0.5, 0.005) hyperprior distribution for the
precision; and ui is the geographic structured random effect which has a conditional
autoregressive (CAR) prior distribution (Banerjee et al, 2003; Bell and Broemeling,
2000; Besag et al, 1991; Best et al, 2005; Earnest et al, 2007; Wakefield, 2007). A
CAR prior for ui is of the form
ui|u(−i) ∼ Normal
(∑
j wijuj
wi+
,
σ2u
wi+
)
wi+ =
∑
j
wij,
where u(−i) denotes the value of the u variate in all areas except the i
th area. The wij is
the ijth element of a symmetric n×n ‘weight’ matrixW with diagonal elements wii ≡
0. We choose wij = 1 if locations i and j are neighbours and wij = 0 otherwise, hence
wi+ is equal to the number of neighbours of location i. The neighbourhood matrices
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of Queensland by Cramb et al (2011b) were applied to the CAR prior distribution in
our models.
3.3.4 Computation
The Bayesian hierarchical models were estimated using R (R Development Core Team,
2011) and WinBUGS (Lunn et al, 2000). The R program was used to handle data
manipulation prior to running the model, and to analyse the posterior densities of the
model parameters. WinBUGS was used to perform MCMC to produce the posterior
samples. Each model was run with 2 chains until convergence (total iterations ranged
from 100,000 to 150,000) and 30,000 simulated samples were retained for inference.
Convergence checks for model parameters were employed in R included the Gelman
and Rubin (1992) convergence diagnostic, trace plots, density plots and autocorrela-
tion plots.
3.3.5 Model fitting and evaluation
Models were fitted to answer the three research questions. In order to answer the first
question (Q1), three models were fitted (M1 1, M1 2 & M1 3), each including the
demographic and stage variables. In addition, Model 1 included remoteness, Model 2
included area disadvantage and Model 3 included both remoteness and disadvantage.
For the second question (Q2), the models from question 1 (M1 1 to M1 3) were re-
fitted with the addition of detection method (M2 1 to M2 3). For the last question
(Q3), the M2 models were extended by adding the interaction between the detection
method and the geographic variables to each model (M3 1 to M3 3). Several other
models were fitted outside the scope of the three questions. One such model, which
consisted of all the demographic, stage and detection method variables (M0 2), was
used to assess the spatial variability or inequalities of relative survival among breast
cancer patients in Queensland.
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The posterior predictive check (PPC) (Gelman et al, 2004) was used to assess how
adequately the model represents the observed data. The assessment procedure is
as follows. First, the expected value µ is calculated using the posterior distribution
of relevant parameters. Second, the expected data d are generated from a Poisson
distribution using the estimated µ, and a posterior predictive distribution is formed.
Third, each observed d is then compared with the corresponding posterior predictive
distribution to assess whether it is encompassed in the 95% credible interval (CI) of
the distribution. An adequate model is often declared if around 95% of the observed
data are within the 95% CI of the posterior predictive distribution.
The Deviance Information Criterion (DIC) was used to determine the preferred model,
with lower values indicating a ‘better’ model (Gelman et al, 2004). DIC is calculated
as the sum of the mean deviance and an estimate of the effective number of parameters
(pD), with smaller deviance indicating better fit, and smaller pD values indicating
less complexity in the fitted model.
The posterior estimate of a relative survival model parameter is declared to be “suf-
ficiently specific” if the 95% CI of the corresponding exponentiated regression coef-
ficient does not include the value “1” (Puigpino´s-Riera et al, 2011; Wakefield, 2007;
Wu et al, 2010).
To assess the spatial variability within the model, disease maps of SLA-specific RER
were generated and a numerical measure was calculated using the variance of the
spatial random effects. The proportion of extra spatial variability was calculated as
the ratio of the marginal spatial structured variance to the sum of the variance of
both marginal spatial structured and unstructured random effects (Eberly and Carlin,
2000; Saez et al, 2012).
3.4 Results
Table 3.1 gives the number of eligible women living in Queensland who had been
diagnosed with breast cancer between 1997 and 2007, as well as the percentage of
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Table 3.1: Number of eligible Queensland females diagnosed with breast cancer (1997-
2007) and the percentage of those who died from any cause (1997-2008)
All BC All causes
incidence death (%)
(1997-2007) (1997-2008)
All Queensland women (0-89 years at diagnosis) 23766 19.5
ARIA+
Major City 14464 19.0
Inner Regional 5066 20.1
Outer Regional 3351 20.3
Remote/Very Remote 885 22.9
SES IRSAD
Quintile 1 Most disadvantaged 2871 22.2
Quintile 2 5179 21.5
Quintile 3 6204 19.7
Quintile 4 5638 18.5
Quintile 5 Most advantaged 3874 16.2
Detection Method
Screening 6902 10.0
Interval 2843 14.5
Non-screen 14021 25.2
Age (years)
0-39 1428 16.4
40-49 4669 11.5
50-59 6443 12.4
60-69 5545 16.1
70-89 5681 38.3
Indigenous Status
Non-Indigenous 20529 21.7
Indigenous 257 31.5
Indigenous Status Unknown 2980 3.8
Marital Status
Married 14801 14.5
Never Married 1441 21.3
Widowed/Divorced/Separated 6787 31.7
Marital Status Unknown 737 6.1
Tumour Stage
Localised 11517 10.8
Advanced 10699 23.7
Stage Unknown 1550 55.4
this cohort who had died from all causes up to December 31st 2008.
The proportions of women who died from any cause during the study period were
larger for women who resided in Remote or Very Remote areas, and those who lived
in SLAs with a socio-economic status of quintile 1 or 2 (disadvantaged). The largest
proportions of all cause mortality were observed in females whose breast cancer was
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detected outside a screening program (non-screen), women aged 70-89, Indigenous,
widowed/divorced/separated as well as unknown tumour stage.
Table 3.2: RER of detection methods, demographic, tumour stage and geographic
status for aged 0-89 Queensland female residents with breast cancer, 1997-2008
RER [95% CI]
Factors Model M0 2 Model M1 1 Model M2 3
ARIA+
Major City — 1.00 1.00
Inner Regional — 1.1208 [0.9643, 1.2710] 1.0957 [0.9578, 1.2420]
Outer Regional — 1.1528 [0.8953, 1.3530] 1.1393 [0.9562, 1.3270]
Remote/Very Remote — 1.4065 [1.0370, 1.7530] 1.3712 [1.0720, 1.6980]
SES IRSAD
Quintile 1 Most disadvantaged — — 1.2060 [0.9971, 1.4430]
Quintile 2 — — 1.1519 [0.9770, 1.3550]
Quintile 3 — — 1.1698 [1.0030, 1.3610]
Quintile 4 — — 1.0928 [0.9367, 1.2710]
Quintile 5 Most advantaged — — 1.00
Detection Method
Screening 0.4136 [0.3545, 0.4777] — 0.4116 [0.3531, 0.4742]
Interval 0.7033 [0.6102, 0.8060] — 0.7014 [0.6087, 0.7989]
Non-screen 1.00 — 1.00
Age (years)
0-39 0.9159 [0.7776, 1.0690] 1.1563 [0.9821, 1.3490] 0.9127 [0.7740, 1.0630]
40-49 0.8243 [0.7273, 0.9322] 0.9128 [0.8046, 1.0320] 0.8230 [0.7241, 0.9291]
50-59 1.00 1.00 1.00
60-69 1.1332 [0.9979, 1.2780] 1.1244 [0.9901, 1.2710] 1.1282 [0.9930, 1.2720]
70-89 1.4869 [1.3140, 1.6770] 1.6122 [1.4250, 1.8140] 1.4835 [1.3170, 1.6720]
Indigenous Status
Non-Indigenous 1.00 1.00 1.00
Indigenous 1.8588 [1.4050, 2.3840] 1.8402 [1.3860, 2.3500] 1.7540 [1.3250, 2.2390]
Indigenous Status Unknown 0.0352 [0.0087, 0.0710] 0.0374 [0.0099, 0.0754] 0.0420 [0.0145, 0.0785]
Marital Status
Married 1.00 1.00 1.00
Never Married 1.2791 [1.0890, 1.4830] 1.3140 [1.1190, 1.5310] 1.2878 [1.0990, 1.4920]
Widowed/Divorced/Separated 1.3924 [1.2660, 1.5270] 1.4134 [1.2860, 1.5490] 1.3922 [1.2640, 1.5260]
Marital Status Unknown 0.4181 [0.1836, 0.7238] 0.4159 [0.1838, 0.7172] 0.4269 [0.2031, 0.7168]
Tumour Stage
Localised 1.00 1.00 1.00
Advanced 4.1156 [3.6040, 4.7000] 4.5599 [3.9830, 5.2240] 4.0447 [3.5230, 4.6150]
Stage Unknown 13.612 [11.690, 15.770] 17.033 [14.600, 19.890] 13.358 [11.470, 15.520]
Spatial Structured Variance 0.0215 [0.0086, 0.0406] 0.0070 [0.0009, 0.0359] 0.0048 [0.0012, 0.0155]
Spatial Unstructured Variance 0.0070 [0.0014, 0.0219] 0.0077 [0.0017, 0.0227] 0.0079 [0.0016, 0.0237]
Extra Spatial Variability 0.7603 0.4387 0.3982
DIC 35457.2 35641.1 35458.0
pD 55.8 49.8 53.9
PPC 0.9853 0.9858 0.9855
3.4.1 Impact of patient demographics, stage and geographic
location (Q1)
The selection of the final model was based on the effect of remoteness and area disad-
vantage. The final DIC values (with pD in brackets) for the three fitted models (M1 1,
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Table 3.3: RER of interaction between detection methods and geographic factors for
eligible Queensland female residents with breast cancer, 1997-2008
Model M3 1 RER [95% CI]
Factors Main Effect Screening Interaction Interval Interaction
ARIA+
Major City 1.00 1.00 1.00
Inner Regional 1.1226 [0.9714, 1.2810] 1.0336 [0.7188, 1.4200] 1.0376 [0.7406, 1.3970]
Outer Regional 1.2471 [1.0150, 1.4590] 0.7671 [0.4827, 1.1200] 0.7867 [0.5172, 1.1330]
Remote/Very Remote 1.4252 [1.0790, 1.7980] 1.3027 [0.7101, 2.0980] 0.8675 [0.4358, 1.4570]
SES IRSAD
Quintile 1 Most disadvantaged — — —
Quintile 2 — — —
Quintile 3 — — —
Quintile 4 — — —
Quintile 5 Most advantaged — — —
Detection Method
Screening 0.4218 [0.3460, 0.5058] — —
Interval 0.7340 [0.6020, 0.8780] — —
Non-screen 1.00 — —
Age (years)
0-39 0.9151 [0.7752, 1.0660] — —
40-49 0.8256 [0.7283, 0.9334] — —
50-59 1.00 — —
60-69 1.1355 [1.0010, 1.2820] — —
70-89 1.4956 [1.3240, 1.6830] — —
Indigenous Status
Non-Indigenous 1.00 — —
Indigenous 1.7885 [1.3640, 2.2970] — —
Indigenous Status Unknown 0.0436 [0.0161, 0.0789] — —
Marital Status
Married 1.00 — —
Never Married 1.2926 [1.1010, 1.4990] — —
Widowed/Divorced/Separated 1.3957 [1.2700, 1.5270] — —
Marital Status Unknown 0.4390 [0.2093, 0.7413] — —
Tumour Stage
Localised 1.00 — —
Advanced 4.0809 [3.5720, 4.6740] — —
Stage Unknown 13.457 [11.570, 16.690] — —
Spatial Structured Variance 0.0060 [0.0012, 0.0202]
Spatial Unstructured Variance 0.0075 [0.0016, 0.0209]
Extra Spatial Variability 0.4344
DIC 35462.5
pD 56.3
PPC 0.9855
M1 2 & M1 3) were 35641.1 (49.8), 35643.8 (53.3) and 35644.1 (53.5) respectively.
Based on this, the final model (Table 3.2) was chosen to be the one that retained
remoteness but excluded area disadvantage (M1 1). There was very little difference
in the RER estimates for the common variables across the three models (results not
shown). Generally the relative excess risk increased for women living in rural/remote
areas, oldest age group (70-89), Indigenous women, those who were not married at
time of diagnosis, and those with an advanced or unknown stage tumour.
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3.4.2 Impact of detection method after adjusting for other
factors (Q2)
The inclusion of detection method provided substantial improvement to the model fit
with much smaller DIC values, as evidenced by models M0 2 and M2 3 in Table 3.2.
The inclusion of geographic remoteness and disadvantage in model M0 2 generated
three models with similar DIC values that differ by less than 5 (M2 1(remoteness):
35455.4 (pD 48.8), M2 2(disadvantage): 35457.7 (57.3), M2 3(remoteness & disad-
vantage): 35458.0 (53.9)). The model including both geographic remoteness and
disadvantage (M2 3) was selected to be the most appropriate model as it provided
additional useful information (Table 3.2). Although models M0 2 and M2 3 had sim-
ilar DIC and pD values, due to the additional geographical information model M2 3
was preferred over M0 2. The only significant change after including detection method
was a reduction in RER among those aged 40–49 years. There remained higher rel-
ative excess risk for breast cancer patients residing in remote areas, disadvantaged
regions, and those not participating in a screening program.
3.4.3 Evidence for interactions (Q3)
Based on the DIC values (M3 1: 35462.5 (pD 56.3), M3 2: 35466.1 (62.4), M3 3:
35474.2 (70.4)), the preferred model with interactions included area remoteness, but
not socio-economic status (Table 3.3). There was no visible change to the main ef-
fect results after including interaction terms. As interactions between the detection
method and area remoteness fluctuated around the baseline value and were not suf-
ficiently specific, a main effects only model was preferred over the interaction model.
3.4.4 Spatial survival inequalities
Figure 3.1 presents a map of RER (divided into quintiles) in each SLA in Queensland
and, in finer detail, the more populated southeast corner of the state, compared
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Figure 3.1: Posterior estimates of RER for each SLA in Queensland & the southeast
corner, based on Model M0 2
to the Queensland average RER (one), before including geographic remoteness and
disadvantage (model M0 2). There was evidence of spatial survival inequalities across
Queensland SLAs (extra spatial variability = 0.76) with higher relative excess risk in
northern and western Queensland and decreased relative excess risk of death in south-
east Queensland. In Brisbane, smaller SLA-specific RER values were observed north
of the Brisbane river and higher values south of the river. After including geographic
remoteness and disadvantage in the analysis (model M2 3), Figure 3.2 (using the same
RER quintile categories as model M0 2) demonstrates a visible reduction in spatial
survival inequalities (extra spatial variability = 0.40).
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Figure 3.2: Posterior estimates of RER for each SLA in Queensland & the southeast
corner, based on Model M2 3
3.5 Discussion
By applying a Bayesian spatial relative survival model to a large population-based
cohort of Queensland women diagnosed with breast cancer, we have reinforced recent
findings showing that participating in mammographic screening is associated with
better breast cancer survival (Berry et al, 2005, 2006; Bordas et al, 2007; Mook et al,
2011; Nagtegaal et al, 2011; Nickson et al, 2012; Roder and Olver, 2012; Shen et al,
2005; Wishart et al, 2008; Wu et al, 2010). Importantly, this study demonstrated
that there was no discernible evidence that this impact of breast cancer screening
on survival varied by the women’s geographical location, even after accounting for
the extent of small area variation, tumour stage at diagnosis and other important
demographic variables.
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The survival advantage that we found for screen-detected cancers does need to be
considered in light of the propensity for overdiagnosis in screening programs, in that
asymptomatic cancers detected through population screening may not progress to
cause symptoms, morbidity or subsequent death, and so would artificially increase
the observed survival (Barratt and Glasziou, 2012; Bell and Burton, 2012; Wishart
et al, 2008). However we found that the survival benefit in participating a screening
program was only marginally reduced after adjusting for tumour stage at diagnosis,
demonstrating that earlier diagnosis did not explain the survival differential. While
we have adjusted for a broad measure of tumour stage at diagnosis, there remains the
possibility that some lead-time bias may be unaccounted by not having more detailed
stage information. In addition, the lack of clinical information on the aggressiveness of
the cancer restricted our ability to completely adjust for the effect of length bias, which
reflects the propensity for screening programs to detect a disproportional number of
slowly growing tumours (Shen et al, 2005). Thus it is possible that some of the
observed association between screening and survival in our study could be explained
by residual length bias, or, to a smaller extent, lead-time bias.
In addition, our finding that breast cancers diagnosed through population-based mam-
mography screening have a two-fold survival advantage is consistent with the direc-
tion and strength of the effect reported by those case control studies that have used
mortality as the end-point. A recent study in Western Australia and meta analysis
of mammographic screening and breast cancer mortality (Nickson et al, 2012) re-
ported that there was a 49% reduction in breast cancer mortality for women who
were screened. This reduction was consistent across a range of studies covering five
countries (Allgood et al, 2008; Fielder et al, 2004; Gabe et al, 2007; Miltenburg et al,
1998; Otto et al, 2012; Palli et al, 1989; Puliti et al, 2008; Roder et al, 2008; van
Schoor et al, 2011).
However we found no evidence that the strong and beneficial impact of screening on
breast cancer survival outcomes varied by geographic location for area disadvantage
or remoteness. In contrast to the reported lower rates of Prostate Specific Antigen
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testing for prostate cancer among men living in rural areas of Australia (Baade et al,
2011c), breast screening participation rates have been reported to be slightly higher
in rural and remote areas than in urban areas (Youlden et al, 2009). These results are
encouraging, and reinforce the priority given to rural and remote areas of the state
by BreastScreen Queensland to offset the barrier of distance by providing mobile
screening vans, in addition to re-locatable and satellite services.
The impact that socio-demographic factors had on breast cancer survival in our study
was consistent with that reported previously in a multilevel analysis of breast cancer
survival in Queensland (Dasgupta et al, 2012) and other related studies (Condon et al,
2005; Cramb et al, 2011a, 2012; Shen et al, 2005, 2007; Wishart et al, 2008). That
these independent associations held within a different methodological framework rein-
force the need to identify ways to reduce the survival inequalities, particularly among
indigenous women, older women and those who are not married. The estimated RER
for age at diagnosis varied slightly when method of detection was added into the
analysis, with poorer survival among younger women reversing to better survival af-
ter adjustment. One explanation of this could be that these cancers are generally
symptomatic (Anders et al, 2008; Axelrod et al, 2008; Baade et al, 2011b; Yankaskas,
2006) and not detected via screening (since the target age for breast screening is 50-
69 years). This explanation is reinforced by the results, in that when the effect of
screening is taken into account, younger women actually have slightly better adjusted
survival.
One of the unique features of the Bayesian spatial methodology is the use of spatial
random effects to accommodate possible spatial variation in the data. The majority
of research investigating breast cancer screening has ignored the spatial location of
cases, and the presence of any spatial correlation (Bell and Burton, 2012; Berry et al,
2006; Mook et al, 2011; Nagtegaal et al, 2011; Roder and Olver, 2012; Shen et al,
2005; Wishart et al, 2008). Inclusion of the random effect components enables a more
realistic estimate of the RER in each SLA location and a better model fit (Besag
et al, 1991; Best et al, 2005; Saez et al, 2012). Information from the random effect
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components can also be used to quantify and understand the spatial variation within
the model, and how this varies between models. The disease maps also facilitate the
visualization of spatial survival inequalities across the study regions, after adjusting
for different health-related factors (Cramb et al, 2012).
Strengths of this study include the use of a large, unselected, population-based cohort
of Queensland females diagnosed with breast cancer, with corresponding information
about screening practices obtained from prospectively collected administrative data,
the collection of which was designed independently of the study, thus removing infor-
mation bias. The Bayesian spatial relative survival models were able to accommodate
the sparse area-specific data by borrowing information from neighbouring regions to
smooth the estimated spatial random effects and directly quantify the estimate of
spatial variation. By focusing on relative survival we were not constrained by any
potential inaccuracies in the cause of death information.
We were not able to obtain information about mammography screening offered by
private hospitals and practices. However the proportion of private mammography
screens has been estimated to be very low, at between 1-4% (Australian Government
Department of Health and Ageing, 2012; Nickson et al, 2012). Therefore, by placing
the privately screened women in the unscreened group, the true screening differential
should not be badly underestimated.
This study has demonstrated a clear survival benefit in respect of breast cancers de-
tected through mammographic screening among women aged less than 90 years at
diagnosis, and that this benefit was consistent after adjusting for spread of disease
and diagnosis. We found no substantive evidence that the screening benefit varied
according to geographic location of residence. However since women diagnosed with
breast cancer while living in rural and remote areas of Queensland are at higher risk
of being diagnosed with advanced disease (Baade et al, 2011b), and since this explains
much of the poorer survival outcomes in these areas (Cramb et al, 2012; Dasgupta
et al, 2012) there remains an urgent need to increase screening and treatment partici-
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pation among women in rural, remote and disadvantaged areas to reduce the current
survival inequalities.

CHAPTER 4
Does Geographic Location Impact the
Survival Differential Between Screen- and
Interval-Detected Breast Cancers?
Preamble
This Chapter considered the examination of differences in survival between screen-
and interval-detected breast cancer patients who participated in a public population-
based breast screening program in Queensland, Australia. This contributes to the
first, second and third objectives outlined in Section 1.2 of this thesis. In this Chapter,
the Bayesian spatial relative survival model is again considered, to identify evidence
of interaction between the two detection methods and patient demographic, clinical
and geographic characteristics. The study further modified the model formulation
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and hierarchical structure to test the hypothesis that the impact of being diagnosed
with an interval-detected compared to a screen-detected breast cancer varied by ge-
ographic location. The hypothesis was tested by examining the survival variation
between screen- and interval-detected breast cancers within each geographic location
to determine the consistency or change of relative excess risk across the state.
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4.1 Abstract
Although mammography screening programs aim to diagnose breast cancer at an
early stage, not all tumours are detected during the regular screening examination.
This study examines the influence of various characteristics, including geographi-
cal residence, on the survival between screen- and interval-detected breast cancers
among participants of a public population-based breast screening program in Queens-
land, Australia. The investigation was performed using the linked population-based
datasets from BreastScreen Queensland and the Queensland Cancer Registry for the
period of 1997 to 2008 for women aged 40 to 89 years at diagnosis. A Bayesian
spatial relative survival modelling approach that accommodates rare outcomes in
small geographic regions was adopted, with the use of Markov chain Monte Carlo
computation, to evaluate the relative excess risk of breast cancer. In the multivari-
ate Bayesian spatial model, higher relative excess risk of mortality was observed in
interval-detected cancer (RER = 1.59, 95% credible interval = [1.33, 1.89]) compared
to screen-detected cancer. Higher cancer survival among the study cohort was also
observed among younger women (40–59 years), those of non-Indigenous ethnicity,
with localised (stage I) tumour stage as well as those not in the work force. There
was no independent association with marital status. Moreover, there was no substan-
tive evidence of either measured geographical or latent random spatial inequalities
in survival among screening participants across Queensland, meaning the higher sur-
vival for screen-detected breast cancer patients compared to interval-detected women
was consistent across the state. These results provide suggestive evidence supporting
the effectiveness of the BreastScreen Queensland screening program in reaching socio-
economically disadvantaged women as well as those living in rural and remote areas
of the state, but also highlights the need for any interval cancer awareness programs
to be geographically widespread.
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4.2 Introduction
In Australia, breast cancer survival has improved over recent decades (Australian
Institute of Health and Welfare, Cancer Australia and Australasian Association of
Cancer Registries, 2008) and is now one of the highest among the world (Coleman
et al, 2011). Mammography screening plays an important role in the early detection
of cancer and has been shown to improve the chance of survival (Berry et al, 2005;
Shen et al, 2005). BreastScreen Queensland (BSQ) is the only population-based,
publically-funded breast screening program in the state of Queensland, Australia. It
provides mammographic screening to detect clinically asymptomatic carcinomas in
an earlier stage and time than those detected symptomatically, with the intent of
facilitating earlier and more effective treatment options leading to improved survival
outcomes.
The majority of BSQ screening program participants who were diagnosed with breast
cancer had their cancer detected during the screening episode (known as screen-
detected (SD) cancers) (Hsieh et al, 2014). However, even when women comply
with the recommended screening intervals, there remain some breast cancers that are
diagnosed in the time interval between screening episodes. These cancers are known as
interval-detected (ID) cancers. ID cancers are a heterogeneous group, including some
“missed” during the previous screen but detected retrospectively, others that are fast
growing tumours that emerge and grow rapidly between two consecutive scheduled
screening episodes, and others that are not visible by mammography (Brekelmans
et al, 1995, 1996; Gilliland et al, 2000; Porter et al, 1999; Warren and Duffy, 2000).
The last two types are true interval cancers, while the first represents a failure of the
screening process. It has been estimated that more than 80% of interval cancers are
“true” interval cancers (Australian Institute of Health and Welfare, 2013; Kavanagh
et al, 1999).
Since tumour growth rate is an important prognostic factor (Brekelmans et al, 1995,
1996; Gilliland et al, 2000), lower survival is expected for patients with interval-
detected cancers compared to screen-detected cancer (Brekelmans et al, 1995; Gilliland
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et al, 2000). This has been demonstrated by other studies (Bordas et al, 2007; Brekel-
mans et al, 1995; Eriksson et al, 2013; Hsieh et al, 2014; McKenzie et al, 2012; Mook
et al, 2011; Nagtegaal et al, 2011; Rayson et al, 2011; Shen et al, 2005), including
in Queensland, where the study results suggested the survival outcomes for interval-
detected breast cancers were worse than for screen-detected cancers for women par-
ticipating in the BreastScreen Queensland program (Hsieh et al, 2014).
Previously we have investigated the impact of spatial location on the survival out-
comes of population-based mammography screening compared to other detection
methods (Hsieh et al, 2014). We found that survival outcomes were greater among
women whose cancer was diagnosed in a screening program compared to non-screening
participants, and that this relationship was consistent across Queensland geographic
characteristics (socio-economic status and area remoteness). However, because the
women who were not participants in the BSQ program were used as the reference
category, the relative excess risk estimates for screen-detected and interval-detected
cancers were not able to be directly compared. In addition, by including all women,
the specific implications for the effectiveness of the BSQ program were unclear. By
adopting and developing our previous statistical model to quantify the impact of spa-
tial location on the survival differential between interval- and screen-detected cancers,
along with the impact of clinical and demographic variables, we hope to better un-
derstand the impact of spatial location on the effectiveness of the population-based
Queensland mammography screening programs.
Given that previous studies have found that women living in more regional areas
of Queensland are more likely to be diagnosed with advanced breast cancer (Baade
et al, 2011b), and that women in these areas face greater barriers in relation to access
(Coughlin et al, 2002; Lustria et al, 2010; McLafferty et al, 2011), our hypothesis was
that the impact of being diagnosed with an interval-detected breast cancer compared
to a screen-detected breast cancer varied by geographic location. If this is the case,
then this would provide quantitative data to prioritise the development of strategies
for reducing the impact or proportion of interval-detected cancers in those areas where
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the survival implications are greatest. Conversely a lack of evidence in support of this
hypothesis would support the consistent effectiveness of the population-based breast
screening program across all geographical areas, thus encouraging the continuation of
current methods.
The key advantages of the Bayesian spatial model in analysing small-area variations
in cancer over non-Bayesian regression models are that they provide a distribution for
the estimated results and can borrow information from the neighbouring regions to
improve model estimation while also adjusting for important covariates (Besag et al,
1991; Cramb et al, 2012; Haining et al, 2007; Liao et al, 2011; Ugarte et al, 2005). This
study adopts a Besag, York and Mollie (BYM) modelling approach (Besag et al, 1991)
that accounts for unstructured and spatially structured heterogeneity to smooth the
estimates at global and local levels. This improves model estimation for areas with a
small number of cases. There are other statistical spatial smoothing techniques, such
as geostatistics kriging, which is a local interpolation method and requires additional
spatial support (i.e. distance) to generate the semivariogram or covariance function
(Goovaerts, 2006). The Bayesian spatial model can be used in health risk analysis and
is equally applicable to a range of other areas that investigate spatial risk factors, such
as environmental and ecological sciences, demography, engineering, robotic vision,
defence, remote sensing and so on.
By utilizing data from the population-based Queensland Cancer Registry, linked with
the BreastScreen Queensland database, we were able to investigate the survival out-
comes for women who participated in the BreastScreen Queensland program and
were diagnosed with an invasive breast cancer between 1997 and 2007. Two specific
objectives are considered for this paper:
1. to examine whether there are differences in survival between screen-detected
and interval-detected invasive breast cancer patients after adjusting for women’s
demographics, clinical and geographic characteristics;
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2. to determine whether the survival differential between screen-detected and interval-
detected invasive breast cancer patients varies by Statistical Local Area (SLA)
and, if so, identify characteristics of those geographic locations with the largest
survival differentials.
4.3 Materials and Methods
4.3.1 Study cohort
Records on breast cancer (ICD-O-3 code = C50) diagnosed among Queensland women
between 1 January 1997 and 31 December 2007 with follow-up to 31 December 2008
were obtained from linked Queensland Cancer Registry (QCR) and BreastScreen
Queensland (BSQ) data. Ethics approval was granted by the Human Research Ethics
Committee of Queensland University of Technology (approval number: 1100000036).
Access to the data was provided by Queensland Health under the Public Health Act
2005 (RD003676). Patient records were anonymized and de-identified prior to data
extraction and analysis. The linkage of data was undertaken by BSQ staff using a
deterministic matching process with over 90% completeness of matching.
The analysis included Queensland participants in BSQ mammography screening who
were diagnosed with invasive breast cancer between ages 40 to 89 years. BSQ actively
invites women aged 50-69 for free 2-yearly screening mammograms. In 2010–2011,
285,886 (57.6%) women within the target age range had a screening mammogram
(Australian Institute of Health and Welfare, 2013).
The initial study cohort consisted of 10,027 Queensland women aged 40 to 89 who
participated in the BSQ program between 1997 and 2007. Of these, 286 were excluded
due to missing data on age (0.3%), detection method (0.6%) or Statistical Local
Area (SLA) (based on the 2006 version of the Australian Standard Geographical
Classification) (0.6%), or whose cancer was diagnosed at autopsy or death certificate
only or had a survival time less than one day (1.4%).
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4.3.2 Explanation of variables
The study variables (see Table 4.1) included observed mortality (count of death for
each combination of patient variables), age group at diagnosis, marital status at time
of diagnosis, Indigenous ethnicity, tumour stage at diagnosis, occupation, detection
method and geographic location. Measures of geographic location included the 478
SLAs in Queensland as well as the area-based measure of socio-economic status (SES)
measured by the Socio-Economic Indexes for Area (SEIFA) Index of Relative Socio-
economic Advantage and Disadvantage (IRSAD) (Australian Bureau of Statistics,
2008) and area remoteness measured by the Accessibility-Remoteness Index of Aus-
tralia Plus (ARIA+), based on road distance from a locality to the closest service
center (Australian Institute of Health and Welfare, 2004).
4.3.3 Relative survival estimates
As an exploratory analysis, the unadjusted 5-year and 10-year relative survival esti-
mates were derived using the period method (Brenner and Hakulinen, 2002; Ellison
and Gibbons, 2006) via the user-written strs program in the Stata software (Stata-
Corp, 2013). Expected survival was estimated using the Ederer II method (Ederer
and Heise, 1959) based on a Queensland SLA-specific life table generated from the
Australian Bureau of Statistics unit record file mortality data. The Ederer II method
considers cancer patients to be at risk from diagnosis until they die or are censored
and is used here to calculate the expected survival rates for patients at each annual
time period. The population mortality was calculated for women only by each SLA,
5-year age group and aggregated by broad calendar years (1997-2002 and 2003-2006),
and then applied to each year within the appropriate time period. Due to accurate
SLA-specific population mortality data not being available for 2007 onward at the
time of publication, the 2003-2006 mortality rates was applied to 2007 and 2008.
Information from the neighbouring areas was added to increase the stability of the
SLA-specific population mortality estimates.
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4.3.4 Statistical model
Consistent with some recent cancer survival analyses (Cramb et al, 2011b, 2012; Dick-
man et al, 2004; Fairley et al, 2008; Pohar and Stare, 2006), a Bayesian spatial relative
survival model was adopted to measure the survival difference between screen- and
interval-detected breast cancer patients. This model estimates the relative excess risk
(RER) of mortality for each of the patient characteristics listed in the ‘Explanation
of variables’ section. To improve estimation in areas with small counts (small areas),
a local smoothing (conditional autoregressive) model was used to incorporate infor-
mation from neighbouring regions into the relative survival estimate for each SLA, as
described below.
Objective 1
To model the observed number of deaths (dǫ) due to any cause among the cohort of
eligible BSQ clients for each stratum (ǫ), a generalized linear model with a Poisson
likelihood was used,
dǫ ∼ Poisson(µǫ). (4.1)
For a relative survival model, the expected number of deaths (µǫ) can be modelled by
µǫ = d
∗
ǫ + yǫ × exp(ηǫ), (4.2)
where d∗ǫ is the expected number of non-breast cancer deaths for each stratum of the
eligible cohort, yǫ is the person-time at risk and ηǫ is the excess hazard.
The exponential of the individual ηǫ components provides the RER for the corre-
sponding model variables (e.g. exp(α), exp(β), exp(δ) and exp(ui + vi)). The excess
hazard (ηǫ) is modelled by
ηǫ = αt + βx+ δz+ ui + vi (4.3)
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where αt is the t
th intercept that varies by follow-up interval for t = 1, 2, . . . , 12; δ
is the coefficient associated with the detection method of predictor variable z; β is
the coefficient vector associated with the vector of predictor variables x listed in the
‘Explanation of variables’ section (except detection method) as well as interactions
between detection method and geographic location; and ui and vi represent the i
th
SLA (i = 1, 2, . . . , 478) with spatially structured and unstructured random effects,
respectively.
The model components αt, δ, β and vi were all assigned a zero mean Gaussian
distribution with a Gamma (0.5,0.005) hyperprior distribution for the precision (=
1/variance). The random effect term ui was assigned a conditional autoregressive
(CAR) prior distribution with a Gamma (0.5,0.005) hyperprior distribution for the
precision (Besag et al, 1991; Haining et al, 2007; Ugarte et al, 2005).
Two versions of this model were implemented:
1. A model containing the covariates age group at diagnosis, Indigenous ethnicity,
tumour stage at diagnosis, occupation and detection method (Model 1).
2. As above, but additionally including the geographical (G) location variable of
socio-economic status and area remoteness categories (Model 1G).
Objective 2
In order to quantify the potential geographic (SLA) inequality in relative survival for
the detection method coefficient (δ) of ID vs. SD in Equation 4.3, the equation was
modified as follows:
ηǫ = αt + βx+ δiz+ ui + vi. (4.4)
where z remains the indicator variable for the detection method, and the coefficient
δi is now a random effect for the i
th SLA. This was assigned a Gaussian prior distri-
bution with a Gaussian (0,0.1) (precision=0.1) hyperprior distribution for the mean
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and a Gamma (0.5,0.005) hyperprior distribution for the precision. Thus exp(δi),
termed SLA-ID RER, provides the RER of interval-detected breast cancer compared
to screen-detected breast cancer in each SLA.
4.3.5 Model computation
Computation was performed using Markov chain Monte Carlo (MCMC) algorithms,
via WinBUGS v1.4.3 (Lunn et al, 2000) interfaced with R v2.14.1 (R Development
Core Team, 2011). All models were run with 2 chains for 100,000 iterations: 70,000
of the iterations were discarded as burn-in and 30,000 were retained for inference.
Model convergence was examined by means of the Gelman and Rubin (Gelman and
Rubin, 1992) convergence diagnostic, trace plots, density plots and autocorrelation
plots.
4.3.6 Model fitting and evaluation
The Deviance Information Criterion (DIC) was used to determine a preferred model,
with smaller values indicating better model fit (Gelman et al, 2004). To examine the
adequacy of the model predictions compared to the observed data, posterior predictive
checks (PPC) (Gelman et al, 2004) were used. The estimated exponentiated regression
coefficient of patient characteristics was considered to be substantively different from
the corresponding baseline if the corresponding 95% credible interval (CrI) did not
include one (Puigpino´s-Riera et al, 2011; Wakefield, 2007; Wu et al, 2010).
Sensitivity assessments for the precision parameters of the fixed effects (δ, β) and
random effects (αt, ui & vi) were conducted by assigning different Gamma distri-
butions to the precision, namely Gamma (0.5,0.005), Gamma (0.5,0.5) and Gamma
(0.005,0.5). The sensitivity of the results to the choice of prior for δi was tested by as-
signing different hyperprior distributions for the mean of the prior, namely Gaussian
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(0,0.001), Gaussian (0,0.01), Gaussian (0,0.1) with different precision and Gamma
(0.5,0.5).
To assess the spatial variation within screening participants (Objective 1), disease
maps, the proportion of extra spatial variability and Tango’s Maximized Excess
Events Test (Tango’s MEET) were used. There are a number of methods for calcu-
lating the extra spatial variability (Eberly and Carlin, 2000; Saez et al, 2012; Ugarte
et al, 2005) and we have chosen the one used by Saez et al (2012) based on the ratio of
the marginal spatial structured variance to the sum of the variance of both marginal
spatial structured and unstructured random effects. Tango’s MEET (Tango, 2000) is
a global clustering test used to determine whether significant variation exists in the
SLA-specific RER estimates.
4.4 Results
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Table 4.1: Breast cancer incidence (1997–2007) and unadjusted relative survival estimates (1997–2008) among BreastScreen
Queensland (BSQ) participants by category
Screen-detected Interval-detected
Na 5-yr RS (%)b
[95% CIc]
10-yr RS (%)
[95% CI]
N 5-yr RS (%)
[95% CI]
10-yr RS (%)
[95% CI]
All BSQ women 6898 95.6 [94.9, 96.4] 90.3 [88.7, 91.8] 2843 88.6 [87.0, 90.0] 82.8 [80.2, 85.1]
Age (years)
40–49 1004 94.2 [92.3, 95.8] 91.1 [88.0, 93.5] 547 90.6 [87.3, 93.2] 84.1 [78.6, 88.4]
50–59 2271 95.2 [94.0, 96.3] 89.7 [87.3, 91.8] 1116 88.6 [86.2, 90.7] 83.1 [79.5, 86.3]
60–69 2265 95.9 [94.6, 97.1] 89.6 [86.7, 92.2] 791 87.3 [84.1, 90.0] 81.3 [76.1, 85.8]
70–89 1358 97.2 [94.8, 99.4] 93.2 [87.9, 98.0] 389 88.5 [82.9, 93.2] 83.3 [72.9, 92.6]
Indigenous Status
Non-Indigenous 5972 94.7 [93.9, 95.6] 88.3 [86.6, 90.0] 2451 86.9 [85.2, 88.5] 80.2 [77.3, 82.8]
Indigenous 67 84.4 [70.4, 93.1] 58.3 [36.3, 76.3] 23 72.6 [45.1, 88.4] 57.4 [21.6, 82.8]
Unknown 859 102.8 [101.5, 103.4] 106.5 [103.5, 108.3] 369 101.2 [95.5, 102.4] 103.4 [97.9, 106.2]
Marital Status
Married 4512 96.3 [95.4, 97.1] 92.1 [90.2, 93.7] 2008 89.0 [87.2, 90.7] 82.7 [79.7, 85.4]
Never Married 336 92.3 [87.6, 95.6] 92.1 [84.9, 97.3] 111 91.4 [82.2, 96.6] 84.3 [67.8, 94.3]
Widowed/Divorced/Separated 1849 94.1 [92.2, 95.7] 84.2 [80.4, 87.6] 635 85.5 [81.7, 88.8] 81.2 [75.3, 86.4]
Unknown 201 102.2 [98.0, 103.9] 110.2 [105.6, 111.9] 89 98.7 [90.0, 101.7] 93.6 [75.9, 102.2]
Tumour Stage
Localised 4488 98.4 [97.6, 99.2] 95.4 [93.6, 97.1] 1223 96.0 [94.1, 97.5] 94.3 [90.9, 97.1]
Advanced 2318 90.7 [89.1, 92.2] 80.8 [77.7, 83.7] 1507 84.5 [82.1, 86.6] 74.7 [70.9, 78.3]
Unknown 92 82.9 [70.6, 91.4] 77.1 [58.2, 91.1] 113 64.2 [52.9, 73.7] 64.1 [49.9, 76.5]
Occupation
Blue collar 269 86.6 [80.9, 90.9] 71.3 [61.8, 79.2] 117 77.6 [67.6, 85.2] 70.2 [56.9, 80.7]
White collar 1001 88.5 [85.9, 90.8] 78.2 [73.6, 82.2] 481 80.8 [76.4, 84.6] 69.2 [62.7, 75.0]
Professional 1157 90.9 [88.6, 92.9] 80.0 [75.6, 83.8] 602 84.0 [80.2, 87.2] 72.9 [66.7, 78.4]
Not in the labour force 2874 97.5 [96.3, 98.5] 93.4 [90.9, 95.6] 1047 89.8 [87.1, 92.0] 86.8 [82.7, 90.4]
Unknown 1597 102.5 [101.6, 103.2] 106.9 [104.5, 108.5] 596 101.2 [99.2, 102.3] 103.6 [99.1, 106.1]
Area Remoteness
Major City 4046 95.9 [94.9, 96.8] 90.6 [88.5, 92.6] 1532 88.4 [86.3, 90.4] 81.7 [78.1, 85.0]
Inner Regional 1553 95.5 [93.7, 96.9] 90.3 [86.8, 93.4] 656 86.9 [83.3, 89.8] 85.3 [80.3, 89.6]
Outer Regional 1004 95.6 [93.4, 97.4] 90.4 [85.9, 94.1] 527 90.9 [87.3, 93.7] 83.5 [77.1, 88.7]
Remote/Very Remote 295 93.1 [88.1, 96.7] 85.9 [76.6, 93.2] 128 89.7 [81.0, 95.1] 78.5 [63.5, 89.2]
Socio-economic Status
Quintile 1 Most disadvantaged 870 94.7 [92.2, 96.8] 88.5 [83.5, 92.6] 368 88.9 [84.1, 92.5] 83.4 [75.9, 89.4]
Quintile 2 1614 95.2 [93.5, 96.7] 88.7 [85.1, 91.8] 626 88.9 [85.4, 91.8] 88.2 [83.1, 92.4]
Quintile 3 1919 95.3 [93.7, 96.7] 89.6 [86.3, 92.4] 819 87.1 [84.0, 89.8] 78.4 [73.2, 83.0]
Quintile 4 1662 96.7 [95.1, 98.0] 92.4 [89.1, 95.2] 661 89.3 [86.0, 92.1] 81.8 [76.2, 86.6]
Quintile 5 Most advantaged 833 96.0 [93.6, 97.8] 93.2 [88.8, 96.7] 369 89.8 [85.3, 93.2] 84.7 [77.4, 90.5]
aNumber of breast cancer patients diagnosed
bThe estimated 5 years unadjusted relative survival (RS) expressed as a percentage.
cConfidence Interval.
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From the exploratory analysis, more than twice as many women in Queensland who
participated in the BSQ screening program were diagnosed with breast cancer through
screening episodes than those diagnosed in the interval between screening episodes
(Table 4.1). This differential held generally across all the patient subgroups. The
unadjusted 5-year and 10-year relative survival for screen-detected BC patients in
QLD was higher for those that were non-Indigenous, married, diagnosed with a lo-
calised (stage I) tumour and those not in the labour force (non-workers). Whilst the
unadjusted relative survival estimates for interval-detected breast cancers were lower
compared to screen-detected cancers, the distribution of survival estimates across
subgroups was similar. There was little difference in 5-year unadjusted relative sur-
vival by area remoteness and socio-economic status categories, and survival remained
higher for screen-detected cancers. There was some evidence of a greater difference
in 10-year unadjusted survival estimates, with generally lower outcomes for remote
or very remote regions and in the more disadvantaged areas.
4.4.1 Objective 1
Women with an interval-detected cancer, aged 60–89 years, of Indigenous ethnicity,
in the work force or with a tumour diagnosed at an advanced or unknown stage had
higher RER of breast cancer mortality compared to their respective baseline level
(Table 4.2). Women’s marital status was not included as it did not enhance the model
with respect to goodness of fit, nor did it have a substantive influence on estimated
relative survival. The relative survival estimates were not substantively altered after
further adjusting for socio-economic status and/or area remoteness (Model 1G in
Table 4.2). Neither geographic factor had substantive influence on the survival of
screening program participants. In addition, ‘Model 1’ had a lower (difference>5)
DIC value than ‘Model 1G’, so ‘Model 1’ was the preferred model. No substantive
interactions between the detection method and other fixed effects were found (results
not shown).
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Table 4.2: Fixed effect relative excess risk (RER) of mortality estimates of the
BreastScreen Queensland study cohort
RER [95% CrIa]
Fixed effects Model 1 Model 1Gb
Detection Method
Screening 1.00 1.00
Interval 1.59 [1.33, 1.89] 1.59 [1.32, 1.89]
Age (years)
40–49 0.77 [0.59, 0.98] 0.77 [0.59, 0.99]
50–59 1.00 1.00
60–69 1.62 [1.29, 2.01] 1.59 [1.26, 1.98]
70–89 2.45 [1.79, 3.23] 2.38 [1.73, 3.15]
Indigenous Status
Non-Indigenous 1.00 1.00
Indigenous 2.92 [1.54, 4.71] 2.73 [1.43, 4.44]
Unknown 0.07 [0.01, 0.18] 0.09 [0.02, 0.20]
Tumour Stage
Localised 1.00 1.00
Advanced 3.05 [2.46, 3.77] 3.05 [2.44, 3.79]
Unknown 7.41 [4.94, 10.51] 7.39 [4.88, 10.42]
Occupation
Blue collar 3.92 [2.71, 5.43] 3.82 [2.64, 5.29]
White collar 3.39 [2.61, 4.37] 3.33 [2.55, 4.27]
Professional 3.15 [2.43, 4.07] 3.10 [2.38, 3.98]
Not in the labour force 1.00 1.00
Unknown 0.10 [0.01, 0.24] 0.13 [0.03, 0.27]
Area Remoteness
Major City — 1.00
Inner Regional — 1.04 [0.78, 1.36]
Outer Regional — 0.81 [0.53, 1.14]
Remote/Very Remote — 1.12 [0.65, 1.74]
Socio-economic Status
Quintile 1 Most disadvantaged — 1.01 [0.66, 1.46]
Quintile 2 — 0.91 [0.62, 1.29]
Quintile 3 — 1.11 [0.79, 1.53]
Quintile 4 — 0.91 [0.63, 1.26]
Quintile 5 Most advantaged — 1.00
Spatial Structured SDc 0.0144 [0.0014, 0.0506] 0.0484 [0.0029, 0.1738]
Spatial Unstructured SD 0.0238 [0.0018, 0.1009] 0.0196 [0.0016, 0.0851]
Extra Spatial Variability 0.4531 0.6455
Tango’s MEET p-value 0.895 0.079
DIC 11372.6 11379.9
pD 36.4 47.3
PPC 0.9873 0.9872
aCredible Interval.
bExpansion to Model 1 by including fixed effects of area remoteness and socio-economic status.
cAbbreviations: SD=Standard Deviation, MEET=Maximized Excess Events Test, DIC=Deviance
Information Criterion, pD=effective number of parameters, PPC=Posterior Predictive Checks.
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Figure 4.1: QLD map with Statistical Local Area-specific Relative Excess Risk (SLA-
specific RER) of mortality for Model 1, and enlarged Brisbane region in the inset
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Table 4.3: Summary Statistics of SLA-ID RER of mortality
Mean valuesa All samplesb
Mean 1.60 1.60
Median 1.60 1.60
Minimum 1.55 0.31
20% 1.60 1.44
40% 1.60 1.55
60% 1.60 1.65
80% 1.61 1.77
Maximum 1.66 7.89
aSummary statistics of the mean value of Statistical Local Area-Interval Detected Relative Excess
Risk (SLA-ID RER).
bSummary statistics of all the sample values of SLA-ID RER across Markov chain Monte Carlo
(MCMC) iterations.
The map of posterior mean RER estimates suggests a trend of increasing SLA-specific
RER (exp(ui+vi)) from the south-east to the north of Queensland among BSQ partic-
ipants (Figure 4.1). Within the Brisbane region (see inset), the RER estimates tend
to be lower north of the Brisbane river. However, the high Tango’s MEET p-value
(0.895) and non-significant extra spatial variability (0.453) indicate that screening
program participants across Queensland were unlikely to experience substantive spa-
tial variation in relative survival from an unmeasured source.
4.4.2 Objective 2
When the detection method was included as a random effect for each SLA, RER
values for the fixed effect β were very similar to those in Table 4.2 with slightly higher
estimates, but an unchanged substantive pattern of variable categories (results not
shown). The overall average value of the SLA-ID RER (exp(δi)) of 1.60 was very
similar to the fixed effect mean RER value of the ‘Interval’ detection method of 1.59
in Table 4.2 (Table 4.3). A plot (Figure 4.2) of ranked SLA by the average SLA-ID
RER values with 95% credible intervals shows that all areas have an interval-detected
RER that is substantively higher than the screen-detected RER, with all lower bounds
of the credible intervals above one.
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Figure 4.2: The mean (solid black line) and 95% credible intervals of the Statistical
Local Area-Interval Detected Relative Excess Risk (SLA-ID RER) of mortality
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4.5 Discussion
This study demonstrated that among women aged 40-89 who participated in the
BSQ screening program, those whose breast cancer was detected in the screening ex-
amination had 60% better survival than those detected during the interval between
screening. The study has identified a set of important survival outcome predictors,
such as detection method, age at diagnosis, Indigenous status, tumour stage at diag-
nosis and occupation. There was no substantive evidence that breast cancer survival
varied by geographical location among this cohort, nor was there any evidence that
the survival differential between interval and screen detected cancers varied by geo-
graphic and clinical predictors. Furthermore, there was no substantive evidence for
the existence of unmeasured spatial predictors (lack of spatial random variation) that
would otherwise influence the survival among the study cohort.
Unsurprisingly, we found that interval-detected breast cancers have worse survival
than screen-detected breast cancers, consistent with previous studies that suggested
this may result from greater aggressiveness of the tumour and/or delayed treatment
(Bordas et al, 2007; Brekelmans et al, 1995; Eriksson et al, 2013; McKenzie et al, 2012;
Mook et al, 2011; Nagtegaal et al, 2011; Rayson et al, 2011; Shen et al, 2005). How-
ever, our study is unique in demonstrating that this differential is consistent across
different geographic categories. This has important implications for our understand-
ing of the effectiveness of the population-based screening program. That there was
no differential suggests that the composition of interval-detected cancers was similar
across Queensland, including, presumably, similar proportions of “missed” and “new
fast growing” breast cancers (Brekelmans et al, 1996; Gilliland et al, 2000; Hofvind
et al, 2008; Porter et al, 1999). Typically, women in rural, regional and disadvantaged
areas of Queensland are screened using mobile screening vans, relocatable and satel-
lite services that are designed to remove many of the barriers associated with distance
(Youlden et al, 2009). Therefore, our finding of no substantive geographic survival
differential in the ratio of interval-detected to screen-detected cancers is suggestive
evidence for the effectiveness and importance of these mobile screening services. This
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is further supported by the results of no substantive spatial random inequality, which
means it is unlikely there are other unknown sources of spatial variation that could
dismiss this hypothesis. As the disease map in Fig. 4.1 was produced by evenly
dividing the spatial variation into quintiles, the substantive differences between the
observed trend and the Queensland average must be assessed by the use of test statis-
tics. Therefore, although the disease map for Model 1 in Fig. 4.1 suggests that the
SLA-specific relative excess risk varies, based on the test statistics there was no sub-
stantive evidence of unmeasured spatial varying relative survival among the study
cohort.
The analyses reported in this paper would have ideally incorporated information
about the types of interval-detected cancer. Those breast cancers missed during the
previous screen but detected retrospectively are not true interval cancers (Brekelmans
et al, 1995, 1996; Porter et al, 1999) but are included in our results. Having this
information would have enabled us to investigate the impact of excluding these non-
interval cancers on the observed results. However, since detailed information on the
type of interval-detected cancers was not provided by BreastScreen Queensland, it
was not possible to investigate this issue in more detail.
The substantive higher relative survival among patients with younger age, non-Indigenous,
localised tumour and not in the labour force was consistent with previous population-
based studies using a variety of methods for all women diagnosed with breast cancer in
Queensland (Cramb et al, 2012; Dasgupta et al, 2012; Hsieh et al, 2014). These find-
ings suggest that the impact of these variables on relative survival is similar regardless
of participation in the BSQ screening program. There is no evidence of substantive
interaction between the detection method and the patient’s demographic and clinical
properties, which suggests that the relative survival differentials within these patient
characteristics were similar for both screen- and interval-detected patients, regardless
of the survival difference between the methods of detection.
The lack of evidence that a women’s marital status at time of diagnosis and socio-
economic status had any substantive influence on survival outcomes for women par-
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ticipating in the BSQ screening program contrasts with previous population-based
studies looking at all women diagnosed with cancer (Cramb et al, 2012; Dasgupta
et al, 2012; Hsieh et al, 2014). Those studies reported that married women, and/or
those living in more aﬄuent areas, had better survival. While the smaller sized co-
hort in our study may have limited the ability to detect differences, studies from
England have also shown that the variation in survival by socio-economic status is
lower for screen-detected breast cancers compared to breast cancers detected among
non-screening program participants (Davies et al, 2013; McKenzie et al, 2012). Thus,
our results suggest that by participating in the BSQ screening program, the impact
of socio-economic status on survival outcomes may be substantially reduced.
By utilizing the flexibility of the Bayesian framework, this study was able to readily
examine the varying survival relationship between participants of the breast screen
program and the large number of small geographic location (the 478 SLA) in greater
detail, including whether these small geographic areas impacted the survival differ-
ential between screen-detected and interval-detected breast cancers. This study also
contributes to the process of disseminating stochastic spatial modelling techniques
used in the epidemiological field to an interdisciplinary audience. To the best of our
knowledge no other studies have used this approach, and this methodology could also
be applied to other non-spatial characteristics to assess whether the differential is
consistent across small geographic areas. The inability to differentiate between fast
growing interval cancers and those that were missed in the previous screening episode
does limit our interpretation of the findings (Brekelmans et al, 1996; Hofvind et al,
2008).
4.6 Conclusion
The lower survival experienced by women whose breast cancer is detected between
their screening episode highlights the importance of detecting and treating these in-
terval cancers earlier. Less than 20% of these cancers can be attributable to faults
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with the screening process (Australian Institute of Health and Welfare, 2013; Ka-
vanagh et al, 1999), suggesting that most of these cancers develop between scheduled
screening episodes. This highlights the importance of raising self-awareness among
women through breast self-examination so that they can recognize any changes that
occur between scheduled screening episodes and seek further medical advice quickly
(Dahlui et al, 2011; Ma et al, 2012; Nelson, 2013; Wilke et al, 2009). While the lack of
geographical variation in this survival differential is encouraging in terms of minimal
health inequalities, the magnitude of the survival differential highlights the need for
any awareness programs to be geographically widespread.

CHAPTER 5
Geographic Variation in the Intended Choice
of Adjuvant Treatments for Women
Diagnosed with Screen-Detected Breast
Cancer in Queensland
Preamble
This Chapter addressed Objectives 2 and 4 in Section 1.2 by the determination and
quantification of spatial inequalities in intended adjuvant (radio-, chemo- and hor-
monal) therapy usage among women with screen-detected breast cancer in Queens-
land, Australia. In this case, the multiple treatments were considered as the primary
outcome variable and were analysed with a Bayesian shared spatial component model.
90 Chapter 5. Geographic Variation in the Intended Choice of
Adjuvant Treatments for Women Diagnosed with Screen-Detected Breast
Cancer in Queensland
This contributes to the identification of common (and treatment-specific) spatial pat-
terns across geographic regions and patient demographic and clinical characteristics
in the intended use of adjuvant therapies (both separately and in combination). As
a contribution to this thesis, the Chapter also compares several alternative model
formulations to the proposed model structure.
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5.1 Abstract
Although early diagnosis and improved treatment can reduce breast cancer mor-
tality, there still appears to be a geographic differential in patient outcomes. This
study aims to determine and quantify spatial inequalities in intended adjuvant (radio-,
chemo- and hormonal) therapy usage among women with screen-detected breast can-
cer in Queensland, Australia. Linked population-based datasets from BreastScreen
Queensland and the Queensland Cancer Registry during 1997−2008 for women aged
40− 89 years were used. We adopted a Bayesian shared spatial component model to
evaluate the relative intended use of each adjuvant therapy across 478 areas as well
as common spatial patterns between treatments. Women living closer to a cancer
treatment facility were more likely to intend to use adjuvant therapy. This was par-
ticularly marked for radiotherapy when travel time to the closest radiation facility
was 4+ hours (OR=0.41, 95% CrI: [0.23, 0.74]) compared to <1 hour. The shared
spatial effect increased towards the centres with concentrations of radiotherapy fa-
cilities, in north-east (Townsville) and south-east (Brisbane) regions of Queensland.
Moreover, the presence of residual shared spatial effects indicates that there are other
unmeasured geographical barriers influencing women’s treatment choices. This high-
lights the need to identify the additional barriers that impact on treatment intentions
among women diagnosed with screen-detected breast cancer, particularly for those
women living further away from cancer treatment centers.
5.2 Background
Breast cancer is the most commonly diagnosed cancer among Australian women and
the second most common cause of cancer-related death for Australian females (Aus-
tralian Institute of Health and Welfare and Australasian Association of Cancer Reg-
istries, 2012; Youlden et al, 2009).
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Improved survival outcomes over time among women diagnosed with breast cancer
have been observed across the developed world, due to a combination of earlier diag-
nosis through mammography screening along with improved treatment (Australian
Institute of Health and Welfare and Australasian Association of Cancer Registries,
2012; Australian Institute of Health and Welfare and Cancer Australia, 2012; Berry
et al, 2005, 2006; Early Breast Cancer Trialists’ Collaborative Group, 2005; Youlden
et al, 2009). However, patient care pathways can vary substantially to those recom-
mended by clinical practice guidelines (Brooks et al, 2012; Fitch et al, 2003; Hall et al,
2004; Koshy et al, 2005; Schootman and Aft, 2001).
Typically, breast cancer treatment involves surgery, with the option of one or more
types of adjuvant therapy. Adjuvant therapy is additional treatment that is com-
monly given before or after surgery for breast cancer and is designed to improve
disease-specific symptoms and overall survival. Adjuvant therapy includes radiother-
apy, which is targeted at specific tissue/s, or chemotherapy and hormonal therapy
which are systemic treatments that impact on the whole body.
Clinical practice guidelines for the treatment of breast cancer depend on a number
of factors including histological type, tumour stage, age of the patient, the informed
decisions of the medical staff and the personal decisions of the patient herself (Fitch
et al, 2003; Hegney et al, 2005; Thompson et al, 2008). These last two components
mean that even if two women have the same clinical and demographic characteristics,
their final treatment strategy may be different.
One potential measure of distinction between women is where they live, and hence
the relative access to different types of adjuvant treatment. In Queensland, until
2011, radiotherapy was only available in the south-east corner, where the majority
of the population lives, and Townsville in the north-east. Since radiation treatment
requires daily administration across consecutive weeks, longer distances to these cen-
ters can form a utilization barrier. In contrast, chemotherapy can be administrated
at more locations, including general practices and hospital outpatient facilities, while
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hormonal therapy can be administrated via ongoing self-administered oral medication
or one off surgical treatment.
A number of international studies have demonstrated that the use of various types
of adjuvant therapies varies by rural location (Martinez et al, 2012a; Nattinger et al,
2001; Schootman and Aft, 2001), age (Martinez et al, 2012b), race (Bhargava and Du,
2009; Li et al, 2003) and access to services (Athas et al, 2000; Bhargava and Du, 2009).
However what is not understood is how these variables impact on women’s selection
of different types of adjuvant treatment, and indeed whether a woman chooses to have
any adjuvant therapy at all. Indeed, there may be some common spatially-structured
underlying factors that influence a woman’s decision to have adjuvant therapy that
represents possible unmeasured influences including travel or financial burden and
stress.
Following this hypothesis, we can use shared component models within a Bayesian
framework (Downing et al, 2008; Held et al, 2005) to quantify and examine the spa-
tial variations of the unmeasured shared component across the state. The Bayesian
shared component model has been shown to be a useful and valuable extension over
individual analysis (Kazembe et al, 2009) in a spatial setting. Because information
is borrowed between responses, the model is able to provide more statistically robust
estimates of spatial inequalities in the choice of adjuvant therapies, even when num-
bers of people diagnosed in specific geographical area are small. Using the clinical
and recommended treatment data from the publicly funded and population-based
BreastScreen Queensland (BSQ) in Australia, a Bayesian shared spatial component
model (Downing et al, 2008; Held et al, 2005; Kazembe et al, 2009) was adopted for
the multiple treatment responses. The aim was to identify common (and treatment-
specific) spatial patterns across geographic areas and patients’ demographic and clin-
ical characteristics in the intended use of adjuvant therapies (both separately and in
combination) for women with screen-detected breast cancer.
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5.3 Materials and Methods
5.3.1 Study cohort
The state of Queensland in Australia hosts more than four million people in an area
of nearly two million square kilometres, spreading from the populous southeast cor-
ner and coastal areas to remote outback regions. The study cohort was obtained by
linking data from BSQ and the Queensland Cancer Registry (QCR). This includes
women who were diagnosed with invasive breast cancer by BSQmammography screen-
ing from 1 January 1997 to 31 December 2007 and followed-up to 31 December 2008.
While specific measurements of data quality for BSQ and QCR data are not available,
both data collections have systematic validation processes in place to ensure that the
collection and recording of information is as accurate as possible.
BSQ is the only population-based public health breast cancer screening service in
Queensland that provides free 2-yearly screening mammograms to women aged 40
and over. BSQ is part of the BreastScreen Australia Program established in 1991 by
the Australian Government and the State and Territory governments. In 2007, over
202,000 women from all age were screened by BSQ with a participation rate for the
50− 69 target age group of 56% over the two year period 2006− 2007 (Youlden et al,
2009). Approximately 29% of invasive breast cancers were diagnosed by screening
throughout the study period 1997− 2007.
Data linkage was undertaken by BSQ staff using a deterministic matching process
with over 90% matching completeness. Ethics approval was granted by the Human
Research Ethics Committee of Queensland University of Technology (approval num-
ber: 1100000036). Access to the data was provided by Queensland Health under the
Public Health Act 2005 (RD003676). Since only de-identified data was provided by
the data custodians and subsequently used in these analyses, no patient consent was
obtained.
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As treatment information was only available for breast cancers diagnosed by screening,
the analysis included only BSQ mammographic screen detected invasive breast cancer
(ICD-O-3 code = C50) for women diagnosed at ages 40 to 89 years with information
about the intended treatment strategy agreed on by the patient and doctor. There
was no specific exclusion criteria in relation to women diagnosed with multiple invasive
breast cancers, of whom there were less than 0.1% in the cohort. Cases were excluded
when age at diagnosis, geographic location or treatment information was missing, if
cancer was identified at autopsy or by death certificate only, or if subjects had a
survival time of less than one day.
5.3.2 Data description
The primary outcome variable included in the analysis was the intended use of breast
cancer adjuvant therapy, being one or more of radiotherapy, chemotherapy and hor-
monal therapy. No information was available regarding treatment uptake or comple-
tion. The information about intended treatment is routinely collected within BSQ,
unlike most other BreastScreen services in other Australian states. For patients who
chose to be treated in a public facility, the treatment information was collected by
BSQ staff via access to the decisions and recommendations made at multi-disciplinary
team (MDT) meetings through Queensland Oncology Online (QOOL) or by consult-
ing breast-care nurses in the relevant departments. For BSQ patients who elected
to be treated at a private treatment facility, a request was made from the treating
surgeon for the intended adjuvant therapy details.
A total of 6,357 women diagnosed with screen-detected invasive cancers with informa-
tion about the intended treatment procedure (including women who chose to not have
any treatment) were included in the study. Of these women, 5,251 of them intended to
receive at least one type of adjuvant therapy and more than a third (37.9%) intended
to use both radiotherapy and hormonal therapy, making this the most common choice
(Table 5.1). A further 11.6% (n=607) intended to use all 3 adjuvant therapies.
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Demographic variables extracted were age group at diagnosis (40−49, 50−59, 60−69
and 70 − 89 years), Indigenous status (Indigenous, non-Indigenous and unknown),
marital status at time of diagnosis (married, never married, widowed/divorced/separated
or unknown) and occupation (blue collar, white collar, professional, not in the labour
force and unknown). Clinical variables were tumour stage at diagnosis (localised,
advanced or unknown), type of invasive tumour (invasive ductal, tubular, lobular
classical, other and unknown), whether the tumour was diagnosed at the woman’s
first mammographic screening episode (yes/no), and intended surgical procedure, ir-
respective of adjuvant therapy, (classified into breast-conserving surgery, mastectomy,
no surgery or unknown).
Patients’ demographic and geographic information, along with tumour stage, were
sourced from QCR, while all other clinical information, intended treatment, and
screening information were sourced from BSQ. Both marital status and occupation
are sourced through the QCR via hospital notifications and death certificates. No
additional data cleaning or verification for these variables is conducted within the
QCR.
Geographic location information was based on the 2006 version of the Australian
Standard Geographical Classification using Statistical Local Areas (SLAs), of which
478 cover Queensland without gap or overlap. SLAs are spatial entities that are
deemed to be relatively homogeneous in terms of the socio-economic characteristics
of the populations they contain. SLAs are often based on the incorporated bodies
of local governments and councils, which are responsible for infrastructure and ser-
vice provision at the local and regional level. Each SLA was classified according to
socio-economic status (SES) as measured by the Index of Relative Socio-economic
Advantage and Disadvantage (IRSAD) (Australian Bureau of Statistics, 2008). This
index was categorized into quintiles, with 1 representing most disadvantaged to 5
being most advantaged. A cancer-specific remoteness index was used (TRAvel to
Cancer Treatment (TRACT)) which measured the road travelling time between each
women’s residential SLA to the closest radiation facility in 2006 using Geographical
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Information System software and a street network database (Baade et al, 2011a).
The TRACT was categorised into <1, 1-<2, 2-<4, 4-<6 and 6 or more hours. While
there was some change in this measure over the study period reflecting new facilities
being commissioned, it was decided to base distances on the 2006 data for consistency
with the area-level SES and to reduce model complexity. Sensitivity analyses (not
published) using different year selections showed little impact on the final results.
The observed number of screen-detected invasive cases was mapped to the 2006 SLA
boundaries based on suburb and postcode of residence (see Figure 5.1). There are 61
SLAs without patients.
5.3.3 Statistical model
For a Bayesian shared spatial component model, suppose Yijk is the indicator (0/1)
of treatment k, k = 1 (radiotherapy), 2 (chemotherapy), 3 (hormonal therapy) for
woman j in SLA i, i = 1, 2, . . . , 478, that follows a Bernoulli distribution, as:
Yijk ∼ Bernoulli(pijk), (5.1)
where pijk is the probability of the j
th women in SLA i having treatment k and is
described with a logistic regression model as:
logit(pijk) = αk + βkXij + uik + ηik, (5.2)
where αk is the treatment-specific intercept; βk is the vector of regression coefficients
for each treatment (k) corresponding to the predictor variables Xij; and uik and ηik
represent spatially unstructured and structured random effects respectively, for the
ith SLA and treatment k.
In this shared component model, the spatially structured random effects (ηik) are
partitioned into components which are shared and specific for each treatment to
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identify spatial patterns in the residual variation as:
ηi1 = δ1φi + si1
ηi2 = δ2φi + si2
ηi3 = δ3φi + si3, (5.3)
where the terms δk are the weight, or scaling parameters, that quantify the relative
contribution of the common spatial component φi in each treatment (Ancelet et al,
2012); φi the shared spatial component is a latent variable with spatial structure
that is shared among all adjuvant therapies and sik are the treatment-specific spatial
components. To ensure identifiability, a standard constraint of requiring the product
of δk to be equal to 1 is applied (Ancelet et al, 2012; Vilas et al, 2011).
The prior distribution for the intercepts αk and regression coefficients βk were assigned
a zero mean Gaussian distribution with a Gamma(0.005, 0.5) hyperprior distribution,
parameterized in terms of the shape and inverse scale parameters, for the precision
(=1/variance). These flat prior distributions were chosen with no knowledge about
the relationship between the response and predictors. The unstructured random
effects uik were described by a multivariate Gaussian prior distribution (Downing
et al, 2008) with a precision matrix Σ ∼ Wishart(Q, 5) where Q is a 3 × 3 iden-
tity matrix to allow for correlation among the treatments. The logarithms of the
weights were assigned Gaussian(0, 5.9) (precision=5.9) prior distributions (Knorr-
Held and Best, 2001), and following the Besag et al (1991) framework the shared and
treatment-specific spatially structured components were assigned intrinsic conditional
autoregressive (CAR) prior distributions with precision hyperprior distributions of
Gamma(0.5, 0.005) (Osnas et al, 2009; Rodeiro and Lawson, 2006). A sum-to-zero
constraint was imposed on the random effects with intrinsic CAR prior distributions
and the neighbours of SLA i were defined as the ones sharing a common geographical
boundary.
The odds ratio is the odds of a particular factor compared with the odds of intended
adjuvant therapies, with a larger odds ratio indicating the factor associated with
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higher odds of choosing particular adjuvant therapies. The shared effect odds ratio
can be interpreted as the relative strength of the unobserved spatially related factors
associated with a breast cancer patient’s choice of adjuvant therapy. These odds
ratios can be presented as a thematic map to highlight the relationship between
shared treatment effects and geographic location. A high shared effect odds ratio
exp(φi) indicates that women living in SLA i are more likely to access treatment
facilities.
5.3.4 Bayesian inference
Bayesian inference of the shared spatial component model was performed using Markov
chain Monte Carlo (MCMC) algorithms as implemented in WinBUGS v1.4.3 (Lunn
et al, 2000) and interfaced with R v2.14.1 (R Development Core Team, 2011). The
full cohort Bayesian shared spatial component model was run with 2 chains for 17,500
iterations: 10,000 of the iterations were discarded as burn-in and a thinning factor
of three was adopted, so that 5,000 iterations were retained for inference. The sub-
cohort models were run with 37,500 iterations and a thinning factor of 3 to facilitate
convergence for the smaller data samples, with the first 30,000 iterations discarded as
burn-in. Model convergence was examined using a range of diagnostics including the
Gelman-Rubin statistics (Gelman and Rubin, 1992), trace plots, density plots and
autocorrelation plots.
5.3.5 Model evaluation
The Deviance Information Criterion (DIC) was used to determine how well a model
fits the data, with smaller values indicating better model fit (Gelman et al, 2004). The
DIC is calculated as the sum of the posterior mean of the deviance and an estimate
of the effective number of parameters (pD), where smaller pD values indicate less
complexity in the fitted model. Posterior predictive checks (PPC) (Gelman et al,
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2004) were used to examine the adequacy of the model predictions compared with
the observed data. These determine the percentage of the observed data within the
95% credible interval of the corresponding posterior predictive distribution. For a
given model, the posterior predictive distribution was formed by simulating data
from the likelihood, for a given individual, based on a random selection of posterior
samples. The estimated posterior odds ratio (here, posterior medians) was considered
to be substantively different from the baseline if the 95% credible interval (CrI) did
not include unity (Puigpino´s-Riera et al, 2011; Wakefield, 2007; Wu et al, 2010).
Figures of SLA level QLD maps, with a set of common fixed cut-off values (<0.77,
0.91, 1.10, 1.30, 1.30+) (Cramb et al, 2011a), were used to display the spatial odds
ratio (exp(φi)) shared by the three adjuvant therapies to assess the shared component
effect. In addition, maps of the treatment-specific spatial effects (exp(u + s)) were
also generated to assess the spatial variation in each adjuvant therapy. Only the
sum of spatially structured s and unstructured random effect u is well-identified by
the data (Eberly and Carlin, 2000), so it is common to map the sum of the spatially
structured and unstructured random effects in shared component models (e.g. Earnest
et al (2010)). Maps of posterior probabilities that the spatial odds ratios exceeded
unity were generated using the threshold rule proposed by Richardson et al (2004) to
identify SLA with probability higher than 0.8 (respectively lower than 0.2), which can
be considered as having an excess odds ratio (respectively a low odds ratio) with little
uncertainty. The relative weight or influence of the common spatial effect between two
therapies was measured as the ratio of two corresponding weights, such as δ2/δ1, δ3/δ1
and δ3/δ2, where δ1 is the weight for radiotherapy, δ2 is the weight for chemotherapy
and δ3 is the weight for hormonal therapy.
The box plots are computed using the posterior samples for the respective parameters
and reflect the general patterns in the estimated posterior median shared spatial
effect across the geographic category of travel time to cancer care facilities and socio-
economic status. These plots are compared with the Queensland average (i.e. above
or below the vertical red line of QLD average = 1) within each geographic category, so
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should not be compared against one another. The box plots are in log-scale and the
rectangular box within the box plot contains 50% of the estimates. Two percentage
columns for each geographic category were also included in the box plots. The left
column represents the percentage of SLAs with less than 20% posterior probabilities
that the spatial odds ratios exceeded unity. The right column presents the percentage
of SLAs with more than 80% probabilities that the spatial odds ratios exceeded unity.
Finally, two other assessments of model robustness were made. First, the sensitivity
of the model to the choice of priors was evaluated by assessing the change in the
posterior parameter estimates to changes in the hyperparameters of selected prior
distributions. Secondly, the model itself was challenged by proposing a range of
alterations to the baseline model and evaluating resultant changes in the posterior
parameter estimates with corresponding 95% CrI and model DIC values.
5.3.6 Model formulation
Seven alternative models were created based on the baseline Bayesian shared spatial
component model (A0) as described by Equation 5.2 and 5.3. The full cohort data
were used to examine each of these alternative models as listed below:
A1: The spatially unstructured random effect u for each adjuvant therapy was as-
signed an independent Gaussian prior distribution.
A2: A second shared component was added and shared between radiotherapy and
chemotherapy.
A3: A second shared component was added and shared between radiotherapy and
hormonal therapy.
A4: A second shared component was added and shared between chemotherapy and
hormonal therapy.
A5: The spatially unstructured random effect u was removed.
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A6: The spatially structured random effect s was removed.
A7: The approximates non-informative or flat priors of zero mean Gaussian distribu-
tion with a constant low precision of 0.0001 was assigned to the intercept (αk)
and regression coefficients (βk).
5.4 Results
In this section, the results of fitting the baseline model A0 and the corresponding
inferences are described in detail. The results of the other models A1 to A7 are then
described and compared to the baseline results.
5.4.1 Baseline Model Results
The Bayesian shared spatial component model (previously described) leads to differ-
ent posterior estimations of the covariates effect depending on the intended treatment
(Table 5.2). For all treatments, there was a suggested trend of decreased use with in-
creasing travel time. This was particularly marked for radiotherapy when travel time
to the closest radiation facility was above 4 hours compared to less than one hour
(OR=0.41, 95% CrI: [0.23,0.74]). Intention to use radiotherapy or hormone therapy
was similar across socio-economic status, while the suggestion of decreasing intention
to use chemotherapy in more disadvantaged areas was compromised by imprecise es-
timates with wide credible intervals. As age increased there was clear evidence of de-
creased use of chemotherapy but increased use of hormonal therapy. There appeared
to be less use of radiotherapy with increasing age, but only the oldest age group had
substantively lower odds (Table 5.2). Women diagnosed with advanced stage breast
cancer were more likely to intend to undertake radiotherapy and chemotherapy and
less likely to choose hormonal therapy. For women with an unknown stage tumour,
the intention to use chemotherapy was substantively higher than for localised tumour
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patients. Members of the study cohort diagnosed with breast cancer in their first at-
tendance at mammography screening were generally substantively less likely to select
any of the adjuvant therapies than women who had attended previous mammograms
before their cancer diagnosis. The intended choice of surgical procedure had an ob-
vious influence on the choice of adjuvant therapy, where patients choosing to have
mastectomy were substantively less likely to have radiotherapy or hormonal therapy
before or after the surgery, but were substantively more likely to have chemotherapy.
Table 5.2 also shows the estimated posterior median value (and its uncertainty) of
the relative influence, or level of importance, of the shared component effect between
adjuvant therapies. The shared effect had the greatest relative influence (highest level
of importance) to both radiotherapy and hormonal therapy, and had least influence
(lowest level of importance) on chemotherapy.
There was a pattern of increasing shared component effect toward regions of con-
centrated radiation facilities in the north-east (Townsville) and south-east (Brisbane)
of Queensland (Figure 5.2 (a)). Plots of the posterior probability of excess shared
effect are shown in Figure 5.3. From Figure 5.4, there is an indication of geographic
differences in the posterior shared component effect. Not only do many of the SLAs
within less than 1 hours travel time have larger median values, but many of these have
probabilities above 80% of genuinely being above the Queensland average. Likewise,
the lower median values for many of the SLAs in areas with more than six hours
of travel time was also supported by the posterior probabilities suggesting the ma-
jority have values below the Queensland average. Similarly, for the socio-economic
status there is an indication of more aﬄuent regions having higher values of the
shared component effect than the Queensland average. This was also demonstrated
by the SLA percentage columns as more aﬄuent areas had much higher percentage
of SLA in the right hand column than the left hand column. There was no obvious
radiotherapy-specific and hormonal therapy spatial effect pattern across Queensland
as shown in both Figures 5.5 and 5.6 and both Figures 5.9 and 5.10 respectively.
The chemotherapy-specific spatial effect plots (Figure 5.7 and 5.8) shows that regions
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with higher spatial variation appear to be around south-east of Queensland. Since
the 95% credible intervals include zero under the baseline model A0, it can be argued
that there is no substantive correlation between adjuvant therapies described by the
treatment-specific unstructured random effects (see Supplementary Table 5.4).
The analysis was repeated by cohort in each broad age group at diagnosis and tumour
stage categories to further examine the variation in the shared component. The
analysis of each separate cohort was not adjusted for the corresponding predictor
variable; for instance, the model analysis of the 40 − 49 age group cohort does not
adjust for age at diagnosis variable but is adjusted for all other variables specified
in the Data description section above. When the study cohort was analysed by
age group and tumour stage at diagnosis (Table 5.3), radiotherapy and hormonal
therapy remained the most influential treatments on the shared component in the
50 − 59 years age group and chemotherapy was still the least influential. In the
70− 89 years age group, all adjuvant therapies were equally influential on the shared
component. The analysis by cohort of localised tumour stage at diagnosis showed a
relative weight pattern similar to that found for the 50− 59 year old cohort, whereas
the shared component was equally influenced by any of the studied adjuvant therapies
in advanced tumour patients.
The trends for the shared component effect in each age group and tumour stage (see
Supplementary Figures 5.11–5.16) were all similar to the map shown in Figure 5.2
which has an increasing effect towards the north-east (Townsville) and south-east
(Brisbane) regions of Queensland. In general, both road travelling time and socio-
economic status box plots for the posterior shared component effect proportion in
each sub-cohort model (age group and tumour stage categories) have patterns similar
to the plots in Figure 5.4 (see Supplementary Figures 5.17 and 5.18).
With respect to model checking, the model converged with Gelman-Rubin statistics
very close to unity for all parameters. Acceptable convergence was further supported
by the trace and autocorrelation plots. In addition, the posterior predictive checks
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(PPC) for the baseline Bayesian model also gave values very close to unity (Table
5.2), which confirmed that the model fitted the data adequately.
Sensitivity analysis was performed to evaluate the choice of the priors in the model.
The precision parameters of α, β, s and φ were given Gamma(0.5, 0.5) and Gamma(0.5, 0.05)
hyperprior distributions, and a less informative normal prior for log(δ), with a pre-
cision of 2.9, was also considered. The results were insensitive to the prior choice
for all fixed effects, shared spatial effects, and treatment-specific effects for all ad-
juvant therapies, except for the hormonal therapy whose treatment-specific spatial
effect was slightly sensitive to the choice of precision. This indicates that there is
sufficient information in the data sources to learn about the fixed effects β, shared
spatial component φ and the treatment-specific spatial components s. The weight
δ for all the adjuvant therapies is insensitive to the less informative δ prior (see
Supplementary Figure 5.19). However, the weight for hormonal therapy showed some
sensitivity to the hyperprior choice of the treatment-specific spatial effects s. The less
informative precision distribution of Gamma(0.5, 0.5) for s caused the 95% CrI of the
relative weight ratio between hormonal therapy and chemotherapy (δ3/δ2) to change
from substantive to not substantive. The more informative precision prior will force
the s to be close to zero, which suggests that by excluding s, the hormonal therapy
treatment-specific spatial variation was then forced into the shared component.
Table 5.1: The count and percentage for the adjuvant therapy combination among
the study cohort.
Type of treatment Na (pct)
Radiotherapy only 800 (15.241%)
Chemotherapy only 205 (3.90%)
Hormonal therapy only 899 (17.12%)
Radiotherapy and chemotherapy 511 (9.73%)
Radiotherapy and hormonal therapy 1990 (37.90%)
Chemotherapy and hormonal therapy 239 (4.55%)
All three therapies 607 (11.56%)
aNumber of patients.
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Table 5.2: Estimated posterior odds ratios of patient characteristics associated with
the intended adjuvant therapies, and relative weights between therapies.
Median posterior odds ratios [95% CrIa]
Factors N Radiotherapy Chemotherapy Hormonal Therapy
Road travelling time (TRACT)
< 1 hour 4514 1.00 1.00 1.00
1− < 2 hours 502 0.88 [0.56, 1.39] 0.74 [0.46, 1.19] 0.94 [0.68, 1.31]
2− < 4 hours 750 0.66 [0.42, 1.04] 0.91 [0.58, 1.45] 0.97 [0.70, 1.35]
4− < 6 hours 317 0.41 [0.23, 0.74] 0.44 [0.25, 0.81] 0.74 [0.49, 1.08]
6 or more hours 274 0.41 [0.24, 0.73] 0.60 [0.34, 1.07] 0.71 [0.48, 1.04]
Socio-economic status (IRSAD)
Quintile 1 Most disadvantaged 817 0.94 [0.65, 1.36] 0.73 [0.50, 1.04] 1.01 [0.77, 1.32]
Quintile 2 1458 0.80 [0.56, 1.12] 0.86 [0.62, 1.19] 0.91 [0.71, 1.15]
Quintile 3 1762 1.03 [0.76, 1.39] 0.91 [0.69, 1.20] 1.01 [0.81, 1.26]
Quintile 4 1539 0.92 [0.68, 1.24] 0.93 [0.70, 1.22] 1.03 [0.83, 1.28]
Quintile 5 Most advantaged 781 1.00 1.00 1.00
Age at diagnosis (years)
40-49 933 1.07 [0.85, 1.34] 1.85 [1.51, 2.27] 0.83 [0.71, 0.98]
50-59 2064 1.00 1.00 1.00
60-69 2074 0.86 [0.72, 1.03] 0.50 [0.42, 0.60] 1.20 [1.06, 1.37]
70-89 1225 0.36 [0.29, 0.44] 0.12 [0.09, 0.16] 1.39 [1.18, 1.63]
Indigenous Status
Non-Indigenous 5467 1.00 1.00 1.00
Indigenous 63 1.66 [0.83, 3.49] 1.16 [0.61, 2.17] 1.33 [0.89, 2.04]
Indigenous Unknown 766 0.87 [0.69, 1.10] 0.40 [0.30, 0.53] 1.06 [0.89, 1.26]
Marital Status
Married 4150 1.00 1.00 1.00
Never Married 305 0.78 [0.57, 1.09] 0.79 [0.56, 1.10] 0.85 [0.68, 1.08]
Widowed/Divorced/Separated 1665 0.83 [0.71, 0.99] 0.95 [0.80, 1.14] 1.05 [0.92, 1.19]
Marital Unknown 176 0.91 [0.59, 1.44] 1.05 [0.62, 1.73] 0.91 [0.67, 1.24]
Tumour Stage
Localised (Stage I) 4081 1.00 1.00 1.00
Advanced (Stage II, III, IV) 2139 2.43 [2.03, 2.90] 11.21 [9.60, 13.05] 0.87 [0.77, 0.97]
Stage Unknown 76 0.59 [0.32, 1.08] 2.83 [1.42, 5.42] 1.24 [0.84, 1.88]
Occupation
Blue collar 245 1.71 [1.18, 2.48] 1.03 [0.71, 1.48] 0.98 [0.76, 1.27]
White collar 907 1.48 [1.18, 1.87] 1.19 [0.96, 1.47] 1.11 [0.95, 1.31]
Professional 1061 1.49 [1.21, 1.84] 1.38 [1.13, 1.71] 1.09 [0.94, 1.28]
Not in the labour force 2631 1.00 1.00 1.00
Unknown 1452 1.28 [1.06, 1.55] 1.05 [0.85, 1.29] 1.27 [1.10, 1.47]
Invasive tumour type
Invasive Ductal 4074 1.00 1.00 1.00
Tubular 167 0.48 [0.33, 0.71] 0.27 [0.12, 0.55] 0.91 [0.68, 1.21]
Lobular Classical 506 0.95 [0.74, 1.22] 0.73 [0.56, 0.95] 1.72 [1.40, 2.12]
Other 434 0.73 [0.56, 0.96] 0.77 [0.57, 1.03] 0.94 [0.78, 1.15]
Unknown 1115 0.81 [0.67, 0.98] 0.69 [0.57, 0.84] 0.70 [0.61, 0.80]
First screen diagnosed
Yes 1508 0.81 [0.69, 0.96] 0.79 [0.66, 0.94] 0.72 [0.63, 0.82]
No 4788 1.00 1.00 1.00
Surgery
Breast-conserving surgery 4255 1.00 1.00 1.00
Mastectomy 2009 0.03 [0.02, 0.03] 1.63 [1.40, 1.91] 0.86 [0.76, 0.98]
No surgery 15 0.15 [0.04, 0.44] 2.26 [0.76, 6.61] 0.86 [0.49, 1.44]
Unknown 17 0.18 [0.06, 0.47] 1.70 [0.64, 4.71] 1.10 [0.66, 1.89]
Relative weight of shared component
Radiotherapy 1.00 — —
Chemotherapy 0.57 [0.36, 0.84] 1.00 —
Hormonal therapy 0.90 [0.68, 1.17] 1.59 [1.09, 2.47] 1.00
PPC 0.9993
aAbbreviations: CrI=Credible interval, N=Number of patients, TRACT=Travel to cancer treat-
ment, IRSAD=Index of relative socio-economic advantage and disadvantage, PPC=Posterior pre-
dictive check.
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Table 5.3: Relative weight of shared component between adjuvant therapies for sep-
arate cohort model adjusted for all other predictor variables.
Median posterior relative weights [95% CrIa]
Radiotherapy Chemotherapy Hormonal Therapy
At age 40-49
Radiotherapy 1.00 — —
Chemotherapy 0.57 [0.31, 0.94] 1.00 —
Hormonal therapy 0.86 [0.57, 1.29] 1.51 [0.92, 2.66] 1.00
At age 50-59
Radiotherapy 1.00 — —
Chemotherapy 0.40 [0.23, 0.65] 1.00 —
Hormonal therapy 0.87 [0.63, 1.19] 2.16 [1.36, 3.63] 1.00
At age 60-69
Radiotherapy 1.00 — —
Chemotherapy 0.58 [0.31, 0.95] 1.00 —
Hormonal therapy 0.81 [0.58, 1.11] 1.39 [0.84, 2.62] 1.00
At age 70-89
Radiotherapy 1.00 — —
Chemotherapy 0.92 [0.48, 1.55] 1.00 —
Hormonal therapy 0.74 [0.50, 1.08] 0.80 [0.48, 1.55] 1.00
Localised tumour
Radiotherapy 1.00 — —
Chemotherapy 0.34 [0.18, 0.58] 1.00 —
Hormonal therapy 0.81 [0.61, 1.05] 2.42 [1.39, 4.47] 1.00
Advanced tumour
Radiotherapy 1.00 — —
Chemotherapy 0.86 [0.63, 1.18] 1.00 —
Hormonal therapy 0.86 [0.61, 1.17] 0.99 [0.72, 1.41] 1.00
aCredible interval.
5.4.2 Other Model Results
All the alternative models (A1–A7) results were assessed in the same way as the base-
line model A0 to facilitate comparison (see Supplementary Tables 5.6–5.12). Posterior
estimates of the covariate effects for each intended treatment were mostly similar to
the baseline model A0. All of these alternative models (A1–A7) had similar substan-
tial posterior estimates for part of the variable of interest compared to the baseline
model A0, such as socio-economic status, age at diagnosis, Indigenous status, marital
status, tumour stage, occupation, invasive tumour type, first screen diagnosed and
the intended surgical procedure. Here we describe the key differences between the
alternative model results compared to the baseline model A0.
Compared with the baseline model A0, fitting model A1 (assigning independent Gaus-
sian distribution to the unstructured random effects ‘u’) resulted in no substantial
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Figure 5.1: Observed number of screen-detected invasive breast cancer at each SLA
across QLD, 1997–2007.
change to the posterior estimate of the fixed effects, the relative weight between treat-
ments, or the shared and treatment-specific spatial components (see Supplementary
Table 5.6). The key difference was that this model had poorer fit to the data with a
substantively larger DIC value compared to the baseline model A0 (see Supplemen-
tary Table 5.5).
Of the three alternative models A2, A3 and A4 with a second shared component
allocated to two out of three adjuvant therapies, all had similar posterior estimates
to the baseline model A0, with the second shared component explaining only a very
little amount of spatial variation (see Supplementary Tables 5.7–5.9). The A3 model,
with the second shared component allocated to radiotherapy and hormonal therapy,
had the key difference that all the relative weights for the first shared component had
a 95% CrI that included unity, which is substantially different to the baseline model
A0. The fit of models A2 and A4 was poorer than the baseline model A0 with higher
DIC values, while model A3 had a similar DIC value to the baseline model A0 (see
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Figure 5.2: Posterior odds ratio for the shared component effect among adjuvant
therapies at SLA level, 1997–2008.
Estimated posterior odds ratio for the 478 SLA shared spatial effect to the intended
adjuvant therapies among all study cohort across QLD. Map (a) with median value
of the shared spatial effect separated into quintiles (<0.77, 0.91, 1.10, 1.30, 1.30+)
and a line plot (b) for the ranked SLA median shared spatial effect values with 95%
credible interval.
Supplementary Table 5.5).
As for the model (A5) without a spatially unstructured random effects term ‘u’,
the comparison with the baseline model A0 showed similar posterior estimates of the
regression coefficients of interest (see Supplementary Table 5.10). However, the excess
treatment-specific spatially structured error term ‘s’ increased, which in turn inflated
the proportion of SLAs with excess odds ratios (computed as exp(s) under this model).
The increase was most obvious for the hormonal therapy specific spatially structured
random effect which had the proportion of SLAs with excess odds ratios increase from
3% in the baseline model to 28% in model A5. Model A5 had a substantially lower
DIC value of 18254 than the baseline model (DIC=18364), indicating better model
fit (see Supplementary Table 5.5).
Under model A6, without a spatially structured random effects term ‘s’, the posterior
estimates changed substantially within the TRACT variable for the radiotherapy and
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Figure 5.3: Posterior probability of excess shared component effect among adjuvant
therapies at SLA level, 1997–2008.
Map (a) posterior probability of excess shared component effect (less than 0.2,
0.2-0.8 and greater than 0.8) and a line plot (b) approximate number of ranked
SLAs with excess shared component effect in QLD.
chemotherapy. Patients in the TRACT categories of more than 2 hours were substan-
tially less likely to use radiotherapy compared with those who only needed to travel
within an hour to a treatment facility (see Supplementary Table 5.11). The intention
to use chemotherapy was in general substantially less in all TRACT categories com-
pared to those with less than an hour of travelling time, except the 2− < 4 hours
category had similar odds ratio to the reference category. One additional difference
to the baseline model A0 is that the most disadvantaged socio-economic (Quintile
1) patients were substantially less likely to intended to use chemotherapy than the
most advantaged (Quintile 5) patients. This alternative model also had the shared
component capture more spatial variation in the absence of ‘s’ as compared to the
baseline model, and there was virtually no excess treatment-specific spatial variability
captured by the unstructured random effect ‘u’. Model A6 did not fit the data better
than the baseline model with a substantially higher DIC value (see Supplementary
Table 5.5).
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Figure 5.4: Box plots of the median shared component effect among adjuvant ther-
apies and percentage of SLA with excess odds ratio for each geographic location,
1997–2008.
Estimated posterior odds ratio for the 478 SLA shared spatial effect to the intended
adjuvant therapies among all study cohort across QLD that had been categorised
into road travelling time and socio-economic status categories, respectively. Box
plots of the median shared spatial effect and percentage of SLA with less than 20%
(to the left of box plot) or more than 80% (to the right of box plot) probability that
shared effect odds ratios exceeded unity by (a) road travelling time and (b)
socio-economic status.
The use of approximate non-informative or flat priors with relatively small constant
values for the precision (Normal(0, 0.0001)) in model A7 gave substantively different
results in the posterior estimate for the TRACT variable across all adjuvant therapies
as compared to the baseline model. In this alternative model, all three therapies
presented a decreasing trend of posterior odds ratios with increasing road travelling
time (TRACT), with radiotherapy and hormonal therapy had substantially lower odds
ratios for those who had more than 2 hours of travelling time, and chemotherapy had
substantively lower odds ratios for patients with more than 4 hours of travelling time
(see Supplementary Table 5.12). In addition, the 95% CrI of relative weight between
chemotherapy and hormonal therapy had changed from substantial in the baseline
model to not substantial in model A7. This flat prior model (A7) had a DIC value
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Figure 5.5: Posterior odds ratio for the radiotherapy-specific spatial effect at SLA
level, 1997–2008.
Estimated posterior odds ratio for the 478 SLA radiotherapy-specific spatial effect
among all study cohort across QLD. Map (a) with median value of the
radiotherapy-specific spatial effect separated into quintiles (<0.77, 0.91, 1.10, 1.30,
1.30+) and a line plot (b) for the ranked SLA median radiotherapy-specific spatial
effect values with 95% credible interval.
of 18367 with pD=422 that was not substantially different to the baseline model
(DIC=18364, pD=417) (see Supplementary Table 5.5).
5.5 Discussion and conclusions
To the best of our knowledge, this is the first study to examine the shared spatial
disparities of women’s intention to use adjuvant therapy after being diagnosed with
screen-detected breast cancer using Bayesian spatial modelling techniques. In this
study we utilised a shared spatial-components modelling strategy to quantify what
factors influence a woman’s intended adjuvant treatment for screen-detected breast
cancer in Queensland. The analysed results were concluded based on the baseline
model A0, unless otherwise specified. We found that the intention to use adjuvant
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Figure 5.6: Posterior probability of excess radiotherapy-specific spatial effect at SLA
level, 1997–2008.
Map (a) posterior probability of excess radiotherapy-specific spatial effect (less than
0.2, 0.2-0.8 and greater than 0.8) and a line plot (b) approximate number of ranked
SLAs with excess radiotherapy-specific spatial effect in QLD.
therapy varied by geographical location, with women living in regions having closer ac-
cess to a cancer treatment facility being more likely to intend to use adjuvant therapy
than those who lived further away. A clear increased posterior median shared spatial
effect was observed towards the north-east (Townsville) and south-east (Brisbane)
regions of Queensland with little uncertainty, supported by the posterior probability
map.
Previous studies have shown that the breast cancer treatment that a woman chooses
to undertake is influenced by ease of access to treatment (Athas et al, 2000; Martinez
et al, 2012a; Nattinger et al, 2001; Schootman and Aft, 2001). Our analysis, based
on the intended treatment, found similar geographic differentials. This suggests that
women may be making decisions regarding their treatment strategy based on per-
ceived barriers to treatment, not simply an inability to take up their intended option.
It is not clear whether this reflects the decision making of women themselves, or the
recommendations made by their referring doctor, and the lack of actual treatment
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Figure 5.7: Posterior odds ratio for the chemotherapy-specific spatial effect at SLA
level, 1997–2008.
Estimated posterior odds ratio for the 478 SLA chemotherapy-specific spatial effect
among all study cohort across QLD. Map (a) with median value of the
chemotherapy-specific spatial effect separated into quintiles (<0.77, 0.91, 1.10, 1.30,
1.30+) and a line plot (b) for the ranked SLA median chemotherapy-specific spatial
effect values with 95% credible interval.
information makes more substantive interpretation impossible.
The use of a shared spatial component is one of the appealing features of the model
as it permits isolation of clusters of areas of common variation for the three adju-
vant therapies. This latent variable which is shared among all adjuvant therapies is
spatially structured, following a specific intrinsic conditional autoregressive (CAR)
model. This means that the shared component acts as a surrogate for some unob-
served spatially structured factors that may explain the geographical variations of the
usage of the three adjuvant therapies (radiotherapy, chemotherapy, hormonal ther-
apy) of interest. Given the strong association with distance to tertiary hospitals, it
appears that the shared term reflects the ease of access to treatment facilities. This
could also reflect the several barriers or considerations associated with undergoing
treatment, such as waiting time to treatments, burden of travel, being away from
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Figure 5.8: Posterior probability of excess chemotherapy-specific spatial effect at SLA
level, 1997–2008.
Map (a) posterior probability of excess chemotherapy-specific spatial effect (less
than 0.2, 0.2-0.8 and greater than 0.8) and a line plot (b) approximate number of
ranked SLAs with excess chemotherapy-specific spatial effect in QLD.
home, lack of closeness to family and friends, work and family demands, financial
burden, feeling of being a burden on others, cost-effectiveness of treatments and pa-
tient’s medication-taking behaviour, as indicated by previous studies (Cahir et al,
2015; Diaby et al, 2015; Fitch et al, 2003; Hegney et al, 2005). Thus the shared
spatial effect maps are consistent with an increasing ease of access to adjuvant treat-
ment facilities towards the north-east (Townsville) and south-east (Brisbane) regions
of Queensland. In addition to the shared component, there remain some potential
sources of treatment-specific effect for chemotherapy in the data. However, at present,
it is unclear what is causing this finding.
While the shared effect has a similar trend for the entire study cohort as well as
the age and tumour stage at diagnosis subgroups, the patterns of relative weight, or
level of importance, of the shared component between adjuvant therapies were not
all the same. The ease of access to treatment facilities barrier seems to be more
influential in the sub-cohort of age 50 − 59 years or with localised tumour stage
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Figure 5.9: Posterior odds ratio for the hormonal-specific spatial effect at SLA level,
1997–2008.
Estimated posterior odds ratio for the 478 SLA hormonal-specific spatial effect
among all study cohort across QLD. Map (a) with median value of the
hormonal-specific spatial effect separated into quintiles (<0.77, 0.91, 1.10, 1.30,
1.30+) and a line plot (b) for the ranked SLA median hormonal-specific spatial
effect values with 95% credible interval.
than any other subgroups. No such differences in relative weight among adjuvant
therapies were detected for the higher risk cohorts of age 70 − 89 or with advanced
stage tumour. This could suggest that the higher risk cohorts, with more urgent
need to have treatment, would be more likely to overcome common barriers between
adjuvant therapies. Meanwhile, the absence of evidence of a difference in relative
weight among adjuvant therapies could also be due to a lack of signal in the data
since only sub-cohorts of patients are considered. The recommendation for hormone
therapy is not determined by tumour type, stage or surgery but by ER/PR status,
which is independent of age (Cancer Australia, 2014; Ross et al, 2004). Estrogen
receptors (ER) and progesterone receptors (PR) may be found in breast cancer cells
and such cancer cells depend on estrogen and progesterone hormones to grow. As
such, our finding of a fairly similar influence of the shared spatial effect between
hormonal therapy and radiotherapy was surprising. While it could be due to the effect
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Figure 5.10: Posterior probability of excess hormonal-specific spatial effect at SLA
level, 1997–2008.
Map (a) posterior probability of excess hormonal-specific spatial effect (less than
0.2, 0.2-0.8 and greater than 0.8) and a line plot (b) approximate number of ranked
SLAs with excess hormonal-specific spatial effect in QLD.
of administering hormonal therapy via surgical treatment, rather than ongoing self-
administered oral medication, the ability to detect differences in relative weight among
adjuvant therapies may be compromised due to a lack of more specific information
about the intended treatment.
The relationship between patient characteristics and the intended choice of adjuvant
therapies is consistent with most other international studies. The intended choice of
adjuvant therapies was not associated with socio-economic status; this is similar to
the British Columbia study (Olson et al, 2012) which found no significant differences
in the use of chemotherapy or hormonal therapy by population size of local health
authorities, while the use of chemotherapy in the United States of America seems to
be influenced by socio-economic factors like poverty among patients ages 65−69 years
(Bhargava and Du, 2009). A more recent study by Ursem et al (2015) also suggested
that low income patients may have low use of adjuvant endocrine therapy. The find-
ing of reduced likelihood of choosing radiotherapy with increased travel time in this
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study supports other studies in the United States of America (Martinez et al, 2012a,b),
which showed that rural area patients were less likely to receive radiotherapy follow-
ing lumpectomy or mastectomy than their urban counterparts. Both radiotherapy
and chemotherapy had a decreased likelihood of being chosen with increased age at
diagnosis, but this relationship was reversed for hormonal therapy. This relationship
between a patient’s age and the use of radiotherapy in Queensland is again consistent
with studies in the United States of America (Martinez et al, 2012a,b) that found
increasing age was associated with decreased likelihood of receiving post-mastectomy
radiation or post-lumpectomy radiation. Radiotherapy and chemotherapy were also
more likely to be the choice for advanced stage tumour patients, but this cohort
was less likely to consider hormonal therapy. Some published evidence (Olson et al,
2012; Schroen et al, 2005; Thompson et al, 2008) has shown that women living in
remote areas tended to favour mastectomy, which may impact on the selection of
adjuvant therapies to prevent the need to travel to a cancer treatment center that is
far away. This phenomenon is particularly strong for the selection of radiotherapy
and marginally influential for hormonal therapy, but the selection of chemotherapy
has an opposite relationship.
The alternative models (A1–A7) provided some different results as compared to the
baseline model A0. By using an independent Gaussian distribution on the unstruc-
tured random effect ‘u’, the results from model A1 were not substantially different to
those of the baseline model, despite a poorer fit to the data (larger DIC value). This
suggests the use of a simple structure prior distribution only on the unstructured
random effects reduces the model’s performance in fitting the data. For the three
alternative models A2, A3 and A4, the second shared component explained only a
very small amount of the spatial variability. This spatial variability was likely to be
explained as part of the treatment-specific components in the baseline model. This
implies that the model does not require an additional shared component.
A model without a spatially unstructured random effects term ‘u’ (A5) and a model
without a spatially structured random effects term ‘s’ (A6) was examined. Compared
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with the baseline model which included both of these terms (A0), we found that model
A5 gave similar posterior estimates of the effects (regression coefficients) of interest,
but the spatially structured error term increased (presumably to accommodate the
lack of the unstructured error term), which in turn inflated the proportion of SLAs
with excess odds ratios (computed as exp(s) under this model). This inflation is
interesting, since it implies that the single (spatial) error term is larger than the
two error terms in the baseline model. Hence this model appears to draw out some
of the partially spatial information that is incorporated in the covariates under the
baseline model, in order to provide an equivalent fit to the data. Since we do not feel
that this behaviour is optimal, and that including the spatially unstructured random
effect term had better theoretical grounds than excluding it, we preferred to focus
on the results of this A0 model rather than the more speculative model A5. Under
model A6, the excess spatial information that was attributed to the spatial random
effects term in the baseline model appeared to be attributed instead to the stronger
spatial covariates, in particular TRACT and the corresponding shared component.
Interestingly, under this model the TRACT regression parameters indicated that
all of the treatment choices were affected by distance from the treatment centre.
This differs from the results of the baseline model, which were that TRACT was a
substantive factor only in the choice of radiotherapy. Thus it seems here that the
lack of a specific spatial term in the model induces greater spatial variation in the
parameters that have a strong spatial signal. This has interesting implications for
spatial modelling in general to support the inclusion of spatial random effect, and
this case study in particular. We have also investigated a seventh alternative model
(A7), which approximates non-informative or flat priors by imposing a relatively
small constant value for the precisions for these prior distributions. This resulted in
substantially different results as compared to the baseline model, where model A7 had
a decreased odds ratios trend in the TRACT variable with increasing travelling for all
the intended adjuvant therapies. The universal decreasing trend of treatment choice
with increasing travel time to closest radiation facility for all adjuvant therapies may
be unrealistic at least for hormonal therapy. However, given the limited data in the
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QLD context, this is difficult to justify.
This study had several limitations resulting from using routinely collected data. One
limitation was the lack of data on actual treatment received and/or completed. The
use of intended treatment data may not reflect the actual treatment undertaken, or
it may not have been completed. Another limitation is that the treatment data were
restricted to screen-detected breast cancer patients, rather than all breast cancer pa-
tients. Although the treatment recommendations by Cancer Australia (Cancer Aus-
tralia, 2014) are not specific to the detection method, it is not known whether women
who access public mammography screening would experience the same perceived bar-
riers to treatment as women who access either no screening or access screening through
private providers. Finally, the proposed Bayesian shared spatial component models
have a complex structure with the inclusion of CAR latent structures and multivari-
ate priors. This complexity has the drawback of increased computational demands,
in particular longer simulation time and careful assessment of MCMC convergence.
It is noted that the PPC is an evaluative diagnostic that, while informative as an
indicator of model fit, may tend to lead to optimistic conclusions since the data used
to validate the model are the same as those used to fit the model.
The primary purpose of most population-based cancer registries is to collect infor-
mation about the number and characteristics of incident cancers. As such, the level
of detail available in these registries about subsequent management is often limited.
Some studies (Hall et al, 2004; Mitchell et al, 2006; Thompson et al, 2008) have used
data linkage to hospital admitted patient data collections to access information about
surgical treatment. However, these data collections typically do not include informa-
tion about adjuvant treatment which can be administered in hospital outpatient and
other types of clinical practices. Therefore it is difficult to gain an understanding of
the geographic variation in actual treatment uptake and completion. For this reason,
while there are limitations in using intended, rather than actual treatment as the
outcome variable, these data advance our understanding of geographical variations in
intention.
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The purpose of this study is to identify and quantify how the shared component effect
influences intended choice between all three adjuvant therapies. It is not to assess how
the intended choice of each individual adjuvant therapy was influenced by patient’s
characteristics. Hence no separate model was fitted for each adjuvant therapy and
compared to the Bayesian shared spatial model.
In conclusion, this study has identified several important results. The choice of ad-
juvant therapy, particularly radiotherapy, was generally strongly associated with the
distance to radiotherapy treatment facilities. Older patients have substantively lower
intention to use radiotherapy and chemotherapy, instead preferring hormonal therapy.
In contrast, those with advanced cancers tend to choose radiotherapy and chemother-
apy, even though the current treatment recommendations for advanced breast cancer
(Cancer Australia, 2014) also recommend hormonal therapy. Moreover, even after
adjusting for key demographic and clinical factors, the presence of residual shared
spatial effects indicates that there are other unmeasured geographical barriers influ-
encing women’s treatment choices. This highlights the need to identify the additional
barriers that impact on treatment intentions among women diagnosed with screen-
detected breast cancer, particularly for those women living further away from cancer
treatment centers.
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5.6 Supplementary materials
5.6.1 Tables
Table 5.4: Estimated posterior correlation of the treatment-specific unstructured ran-
dom effects between adjuvant therapies.
Median posterior correlation [95% CrIa] Radiotherapy Chemotherapy Hormonal Therapy
Radiotherapy 15.82 [9.09, 25.51] — —
Chemotherapy -0.78 [-6.62, 4.88] 13.49 [7.92, 22.86] —
Hormonal therapy -2.41 [-9.10, 3.62] 0.69 [-5.03, 6.54] 18.51 [11.95, 29.81]
aAbbreviations: CrI=Credible interval.
Table 5.5: Model Comparison.
Model pDa DICb
(baseline) A0 417 18364
(spatially unstructured random effect ‘u’ with independent Gaussian prior) A1 434 18380
(second shared component for radiotherapy and chemotherapy) A2 422 18370
(second shared component for radiotherapy and hormonal therapy) A3 413 18363
(second shared component for chemotherapy and hormonal therapy) A4 422 18371
(without spatially unstructured random effect ‘u’) A5 294 18254
(without spatially unstructured random effect ‘s’) A6 397 18380
(flat prior for intercept and regression coefficients) A7 425 18369
aAbbreviations: pD=Effective number of parameters.
bAbbreviations: DIC=Deviance Information Criterion.
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Table 5.6: Model A1 (independent Gaussian prior for ‘u’) for estimated posterior
odds ratios of patient characteristics associated with the intended adjuvant therapies,
and relative weights between therapies.
Median posterior odds ratios [95% CrIa]
Factors N Radiotherapy Chemotherapy Hormonal Therapy
Road travelling time (TRACT)
< 1 hour 4514 1.00 1.00 1.00
1− < 2 hours 502 0.88 [0.55, 1.39] 0.75 [0.48, 1.19] 0.93 [0.67, 1.31]
2− < 4 hours 750 0.65 [0.42, 1.04] 0.92 [0.60, 1.44] 0.99 [0.71, 1.36]
4− < 6 hours 317 0.41 [0.24, 0.73] 0.44 [0.24, 0.80] 0.74 [0.49, 1.08]
6 or more hours 274 0.41 [0.23, 0.70] 0.60 [0.34, 1.07] 0.72 [0.49, 1.04]
Socio-economic status (IRSAD)
Quintile 1 Most disadvantaged 817 0.93 [0.64, 1.36] 0.72 [0.50, 1.04] 1.02 [0.78, 1.34]
Quintile 2 1458 0.80 [0.57, 1.10] 0.84 [0.60, 1.17] 0.91 [0.73, 1.16]
Quintile 3 1762 1.03 [0.76, 1.37] 0.90 [0.67, 1.19] 1.02 [0.82, 1.25]
Quintile 4 1539 0.91 [0.68, 1.22] 0.92 [0.68, 1.22] 1.04 [0.84, 1.28]
Quintile 5 Most advantaged 781 1.00 1.00 1.00
Age at diagnosis (years)
40-49 933 1.07 [0.85, 1.34] 1.85 [1.52, 2.25] 0.83 [0.71, 0.98]
50-59 2064 1.00 1.00 1.00
60-69 2074 0.86 [0.72, 1.03] 0.50 [0.42, 0.60] 1.20 [1.05, 1.38]
70-89 1225 0.36 [0.29, 0.45] 0.12 [0.09, 0.16] 1.39 [1.19, 1.62]
Indigenous Status
Non-Indigenous 5467 1.00 1.00 1.00
Indigenous 63 1.67 [0.83, 3.49] 1.16 [0.60, 2.19] 1.33 [0.88, 2.05]
Indigenous Unknown 766 0.87 [0.69, 1.09] 0.40 [0.30, 0.53] 1.06 [0.89, 1.26]
Marital Status
Married 4150 1.00 1.00 1.00
Never Married 305 0.78 [0.56, 1.08] 0.80 [0.57, 1.11] 0.85 [0.67, 1.08]
Widowed/Divorced/Separated 1665 0.83 [0.71, 0.99] 0.95 [0.80, 1.14] 1.05 [0.93, 1.19]
Marital Unknown 176 0.92 [0.59, 1.44] 1.07 [0.63, 1.78] 0.91 [0.67, 1.24]
Tumour Stage
Localised (Stage I) 4081 1.00 1.00 1.00
Advanced (Stage II, III, IV) 2139 2.43 [2.05, 2.91] 11.25 [9.67, 13.15] 0.87 [0.77, 0.98]
Stage Unknown 76 0.58 [0.31, 1.09] 2.83 [1.43, 5.42] 1.24 [0.84, 1.90]
Occupation
Blue collar 245 1.71 [1.18, 2.50] 1.03 [0.71, 1.48] 0.98 [0.76, 1.26]
White collar 907 1.49 [1.19, 1.87] 1.19 [0.96, 1.47] 1.11 [0.94, 1.32]
Professional 1061 1.49 [1.22, 1.85] 1.38 [1.13, 1.71] 1.09 [0.94, 1.28]
Not in the labour force 2631 1.00 1.00 1.00
Unknown 1452 1.28 [1.06, 1.55] 1.04 [0.85, 1.28] 1.27 [1.10, 1.47]
Invasive tumour type
Invasive Ductal 4074 1.00 1.00 1.00
Tubular 167 0.48 [0.33, 0.71] 0.27 [0.12, 0.55] 0.91 [0.68, 1.21]
Lobular Classical 506 0.95 [0.75, 1.22] 0.73 [0.55, 0.95] 1.72 [1.40, 2.13]
Other 434 0.73 [0.56, 0.98] 0.77 [0.56, 1.04] 0.95 [0.77, 1.15]
Unknown 1115 0.81 [0.67, 0.98] 0.69 [0.57, 0.84] 0.70 [0.61, 0.81]
First screen diagnosed
Yes 1508 0.81 [0.68, 0.96] 0.78 [0.66, 0.93] 0.72 [0.63, 0.81]
No 4788 1.00 1.00 1.00
Surgery
Breast-conserving surgery 4255 1.00 1.00 1.00
Mastectomy 2009 0.03 [0.02, 0.03] 1.63 [1.40, 1.91] 0.86 [0.77, 0.97]
No surgery 15 0.15 [0.04, 0.44] 2.28 [0.74, 6.91] 0.86 [0.48, 1.49]
Unknown 17 0.18 [0.06, 0.48] 1.73 [0.66, 4.70] 1.11 [0.66, 1.90]
Relative weight of shared component
Radiotherapy 1.00 — —
Chemotherapy 0.58 [0.38, 0.83] 1.00 —
Hormonal therapy 0.89 [0.68, 1.17] 1.54 [1.09, 2.28] 1.00
PPC 0.9993
aAbbreviations: CrI=Credible interval, N=Number of patients, TRACT=Travel to cancer treat-
ment, IRSAD=Index of relative socio-economic advantage and disadvantage, PPC=Posterior pre-
dictive check.
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Table 5.7: Model A2 (2nd shared component for radiotherapy and chemotherapy) for
estimated posterior odds ratios of patient characteristics associated with the intended
adjuvant therapies, and relative weights between therapies.
Median posterior odds ratios [95% CrIa]
Factors N Radiotherapy Chemotherapy Hormonal Therapy
Road travelling time (TRACT)
< 1 hour 4514 1.00 1.00 1.00
1− < 2 hours 502 0.87 [0.55, 1.38] 0.76 [0.47, 1.21] 0.93 [0.67, 1.29]
2− < 4 hours 750 0.65 [0.41, 1.04] 0.92 [0.59, 1.47] 0.98 [0.71, 1.34]
4− < 6 hours 317 0.41 [0.23, 0.75] 0.44 [0.24, 0.81] 0.75 [0.50, 1.09]
6 or more hours 274 0.42 [0.24, 0.77] 0.60 [0.34, 1.11] 0.72 [0.48, 1.05]
Socio-economic status (IRSAD)
Quintile 1 Most disadvantaged 817 0.96 [0.65, 1.39] 0.72 [0.49, 1.06] 1.01 [0.78, 1.33]
Quintile 2 1458 0.81 [0.59, 1.13] 0.85 [0.62, 1.19] 0.92 [0.72, 1.16]
Quintile 3 1762 1.04 [0.76, 1.41] 0.91 [0.68, 1.22] 1.01 [0.82, 1.26]
Quintile 4 1539 0.93 [0.69, 1.26] 0.93 [0.70, 1.23] 1.03 [0.83, 1.27]
Quintile 5 Most advantaged 781 1.00 1.00 1.00
Age at diagnosis (years)
40-49 933 1.07 [0.85, 1.33] 1.84 [1.51, 2.24] 0.83 [0.71, 0.98]
50-59 2064 1.00 1.00 1.00
60-69 2074 0.86 [0.72, 1.03] 0.50 [0.42, 0.60] 1.20 [1.05, 1.37]
70-89 1225 0.36 [0.29, 0.44] 0.12 [0.09, 0.16] 1.38 [1.18, 1.63]
Indigenous Status
Non-Indigenous 5467 1.00 1.00 1.00
Indigenous 63 1.68 [0.83, 3.55] 1.17 [0.60, 2.21] 1.33 [0.88, 2.04]
Indigenous Unknown 766 0.86 [0.69, 1.08] 0.40 [0.31, 0.52] 1.06 [0.88, 1.26]
Marital Status
Married 4150 1.00 1.00 1.00
Never Married 305 0.77 [0.56, 1.09] 0.79 [0.56, 1.09] 0.85 [0.67, 1.08]
Widowed/Divorced/Separated 1665 0.83 [0.71, 0.99] 0.95 [0.80, 1.14] 1.05 [0.93, 1.19]
Marital Unknown 176 0.92 [0.59, 1.46] 1.06 [0.62, 1.75] 0.91 [0.67, 1.24]
Tumour Stage
Localised (Stage I) 4081 1.00 1.00 1.00
Advanced (Stage II, III, IV) 2139 2.44 [2.04, 2.91] 11.23 [9.62, 13.13] 0.87 [0.77, 0.97]
Stage Unknown 76 0.59 [0.32, 1.09] 2.83 [1.43, 5.34] 1.24 [0.84, 1.88]
Occupation
Blue collar 245 1.70 [1.18, 2.48] 1.03 [0.72, 1.47] 0.98 [0.76, 1.27]
White collar 907 1.49 [1.19, 1.88] 1.18 [0.95, 1.47] 1.11 [0.94, 1.30]
Professional 1061 1.50 [1.22, 1.86] 1.38 [1.12, 1.70] 1.09 [0.94, 1.28]
Not in the labour force 2631 1.00 1.00 1.00
Unknown 1452 1.29 [1.06, 1.56] 1.04 [0.84, 1.28] 1.27 [1.09, 1.46]
Invasive tumour type
Invasive Ductal 4074 1.00 1.00 1.00
Tubular 167 0.48 [0.33, 0.71] 0.27 [0.12, 0.55] 0.91 [0.68, 1.22]
Lobular Classical 506 0.96 [0.75, 1.23] 0.73 [0.56, 0.94] 1.72 [1.41, 2.12]
Other 434 0.74 [0.56, 0.97] 0.76 [0.56, 1.04] 0.94 [0.78, 1.16]
Unknown 1115 0.81 [0.67, 0.98] 0.69 [0.57, 0.84] 0.70 [0.61, 0.80]
First screen diagnosed
Yes 1508 0.81 [0.68, 0.96] 0.79 [0.67, 0.93] 0.72 [0.63, 0.81]
No 4788 1.00 1.00 1.00
Surgery
Breast-conserving surgery 4255 1.00 1.00 1.00
Mastectomy 2009 0.03 [0.02, 0.03] 1.63 [1.40, 1.91] 0.86 [0.77, 0.97]
No surgery 15 0.14 [0.04, 0.44] 2.26 [0.73, 6.76] 0.85 [0.49, 1.48]
Unknown 17 0.18 [0.07, 0.46] 1.73 [0.65, 4.73] 1.11 [0.65, 1.90]
Relative weight of shared component 1
Radiotherapy 1.00 — —
Chemotherapy 0.57 [0.35, 0.85] 1.00 —
Hormonal therapy 0.88 [0.68, 1.15] 1.54 [1.04, 2.52] 1.00
Relative weight of shared component 2
Chemotherapy 0.82 [0.21, 3.77] 1.00 —
PPC 0.9989
aAbbreviations: CrI=Credible interval, N=Number of patients, TRACT=Travel to cancer treat-
ment, IRSAD=Index of relative socio-economic advantage and disadvantage, PPC=Posterior pre-
dictive check.
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Table 5.8: Model A3 (2nd shared component for radiotherapy and hormonal ther-
apy) for estimated posterior odds ratios of patient characteristics associated with the
intended adjuvant therapies, and relative weights between therapies.
Median posterior odds ratios [95% CrIa]
Factors N Radiotherapy Chemotherapy Hormonal Therapy
Road travelling time (TRACT)
< 1 hour 4514 1.00 1.00 1.00
1− < 2 hours 502 0.86 [0.55, 1.37] 0.72 [0.45, 1.18] 0.94 [0.67, 1.31]
2− < 4 hours 750 0.66 [0.41, 1.05] 0.88 [0.56, 1.43] 0.98 [0.71, 1.35]
4− < 6 hours 317 0.41 [0.23, 0.74] 0.42 [0.23, 0.77] 0.74 [0.49, 1.11]
6 or more hours 274 0.41 [0.24, 0.73] 0.57 [0.31, 1.02] 0.72 [0.48, 1.06]
Socio-economic status (IRSAD)
Quintile 1 Most disadvantaged 817 0.97 [0.67, 1.40] 0.72 [0.50, 1.04] 1.01 [0.77, 1.33]
Quintile 2 1458 0.82 [0.59, 1.16] 0.85 [0.62, 1.18] 0.91 [0.72, 1.17]
Quintile 3 1762 1.05 [0.79, 1.43] 0.90 [0.68, 1.21] 1.01 [0.81, 1.26]
Quintile 4 1539 0.94 [0.70, 1.25] 0.92 [0.70, 1.21] 1.04 [0.84, 1.28]
Quintile 5 Most advantaged 781 1.00 1.00 1.00
Age at diagnosis (years)
40-49 933 1.07 [0.86, 1.36] 1.85 [1.51, 2.25] 0.83 [0.71, 0.98]
50-59 2064 1.00 1.00 1.00
60-69 2074 0.86 [0.72, 1.03] 0.50 [0.42, 0.60] 1.20 [1.05, 1.37]
70-89 1225 0.36 [0.29, 0.45] 0.12 [0.09, 0.16] 1.39 [1.18, 1.63]
Indigenous Status
Non-Indigenous 5467 1.00 1.00 1.00
Indigenous 63 1.69 [0.84, 3.45] 1.14 [0.60, 2.11] 1.32 [0.88, 2.07]
Indigenous Unknown 766 0.87 [0.70, 1.09] 0.40 [0.30, 0.53] 1.06 [0.89, 1.26]
Marital Status
Married 4150 1.00 1.00 1.00
Never Married 305 0.78 [0.56, 1.09] 0.79 [0.57, 1.10] 0.85 [0.68, 1.08]
Widowed/Divorced/Separated 1665 0.83 [0.71, 0.98] 0.95 [0.80, 1.14] 1.05 [0.93, 1.19]
Marital Unknown 176 0.91 [0.59, 1.45] 1.06 [0.62, 1.77] 0.91 [0.67, 1.24]
Tumour Stage
Localised (Stage I) 4081 1.00 1.00 1.00
Advanced (Stage II, III, IV) 2139 2.44 [2.05, 2.90] 11.19 [9.62, 13.07] 0.86 [0.77, 0.97]
Stage Unknown 76 0.58 [0.32, 1.10] 2.87 [1.46, 5.44] 1.24 [0.83, 1.87]
Occupation
Blue collar 245 1.71 [1.18, 2.49] 1.03 [0.73, 1.48] 0.98 [0.75, 1.26]
White collar 907 1.49 [1.19, 1.88] 1.18 [0.95, 1.46] 1.11 [0.95, 1.31]
Professional 1061 1.50 [1.22, 1.86] 1.38 [1.13, 1.70] 1.09 [0.93, 1.28]
Not in the labour force 2631 1.00 1.00 1.00
Unknown 1452 1.29 [1.06, 1.56] 1.04 [0.85, 1.28] 1.27 [1.09, 1.46]
Invasive tumour type
Invasive Ductal 4074 1.00 1.00 1.00
Tubular 167 0.48 [0.33, 0.72] 0.27 [0.12, 0.55] 0.90 [0.68, 1.21]
Lobular Classical 506 0.95 [0.75, 1.22] 0.73 [0.56, 0.94] 1.72 [1.39, 2.12]
Other 434 0.74 [0.56, 0.96] 0.77 [0.56, 1.02] 0.94 [0.77, 1.15]
Unknown 1115 0.81 [0.67, 0.98] 0.69 [0.57, 0.84] 0.70 [0.61, 0.81]
First screen diagnosed
Yes 1508 0.81 [0.68, 0.97] 0.79 [0.67, 0.93] 0.72 [0.63, 0.82]
No 4788 1.00 1.00 1.00
Surgery
Breast-conserving surgery 4255 1.00 1.00 1.00
Mastectomy 2009 0.03 [0.02, 0.03] 1.63 [1.39, 1.90] 0.86 [0.76, 0.97]
No surgery 15 0.15 [0.04, 0.45] 2.24 [0.76, 7.24] 0.86 [0.48, 1.47]
Unknown 17 0.18 [0.07, 0.48] 1.72 [0.65, 4.54] 1.11 [0.66, 1.89]
Relative weight of shared component 1
Radiotherapy 1.00 — —
Chemotherapy 0.74 [0.40, 1.71] 1.00 —
Hormonal therapy 0.87 [0.61, 1.26] 1.19 [0.54, 2.09] 1.00
Relative weight of shared component 2
Hormonal Therapy 1.01 [0.32, 2.83] — 1.00
PPC 0.9990
aAbbreviations: CrI=Credible interval, N=Number of patients, TRACT=Travel to cancer treat-
ment, IRSAD=Index of relative socio-economic advantage and disadvantage, PPC=Posterior pre-
dictive check.
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Table 5.9: Model A4 (2nd shared component for chemotherapy and hormonal ther-
apy) for estimated posterior odds ratios of patient characteristics associated with the
intended adjuvant therapies, and relative weights between therapies.
Median posterior odds ratios [95% CrIa]
Factors N Radiotherapy Chemotherapy Hormonal Therapy
Road travelling time (TRACT)
< 1 hour 4514 1.00 1.00 1.00
1− < 2 hours 502 0.86 [0.54, 1.39] 0.73 [0.46, 1.20] 0.94 [0.67, 1.32]
2− < 4 hours 750 0.66 [0.41, 1.06] 0.89 [0.56, 1.44] 0.98 [0.71, 1.35]
4− < 6 hours 317 0.42 [0.23, 0.77] 0.43 [0.23, 0.80] 0.74 [0.50, 1.07]
6 or more hours 274 0.43 [0.23, 0.76] 0.57 [0.33, 1.05] 0.71 [0.48, 1.03]
Socio-economic status (IRSAD)
Quintile 1 Most disadvantaged 817 0.97 [0.67, 1.40] 0.72 [0.49, 1.04] 1.01 [0.77, 1.30]
Quintile 2 1458 0.83 [0.60, 1.15] 0.85 [0.61, 1.15] 0.91 [0.72, 1.16]
Quintile 3 1762 1.06 [0.79, 1.43] 0.90 [0.67, 1.20] 1.01 [0.81, 1.25]
Quintile 4 1539 0.94 [0.70, 1.24] 0.92 [0.69, 1.21] 1.03 [0.84, 1.26]
Quintile 5 Most advantaged 781 1.00 1.00 1.00
Age at diagnosis (years)
40-49 933 1.07 [0.85, 1.33] 1.84 [1.51, 2.26] 0.83 [0.71, 0.98]
50-59 2064 1.00 1.00 1.00
60-69 2074 0.86 [0.72, 1.03] 0.50 [0.42, 0.61] 1.20 [1.05, 1.37]
70-89 1225 0.36 [0.29, 0.45] 0.12 [0.09, 0.16] 1.38 [1.18, 1.63]
Indigenous Status
Non-Indigenous 5467 1.00 1.00 1.00
Indigenous 63 1.69 [0.80, 3.47] 1.15 [0.61, 2.15] 1.32 [0.87, 2.05]
Indigenous Unknown 766 0.87 [0.69, 1.09] 0.40 [0.30, 0.53] 1.05 [0.89, 1.25]
Marital Status
Married 4150 1.00 1.00 1.00
Never Married 305 0.78 [0.56, 1.09] 0.79 [0.57, 1.11] 0.85 [0.67, 1.08]
Widowed/Divorced/Separated 1665 0.83 [0.71, 0.98] 0.95 [0.80, 1.14] 1.05 [0.93, 1.19]
Marital Unknown 176 0.92 [0.59, 1.43] 1.06 [0.62, 1.78] 0.91 [0.67, 1.24]
Tumour Stage
Localised (Stage I) 4081 1.00 1.00 1.00
Advanced (Stage II, III, IV) 2139 2.43 [2.05, 2.90] 11.25 [9.60, 13.13] 0.87 [0.77, 0.98]
Stage Unknown 76 0.58 [0.32, 1.07] 2.84 [1.45, 5.36] 1.24 [0.83, 1.88]
Occupation
Blue collar 245 1.70 [1.18, 2.50] 1.03 [0.71, 1.46] 0.98 [0.76, 1.27]
White collar 907 1.49 [1.19, 1.87] 1.18 [0.95, 1.47] 1.11 [0.94, 1.31]
Professional 1061 1.50 [1.21, 1.86] 1.39 [1.13, 1.70] 1.09 [0.94, 1.27]
Not in the labour force 2631 1.00 1.00 1.00
Unknown 1452 1.29 [1.07, 1.55] 1.04 [0.85, 1.28] 1.27 [1.09, 1.47]
Invasive tumour type
Invasive Ductal 4074 1.00 1.00 1.00
Tubular 167 0.48 [0.33, 0.70] 0.27 [0.12, 0.55] 0.91 [0.66, 1.23]
Lobular Classical 506 0.95 [0.74, 1.23] 0.73 [0.56, 0.94] 1.72 [1.41, 2.13]
Other 434 0.73 [0.56, 0.96] 0.76 [0.57, 1.03] 0.94 [0.77, 1.16]
Unknown 1115 0.81 [0.67, 0.98] 0.69 [0.57, 0.84] 0.70 [0.61, 0.80]
First screen diagnosed
Yes 1508 0.81 [0.68, 0.96] 0.79 [0.66, 0.93] 0.72 [0.63, 0.81]
No 4788 1.00 1.00 1.00
Surgery
Breast-conserving surgery 4255 1.00 1.00 1.00
Mastectomy 2009 0.03 [0.02, 0.03] 1.63 [1.39, 1.91] 0.86 [0.76, 0.97]
No surgery 15 0.15 [0.04, 0.43] 2.26 [0.76, 6.94] 0.86 [0.48, 1.46]
Unknown 17 0.18 [0.07, 0.47] 1.71 [0.63, 4.68] 1.10 [0.66, 1.92]
Relative weight of shared component 1
Radiotherapy 1.00 — —
Chemotherapy 0.54 [0.31, 0.82] 1.00 —
Hormonal therapy 0.85 [0.62, 1.14] 1.58 [1.02, 2.65] 1.00
Relative weight of shared component 2
Hormonal Therapy — 1.22 [0.28, 5.45] 1.00
PPC 0.9992
aAbbreviations: CrI=Credible interval, N=Number of patients, TRACT=Travel to cancer treat-
ment, IRSAD=Index of relative socio-economic advantage and disadvantage, PPC=Posterior pre-
dictive check.
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Table 5.10: Model A5 (without spatially unstructured random effect ‘u’) for estimated
posterior odds ratios of patient characteristics associated with the intended adjuvant
therapies, and relative weights between therapies.
Median posterior odds ratios [95% CrIa]
Factors N Radiotherapy Chemotherapy Hormonal Therapy
Road travelling time (TRACT)
< 1 hour 4514 1.00 1.00 1.00
1− < 2 hours 502 0.91 [0.57, 1.44] 0.76 [0.48, 1.19] 0.94 [0.68, 1.30]
2− < 4 hours 750 0.67 [0.43, 1.09] 0.89 [0.57, 1.41] 0.96 [0.70, 1.33]
4− < 6 hours 317 0.44 [0.25, 0.77] 0.45 [0.25, 0.81] 0.75 [0.51, 1.08]
6 or more hours 274 0.46 [0.27, 0.81] 0.59 [0.34, 1.06] 0.72 [0.49, 1.03]
Socio-economic status (IRSAD)
Quintile 1 Most disadvantaged 817 0.97 [0.68, 1.38] 0.75 [0.52, 1.06] 1.01 [0.78, 1.30]
Quintile 2 1458 0.81 [0.60, 1.10] 0.88 [0.65, 1.20] 0.92 [0.73, 1.14]
Quintile 3 1762 1.04 [0.79, 1.40] 0.91 [0.70, 1.20] 1.00 [0.82, 1.22]
Quintile 4 1539 0.93 [0.71, 1.22] 0.93 [0.71, 1.22] 1.03 [0.85, 1.25]
Quintile 5 Most advantaged 781 1.00 1.00 1.00
Age at diagnosis (years)
40-49 933 1.07 [0.86, 1.34] 1.83 [1.49, 2.23] 0.84 [0.71, 0.98]
50-59 2064 1.00 1.00 1.00
60-69 2074 0.86 [0.72, 1.02] 0.50 [0.42, 0.60] 1.20 [1.05, 1.37]
70-89 1225 0.37 [0.30, 0.45] 0.12 [0.09, 0.16] 1.38 [1.17, 1.62]
Indigenous Status
Non-Indigenous 5467 1.00 1.00 1.00
Indigenous 63 1.67 [0.82, 3.47] 1.18 [0.63, 2.20] 1.32 [0.87, 2.02]
Indigenous Unknown 766 0.87 [0.70, 1.09] 0.40 [0.30, 0.53] 1.06 [0.89, 1.26]
Marital Status
Married 4150 1.00 1.00 1.00
Never Married 305 0.78 [0.57, 1.08] 0.79 [0.57, 1.08] 0.85 [0.67, 1.09]
Widowed/Divorced/Separated 1665 0.83 [0.71, 0.98] 0.95 [0.80, 1.14] 1.04 [0.92, 1.18]
Marital Unknown 176 0.91 [0.58, 1.43] 1.06 [0.62, 1.77] 0.91 [0.67, 1.24]
Tumour Stage
Localised (Stage I) 4081 1.00 1.00 1.00
Advanced (Stage II, III, IV) 2139 2.41 [2.03, 2.88] 10.98 [9.43, 12.83] 0.87 [0.77, 0.97]
Stage Unknown 76 0.59 [0.32, 1.08] 2.83 [1.40, 5.32] 1.22 [0.82, 1.82]
Occupation
Blue collar 245 1.70 [1.17, 2.47] 1.03 [0.71, 1.45] 0.98 [0.76, 1.27]
White collar 907 1.49 [1.18, 1.85] 1.18 [0.95, 1.46] 1.11 [0.94, 1.30]
Professional 1061 1.50 [1.22, 1.86] 1.38 [1.13, 1.70] 1.09 [0.93, 1.28]
Not in the labour force 2631 1.00 1.00 1.00
Unknown 1452 1.29 [1.07, 1.55] 1.05 [0.85, 1.28] 1.26 [1.09, 1.46]
Invasive tumour type
Invasive Ductal 4074 1.00 1.00 1.00
Tubular 167 0.49 [0.34, 0.71] 0.27 [0.12, 0.54] 0.91 [0.68, 1.22]
Lobular Classical 506 0.95 [0.75, 1.22] 0.73 [0.56, 0.94] 1.71 [1.40, 2.11]
Other 434 0.74 [0.57, 0.97] 0.76 [0.57, 1.02] 0.95 [0.77, 1.16]
Unknown 1115 0.82 [0.67, 0.98] 0.69 [0.57, 0.84] 0.70 [0.61, 0.80]
First screen diagnosed
Yes 1508 0.81 [0.69, 0.96] 0.79 [0.67, 0.94] 0.72 [0.63, 0.82]
No 4788 1.00 1.00 1.00
Surgery
Breast-conserving surgery 4255 1.00 1.00 1.00
Mastectomy 2009 0.03 [0.02, 0.04] 1.63 [1.39, 1.91] 0.86 [0.77, 0.97]
No surgery 15 0.15 [0.04, 0.43] 2.23 [0.75, 6.71] 0.87 [0.49, 1.49]
Unknown 17 0.18 [0.07, 0.48] 1.65 [0.59, 4.51] 1.09 [0.65, 1.85]
Relative weight of shared component
Radiotherapy 1.00 — —
Chemotherapy 0.54 [0.33, 0.79] 1.00 —
Hormonal therapy 0.85 [0.65, 1.10] 1.57 [1.08, 2.53] 1.00
PPC 0.9992
aAbbreviations: CrI=Credible interval, N=Number of patients, TRACT=Travel to cancer treat-
ment, IRSAD=Index of relative socio-economic advantage and disadvantage, PPC=Posterior pre-
dictive check.
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Table 5.11: Model A6 (without spatially structured random effect ‘s’) for estimated
posterior odds ratios of patient characteristics associated with the intended adjuvant
therapies, and relative weights between therapies.
Median posterior odds ratios [95% CrIa]
Factors N Radiotherapy Chemotherapy Hormonal Therapy
Road travelling time (TRACT)
< 1 hour 4514 1.00 1.00 1.00
1− < 2 hours 502 0.84 [0.55, 1.30] 0.57 [0.39, 0.85] 0.96 [0.68, 1.34]
2− < 4 hours 750 0.62 [0.43, 0.89] 0.74 [0.54, 1.01] 0.99 [0.73, 1.35]
4− < 6 hours 317 0.39 [0.23, 0.65] 0.35 [0.22, 0.56] 0.77 [0.51, 1.11]
6 or more hours 274 0.36 [0.23, 0.61] 0.46 [0.28, 0.72] 0.75 [0.51, 1.08]
Socio-economic status (IRSAD)
Quintile 1 Most disadvantaged 817 0.89 [0.62, 1.27] 0.67 [0.47, 0.95] 1.04 [0.80, 1.35]
Quintile 2 1458 0.76 [0.55, 1.04] 0.79 [0.58, 1.07] 0.95 [0.75, 1.20]
Quintile 3 1762 0.94 [0.72, 1.30] 0.83 [0.64, 1.09] 1.06 [0.85, 1.30]
Quintile 4 1539 0.88 [0.65, 1.17] 0.86 [0.66, 1.12] 1.07 [0.87, 1.32]
Quintile 5 Most advantaged 781 1.00 1.00 1.00
Age at diagnosis (years)
40-49 933 1.07 [0.85, 1.35] 1.85 [1.52, 2.25] 0.83 [0.71, 0.97]
50-59 2064 1.00 1.00 1.00
60-69 2074 0.86 [0.72, 1.02] 0.51 [0.42, 0.60] 1.20 [1.05, 1.37]
70-89 1225 0.36 [0.29, 0.44] 0.13 [0.10, 0.17] 1.38 [1.18, 1.61]
Indigenous Status
Non-Indigenous 5467 1.00 1.00 1.00
Indigenous 63 1.66 [0.81, 3.43] 1.10 [0.58, 2.05] 1.35 [0.90, 2.09]
Indigenous Unknown 766 0.86 [0.69, 1.08] 0.40 [0.30, 0.53] 1.06 [0.89, 1.26]
Marital Status
Married 4150 1.00 1.00 1.00
Never Married 305 0.79 [0.57, 1.10] 0.80 [0.57, 1.13] 0.85 [0.67, 1.07]
Widowed/Divorced/Separated 1665 0.84 [0.71, 0.99] 0.96 [0.81, 1.14] 1.04 [0.92, 1.19]
Marital Unknown 176 0.92 [0.59, 1.42] 1.06 [0.63, 1.75] 0.91 [0.67, 1.23]
Tumour Stage
Localised (Stage I) 4081 1.00 1.00 1.00
Advanced (Stage II, III, IV) 2139 2.43 [2.04, 2.90] 11.09 [9.48, 12.92] 0.87 [0.77, 0.97]
Stage Unknown 76 0.59 [0.32, 1.09] 2.75 [1.39, 5.16] 1.23 [0.84, 1.88]
Occupation
Blue collar 245 1.71 [1.19, 2.48] 1.03 [0.71, 1.47] 0.98 [0.76, 1.28]
White collar 907 1.49 [1.19, 1.86] 1.20 [0.97, 1.48] 1.11 [0.95, 1.30]
Professional 1061 1.48 [1.20, 1.84] 1.38 [1.13, 1.69] 1.10 [0.94, 1.28]
Not in the labour force 2631 1.00 1.00 1.00
Unknown 1452 1.26 [1.04, 1.52] 1.05 [0.85, 1.28] 1.27 [1.10, 1.47]
Invasive tumour type
Invasive Ductal 4074 1.00 1.00 1.00
Tubular 167 0.48 [0.33, 0.70] 0.27 [0.12, 0.55] 0.91 [0.68, 1.22]
Lobular Classical 506 0.96 [0.74, 1.23] 0.72 [0.56, 0.94] 1.72 [1.42, 2.12]
Other 434 0.74 [0.57, 0.96] 0.78 [0.58, 1.04] 0.94 [0.77, 1.15]
Unknown 1115 0.81 [0.68, 0.98] 0.69 [0.57, 0.85] 0.70 [0.61, 0.81]
First screen diagnosed
Yes 1508 0.81 [0.69, 0.96] 0.79 [0.67, 0.93] 0.72 [0.63, 0.82]
No 4788 1.00 1.00 1.00
Surgery
Breast-conserving surgery 4255 1.00 1.00 1.00
Mastectomy 2009 0.03 [0.02, 0.03] 1.62 [1.38, 1.90] 0.87 [0.77, 0.98]
No surgery 15 0.14 [0.04, 0.42] 2.40 [0.78, 7.52] 0.84 [0.48, 1.41]
Unknown 17 0.18 [0.07, 0.48] 1.69 [0.64, 4.56] 1.11 [0.66, 1.91]
Relative weight of shared component
Radiotherapy 1.00 — —
Chemotherapy 0.44 [0.28, 0.64] 1.00 —
Hormonal therapy 0.98 [0.80, 1.22] 2.25 [1.55, 3.48] 1.00
PPC 0.9990
aAbbreviations: CrI=Credible interval, N=Number of patients, TRACT=Travel to cancer treat-
ment, IRSAD=Index of relative socio-economic advantage and disadvantage, PPC=Posterior pre-
dictive check.
130 Chapter 5. Geographic Variation in the Intended Choice of
Adjuvant Treatments for Women Diagnosed with Screen-Detected Breast
Cancer in Queensland
Table 5.12: Model A7 (flat priors for intercept and regression coefficients) for esti-
mated posterior odds ratios of patient characteristics associated with the intended
adjuvant therapies, and relative weights between therapies.
Median posterior odds ratios [95% CrIa]
Factors N Radiotherapy Chemotherapy Hormonal Therapy
Road travelling time (TRACT)
< 1 hour 4514 1.00 1.00 1.00
1− < 2 hours 502 0.60 [0.36, 1.01] 0.60 [0.36, 1.01] 0.64 [0.40, 1.00]
2− < 4 hours 750 0.37 [0.21, 0.65] 0.64 [0.39, 1.12] 0.55 [0.32, 0.92]
4− < 6 hours 317 0.19 [0.10, 0.38] 0.26 [0.13, 0.53] 0.33 [0.18, 0.64]
6 or more hours 274 0.20 [0.11, 0.40] 0.38 [0.20, 0.76] 0.33 [0.18, 0.64]
Socio-economic status (IRSAD)
Quintile 1 Most disadvantaged 817 0.97 [0.66, 1.41] 0.72 [0.49, 1.06] 1.04 [0.76, 1.42]
Quintile 2 1458 0.80 [0.57, 1.10] 0.84 [0.60, 1.18] 0.90 [0.69, 1.19]
Quintile 3 1762 1.02 [0.75, 1.38] 0.89 [0.66, 1.20] 1.00 [0.78, 1.28]
Quintile 4 1539 0.91 [0.67, 1.21] 0.91 [0.68, 1.22] 1.02 [0.81, 1.29]
Quintile 5 Most advantaged 781 1.00 1.00 1.00
Age at diagnosis (years)
40-49 933 1.07 [0.85, 1.35] 1.85 [1.51, 2.27] 0.83 [0.70, 0.98]
50-59 2064 1.00 1.00 1.00
60-69 2074 0.85 [0.71, 1.02] 0.49 [0.41, 0.59] 1.22 [1.06, 1.40]
70-89 1225 0.35 [0.28, 0.43] 0.11 [0.09, 0.15] 1.43 [1.21, 1.69]
Indigenous Status
Non-Indigenous 5467 1.00 1.00 1.00
Indigenous 63 1.86 [0.86, 4.17] 1.19 [0.58, 2.38] 1.72 [0.96, 3.16]
Indigenous Unknown 766 0.86 [0.69, 1.08] 0.38 [0.29, 0.51] 1.07 [0.89, 1.28]
Marital Status
Married 4150 1.00 1.00 1.00
Never Married 305 0.77 [0.55, 1.10] 0.77 [0.55, 1.08] 0.83 [0.64, 1.07]
Widowed/Divorced/Separated 1665 0.83 [0.71, 0.98] 0.96 [0.80, 1.14] 1.04 [0.91, 1.18]
Marital Unknown 176 0.92 [0.57, 1.48] 1.06 [0.59, 1.83] 0.86 [0.60, 1.26]
Tumour Stage
Localised (Stage I) 4081 1.00 1.00 1.00
Advanced (Stage II, III, IV) 2139 2.49 [2.09, 2.98] 11.64 [9.98, 13.61] 0.86 [0.77, 0.97]
Stage Unknown 76 0.67 [0.33, 1.33] 3.18 [1.49, 6.55] 1.70 [0.96, 3.02]
Occupation
Blue collar 245 1.75 [1.20, 2.59] 1.04 [0.72, 1.51] 0.99 [0.74, 1.31]
White collar 907 1.50 [1.19, 1.89] 1.18 [0.95, 1.47] 1.14 [0.95, 1.35]
Professional 1061 1.51 [1.22, 1.87] 1.39 [1.12, 1.73] 1.12 [0.94, 1.31]
Not in the labour force 2631 1.00 1.00 1.00
Unknown 1452 1.30 [1.07, 1.58] 1.05 [0.85, 1.29] 1.29 [1.11, 1.50]
Invasive tumour type
Invasive Ductal 4074 1.00 1.00 1.00
Tubular 167 0.47 [0.31, 0.69] 0.18 [0.06, 0.43] 0.88 [0.64, 1.25]
Lobular Classical 506 0.95 [0.74, 1.25] 0.71 [0.54, 0.93] 1.84 [1.48, 2.28]
Other 434 0.72 [0.55, 0.97] 0.75 [0.56, 1.01] 0.94 [0.75, 1.15]
Unknown 1115 0.81 [0.67, 0.98] 0.68 [0.55, 0.82] 0.68 [0.59, 0.79]
First screen diagnosed
Yes 1508 0.81 [0.69, 0.96] 0.78 [0.65, 0.93] 0.71 [0.62, 0.81]
No 4788 1.00 1.00 1.00
Surgery
Breast-conserving surgery 4255 1.00 1.00 1.00
Mastectomy 2009 0.03 [0.02, 0.03] 1.66 [1.41, 1.94] 0.86 [0.76, 0.97]
No surgery 15 0.04 [0.01, 0.19] 3.61 [0.85, 14.65] 0.41 [0.12, 1.41]
Unknown 17 0.10 [0.03, 0.29] 2.38 [0.69, 7.88] 1.51 [0.52, 4.65]
Relative weight of shared component
Radiotherapy 1.00 — —
Chemotherapy 0.57 [0.36, 0.86] 1.00 —
Hormonal therapy 0.87 [0.63, 1.13] 1.51 [0.97, 2.39] 1.00
PPC 0.9991
aAbbreviations: CrI=Credible interval, N=Number of patients, TRACT=Travel to cancer treat-
ment, IRSAD=Index of relative socio-economic advantage and disadvantage, PPC=Posterior pre-
dictive check.
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Figure 5.11: Posterior median odds ratio maps for the 40-49 age group shared com-
ponent effect, 1997–2008.
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Figure 5.12: Posterior median odds ratio maps for the 50-59 age group shared com-
ponent effect, 1997–2008.
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Figure 5.13: Posterior median odds ratio maps for the 60-69 age group shared com-
ponent effect, 1997–2008.
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Figure 5.14: Posterior median odds ratio maps for the 70-89 age group shared com-
ponent effect, 1997–2008.
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Figure 5.15: Posterior median odds ratio maps for the localised tumour shared com-
ponent effect, 1997–2008.
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Figure 5.16: Posterior median odds ratio maps for the advanced tumour shared com-
ponent effect, 1997–2008.
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Figure 5.17: Box plots for the median shared component effect by road travelling
time for age and tumour stage at diagnosis, 1997–2008.
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Figure 5.18: Box plots for the median shared component effect by socio-economic
status for age and tumour stage at diagnosis, 1997–2008.
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Figure 5.19: Distribution of shared component weights δ.
CHAPTER 6
Spatially varying coefficient inequalities:
Evaluating how the impact of patient
characteristics on breast cancer survival
varies by location
Preamble
The findings of spatial heterogeneity within breast cancer data motivated taking a
further step to analyse the spatial association between covariates and health outcomes.
Hence, in this Chapter, the analysis of breast cancer data using the Bayesian relative
survival model is revisited. In this instance, various spatial hierarchical models were
analysed to examine spatially varying covariate effects and identify any unobserved
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spatial subgroups within a relative survival study. The Bayesian relative survival
model was fitted using various model structures, including a spatial regression model,
a varying coefficient model and a finite mixture of regressions model to evaluate the
relative excess risk of breast cancer. The results of each model were assessed and
compared to addressed Objectives 2 and 5 in Section 1.2.
This Chapter has been submitted as a journal article and is currently under review.
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6.1 Abstract
An increasing number of studies have identified spatial differences in breast cancer
survival. However little is known about whether the structure and dynamics of this
spatial inequality are consistent across a region. This study aims to evaluate the
spatially varying nature of predictors of spatial inequality in relative survival for
women diagnosed with breast cancer across Queensland, Australia. All Queensland
women aged less than 90 years diagnosed with invasive breast cancers from 1997 to
2007 and followed up to the end of 2008 were extracted from linked Queensland Cancer
Registry and BreastScreen Queensland data. Bayesian relative survival models were
fitted using various model structures (a spatial regression model, a varying coefficient
model and a finite mixture of regressions model) to evaluate the relative excess risk of
breast cancer, with the use of Markov chain Monte Carlo computation. The spatially
varying coefficient models revealed that some covariate effects may not be constant
across the geographic regions of the study. Although the overall spatial patterns
showed lower survival among women living in more remote areas, and higher survival
among the urbanised south-east corner, women less than 40 years of age at diagnosis
exhibited higher survival in the more remote areas which then decreased toward the
south-east of Queensland. The spatial survival pattern for younger women contrasted
with that for older women and may be indicative of different factors impacting on
spatial survival patterns for younger women.
6.2 Introduction
The association between risk factors and small-area health outcomes of breast cancer
patients is of key interest. Previous studies have used Bayesian spatial regression
models to examine small-area variation in relative survival for breast cancer in Spain
(Saez et al, 2012) and Australia (Cramb et al, 2012; Hsieh et al, 2014, 2015). In the
latter studies, a range of patient characteristics, including women’s age at diagnosis,
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Indigenous status, marital status, tumour stage at diagnosis, occupation, detection
method and area of residence were shown to be associated with breast cancer relative
survival in Queensland, Australia (Cramb et al, 2012; Hsieh et al, 2014, 2015). In
general, patients who were older, Indigenous, diagnosed with an advanced stage tu-
mour or living in a remote area were at higher breast cancer mortality risk. Women
with lower breast cancer mortality risk included patients who had participated in a
breast cancer screening program, had a tumour diagnosed early, while it was still
localised, or were not in the labour force or married. In addition, there was evidence
of spatial inequalities in breast cancer patient survival across Queensland, often with
poorer survival in more remote areas.
In all of these models the regression coefficients were assumed to have a constant in-
fluence across the entire study region, although we have previously (Hsieh et al, 2015)
examined a potential spatially varying effect for one particular predictor variable, the
method of detecting breast cancer. In these constant coefficient models, the spatial
nature of the data is captured through the inclusion of a single random effect that
takes into account similarities between neighbouring regions, thus inducing a type of
flexible local smoothing (Cramb et al, 2012; Hsieh et al, 2014, 2015). Determining if
the association of key factors varies over small-areas would help to better describe and
understand the varying survival rates in breast cancer among women in Queensland.
In addition, as the cancer data are collected over space, it is useful and important to
analyse the spatial association between covariates and health outcomes. Thus, more
sophisticated spatial models are applied to analyse the spatial cancer data.
In this paper we apply a Bayesian spatial regression model with spatially varying
coefficients to examine the potentially spatial varying effects of breast cancer risk
factors. Hastie and Tibshirani (1993) introduced the varying coefficient terms to
accommodate a particular type of interaction between explanatory variables. This
interaction takes the form of β(s)x, where the coefficient β of the explanatory variable
x is varying smoothly according to another explanatory variable s, which is generally
a continuous variable such as time or space. Numerous authors have studied varying
142 Chapter 6. Spatially varying coefficient inequalities: Evaluating
how the impact of patient characteristics on breast cancer survival varies
by location
coefficient models and found the model to be flexible and appealing for investigating
dynamic patterns in the data (Choi et al, 2012; Gelfand et al, 2003; Huang et al,
2014; Reich et al, 2010; Wang et al, 2014). The varying coefficient model provides a
clearly interpretable approach for modelling the dynamic spatial relationship between
the covariate and response variable.
Another type of model, the finite mixture of regressions model, has a similar capability
to incorporate the changing influence of covariates on the response across a spatial
domain (Antoniadis, 2010; McLachlan and Peel, 2004). However, in contrast to the
varying coefficient model, the finite mixture of regressions model separates the data
records into a number of subsets and analyses each of these subsets as a separate
component. This allows the vector of regression coefficients to vary from component to
component (Zou et al, 2013), where in the spatial scenario the components represent
clusters of geographic regions. For comparison, we also apply a Bayesian finite mixture
of regressions models to the Queensland breast cancer dataset (McLachlan and Peel,
2004). If the data support a finite mixture of regressions model to varying from
clusters of geographic location, it may then be of interest to consider if the clusters
reveal any unobserved covariate effect that could influence the health outcome.
In summary, this study aims to evaluate spatial variation in the factors influencing
relative survival from breast cancer across the diverse geographic and demographic
regions of Queensland, Australia, using three different modelling strategies, in which
the spatial variation is modelled via a single random effect, through varying coeffi-
cients or through mixture components.
6.3 Materials and Methods
6.3.1 Study cohort
All Queensland women aged less than 90 years and diagnosed with an invasive breast
cancer (ICD-O-3 code = C50) between 1 January 1997 to 31 December 2007 and
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followed up to 31 December 2008 were included in the study. The datasets from
Queensland Cancer Registry (QCR) and BreastScreen Queensland (BSQ) were linked
by BSQ staff using a deterministic matching process with over 90% matching com-
pleteness.
Patient records were anonymized and de-identified prior to data extraction and anal-
ysis. Ethics approval was granted by the Human Research Ethics Committee of
Queensland University of Technology (approval number: 1100000036). Access to
the data was provided by Queensland Health under the Public Health Act 2005
(RD003676).
Cases were excluded for patients with missing information, including age at diagnosis,
geographic location, and those who were identified at autopsy or by death certificate
only, or who had a survival time of less than one day.
6.3.2 Explanatory variables
The study variables (see Table 6.1) included age group at diagnosis, Indigenous eth-
nicity, marital status at diagnosis, tumour stage at diagnosis, BreastScreen program
participant indicator and geographic location information. The screen- and interval-
detected breast cancer patients from the BSQ screening program were collapsed into
a single category and compared to those who did not participate in the BSQ program,
to form a binary BSQ participant indicator.
Geographic location information of the 478 Statistical Local Areas (SLAs) was based
on the 2006 version of the Australian Standard Geographical Classification covering
the whole of Queensland without gap or overlap.
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6.3.3 Response variable
The response variable is the observed number of deaths (dǫ) due to any cause among
the cohort of eligible Queensland breast cancer patients for each stratum (ǫ). This
was modelled by a generalized linear model with a Poisson likelihood,
dǫ ∼ Poisson(µǫ). (6.1)
In a relative survival model, the expected number of deaths (µǫ) can be modelled by
µǫ = d
∗
ǫ + yǫ × exp(ηǫ), (6.2)
where d∗ǫ is the expected numbers of non-breast cancer deaths for each stratum of
the eligible cohort (Cramb et al, 2012), yǫ is the person-time at risk and ηǫ is the
excess hazard. The expected number of non-breast cancer deaths were calculated
using population mortality rates for each SLA that smoothed over neighbouring SLA
data to provide greater stability.
The exponential of the individual components of ηǫ provides the relative excess risk
of death (RER) for the corresponding model variables. The specific model equations
for the excess hazard are described below.
6.3.4 Statistical models
As an exploratory analysis, each single predictive variable was separately fitted in the
spatial regression, finite mixture of regressions and varying coefficient models. This
was a simple process to assess the possibility of confounders or missing interactions
in the data. Three models were then fitted using the full set of covariates.
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Spatial regression model
The excess hazard (ηǫ) is modelled by
ηǫ = αt + βx+ ui + vi (6.3)
where αt is the t
th intercept that varies by follow-up interval for t = 1, 2, . . . , 12; β is
the coefficient vector associated with the vector of predictor variables x listed in the
‘Explanatory variables’ section; and ui and vi represent the spatially structured and
unstructured random effects respectively for the ith SLA, i = 1, 2, . . . , 478.
The model components αt, β and vi were all assigned a zero mean Gaussian distribu-
tion with a flat hyperprior distribution Gamma(0.005, 0.5), parameterized in terms
of the shape and inverse scale parameters, for the precision. The random effect term
ui was assigned an intrinsic conditional autoregressive (CAR) (Besag et al, 1991)
prior distribution with a Gamma(0.5, 0.005) hyperprior distribution for the precision
(Osnas et al, 2009; Rodeiro and Lawson, 2006).
The exponential of each of the components in Equation 6.3 give the estimated RER
of the corresponding variables (i.e. exp(α), exp(β) and exp(ui + vi)).
Varying coefficient model
In this model the excess hazard (ηǫ) in Equation 6.3 is modified as follows:
ηǫ = αt + (β + δi)x+ ui + vi. (6.4)
The modification allows for an additional spatial random effect term δi for each of the
covariates. The prior distributions for all other variables in Equation 6.4 are the same
as for the spatial regression model variables in Equation 6.3. The additional spatial
random effect term δi for each SLA was assigned a multivariate intrinsic Gaussian
CAR prior distribution with a precision matrix described by a Wishart distribution
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Σ ∼Wishart(Q, k), where Q is a k×k identity matrix, to allow for correlation among
the k variables.
Models with no additional spatially structured random effect (ui) in Equation 6.4
were also considered.
Finite mixture of regressions model
In this model the excess hazard (ηǫ) in Equation 6.3 is modified as follows:
ηǫ = αtj + βjx+ uij + vij with probability πj (6.5)
πj ∼ Dirichlet(φ1, ..., φJ) (6.6)
Here the excess hazard (ηǫ) has been allocated into a number of clustered SLA sub-
groups j = 1, . . . , J . The total number of subgroups was allowed to range from J =
2 to 6. The upper bound of 6 was chosen based on previous studies that SLAs can be
collapsed into 4− 5 spatial regions based on their geographic characteristics such as
socio-economic status and area remoteness index (Baade et al, 2011b; Cramb et al,
2011b; Hsieh et al, 2014). Each mixture subgroup of excess hazard was assigned a
mixing probability of πj where 0 < πj < 1 and
∑J
j=1 πj = 1. The 478 SLAs were
assigned into different geographic subgroups (j) by a multinomial distribution with
parameters (π1, . . . , πJ). These parameters were assigned a vague Dirichlet prior as
in Equation 6.6, with all concentration parameters (φ1, . . . , φJ) set equal to 1. The
model components αtj, βj and vij were all assigned a zero mean Gaussian distribu-
tion with a hyperprior distribution Gamma(0.5, 0.005), parameterized in terms of the
shape and inverse scale parameters, for the precision.
Models with no spatially structured (uij) or unstructured (vij) random effect in Equa-
tion 6.5 were also examined.
Alternative prior representations for πj (Equation 6.6) were also evaluated, including
the Dirichlet distribution with varying concentration parameter (φ) and the πj ∼
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GEM(φ) distribution, after Griffiths, Engen and McCloskey, as in Pitman (2002).
As these methods did not alter the results, the simplest method, namely a Dirichlet
distribution with a vague constant concentration parameter (φ1, . . . , φJ = 1), was
implemented.
6.3.5 Model computation
All models were estimated using Markov chain Monte Carlo (MCMC) via WinBUGS
v1.4.3 (Lunn et al, 2000) interfaced with R v2.14.1 (R Development Core Team,
2011). All models were run with 2 chains and a thinning factor of two. The spatial
regression and varying coefficient model was run for 30,000 iterations with 20,000 for
burn-in, so 5,000 iterations were retained for inference. The mixture of regressions
model was run for 300,000 iterations with a burn-in of 290,000 and thinning factor
of two, which left 5,000 iterations for inference. The larger burn-in was required
to allow the mixture components to become well differentiated. Model convergence
was examined by means of the Gelman-Rubin convergence diagnostic (Gelman and
Rubin, 1992), trace plots, posterior density plots and autocorrelation plots.
6.3.6 Model evaluation
As all the fitted models used the same dataset, the Deviance Information Criterion
(DIC) was used to determine how well each model fits the analysed data, with smaller
values indicating better model fit (Gelman et al, 2004). The DIC is the sum of the
mean deviance and an estimate of the effective number of parameters (pD), with the
complexity of a model increasing with ascending pD values and vice versa. Posterior
predictive checks (PPC) (Gelman et al, 2004) were applied to examine the adequacy
of the model predictions compared with the observed data. The exponentiated regres-
sion coefficients were considered to be substantively raised or lowered (for continuous
variables) or different from their respective baseline covariate category (for categorical
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variables) if the 95% credible interval (CrI) did not include unity (Puigpino´s-Riera
et al, 2011; Wakefield, 2007; Wu et al, 2010).
In order to assess the spatial RER inequalities from the varying coefficient model,
the random effect terms (ui, vi and δi) were mapped to visually identify any spatial
patterns. A set of common fixed cut-off values (<0.77, 0.91, 1.10, 1.30, 1.30+) was also
used to divide the mapped values into five separate groups to reduce the likelihood of
reporting spurious differences and to facilitate comparison of spatial patterns between
maps (Cramb et al, 2011a,b). The SLA-specific RER (exp(ui + vi)) map gives the
pattern of overall spatial RER inequalities of the baseline group of patients (i.e. aged
50 − 59, non-Indigenous, married, localised (stage I) tumour and BSQ participant)
compared to the Queensland average (value of 1). The exponentiated spatially varying
coefficient (SVC) effects (exp(δi)) for each predictive variable were also mapped to
reveal spatial varying patterns (see Supplementary Figs. 6.4 and 6.5). In order to
compare across various SVC effects, the combined spatial variation (exp(δi + ui +
vi)) with regard to the covariate-specific Queensland average (value of 1), called the
relative spatially varying coefficient (RSVC), was also calculated and mapped. Maps
of the posterior probability that the RSVC exceeded unity were created to assess the
RSVC pattern with the incorporation of posterior uncertainty. Applying the cut-off
suggested by Richardson et al (2004), a probability higher than 0.8 or lower than 0.2
indicates there is little uncertainty that this differs from unity.
All model convergence measures indicated acceptable convergence, as the Gelman-
Rubin test statistics were close to unity, trace plots showed good mixing of chains
and autocorrelation plots diminished rapidly.
6.4 Results
Table 6.1 presents all the spatially constant median RER estimates for the spatial
regression model, the range of estimates for varying coefficient model, and the analo-
gous estimates for the two component finite mixture of regressions model with mixing
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probabilities for each cluster. The other finite mixture of regressions model with 3−6
components were having similar results as to the two component model, and hence
the results are not shown. The estimated constant covariate results for the spatial
regression model are the same as in the previous study (Hsieh et al, 2014). Higher
relative excess risk of mortality was observed in older patients, of Indigenous ethnic-
ity, never married, widowed, divorced or separated, with an advanced tumour or not
participating in a screening program. Very similar constant covariate effects were also
observed in the varying coefficient and finite mixture of regressions model.
For the finite mixture of regressions model, only a single cluster had substantial
weight, with a mixing probability of almost 1 (Cluster P=0.998). Moreover, the me-
dian RER and 95% credible interval of this cluster were almost identical to the values
obtained for the spatial regression model. This suggests that there is no evidence of
geographic clusters in which the relative survival from breast cancer differ. The re-
moval of both spatially structured and unstructured random effects from the mixture
model did not provide a substantial improvement to the model fit (Table 6.2).
In contrast, the varying coefficient model provided a similar fit to the data as the
spatial regression model, as evidenced by the DIC statistics, but indicated distinct
differences in spatial variation across the region, shown by the range of varying co-
efficient (VC) for the model parameters (Table 6.1). The general pattern of spatial
variation in Fig. 6.1 shows an increased trend of SLA-specific RER towards the north
and west of Queensland, which is most similar to the SLA-specific RER maps for the
spatial regression model and finite mixture of regressions model (see Supplementary
Fig. 6.6), but with reduced spatial variation. The maps of estimated RSVC effects
shown in Figs. 6.2 and 6.3 illustrate different spatial patterns among the predictive
variable categories compared to the SLA-specific RER map of combined spatially
structured (ui) and unstructured (vi) random effects in Fig. 6.1. While some of the
relative spatially varying coefficients in Figs. 6.2 and 6.3 show a similar increasing
trend across Queensland, there are other predictive variable categories that show dif-
ferent RSVC trends. Of particular interest is the RSVC map for those <40 years
150 Chapter 6. Spatially varying coefficient inequalities: Evaluating
how the impact of patient characteristics on breast cancer survival varies
by location
of age at diagnosis (Fig. 6.2 (a)), which has an opposite RSVC trend that increases
toward the south-east of Queensland with supporting evidence of corresponding ex-
cess posterior probability map of RSVC in Supplementary Fig. 6.7. Moreover, the
predictive variable category of women in the age group of 40− 49 years (Fig. 6.2 (b))
and those that were never married (Fig. 6.3 (a)) had most SLAs in north Queensland
with highest RSVC values, which were also supported by the corresponding poste-
rior probability maps in Supplementary Figs. 6.7 and 6.8. The exclusion of spatially
structured random effects (ui) of the response variable from the varying coefficient
model did not improve the outcome and thus the full varying coefficient model was
preferred (Table 6.2).
Sensitivity analyses were conducted by changing the parameters αt, β, ui and vi to
Gamma(0.5, 0.5). The sensitivity to the choice of prior for δi was assessed by imposing
different diagonal values (0.01, 0.5, 1 and 2) on the Qmatrix of the hyperprior Wishart
distribution. These analyses showed that the RSVC trends were not sensitive to the
choice of distribution on αt, β and vi but, as anticipated, substantive changes to the
precision of the spatially structured random effect ui may result in increased RSVC
values.
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Table 6.1: Posterior estimates of relative excess risk (RER) of mortality across Queensland, 1997-2008.
Median RER [95% CrIa] (unless otherwise specified)
Spatial Regression Varying Coefficient Finite Mixture
Factors N Median RER VC rangeb Cluster Pc=0.998
Age at diagnosis (years)
<40 1428 0.90 [0.77, 1.06] 0.84 [0.70, 1.01] [0.520, 1.66] 0.91 [0.78, 1.06]
40-49 4669 0.82 [0.72, 0.93] 0.83 [0.71, 0.95] [0.601, 2.10] 0.82 [0.73, 0.93]
50-59 6443 1.00 1.00 — 1.00
60-69 5545 1.12 [0.98, 1.27] 1.11 [0.95, 1.28] [0.636, 1.46] 1.13 [0.99, 1.28]
70-89 5681 1.46 [1.29, 1.66] 1.45 [1.25, 1.68] [0.652, 1.40] 1.48 [1.31, 1.67]
Indigenous Status
Indigenous 257 1.83 [1.40, 2.37] 1.63 [1.12, 2.32] [0.718, 1.72] 1.85 [1.40, 2.39]
Non-Indigenous 20529 1.00 1.00 — 1.00
Unknown 2980 0.03 [0.01, 0.07] 0.02 [0.01, 0.05] [0.731, 1.74] 0.03 [0.01, 0.07]
Marital Status
Married 14801 1.00 1.00 — 1.00
Never Married 1441 1.25 [1.07, 1.46] 1.29 [1.08, 1.56] [0.594, 1.79] 1.26 [1.08, 1.47]
Widowed/Divorced/Separated 6787 1.38 [1.25, 1.51] 1.38 [1.24, 1.54] [0.739, 1.36] 1.38 [1.26, 1.52]
Unknown 737 0.38 [0.16, 0.70] 0.19 [0.03, 0.52] [0.220,21.75] 0.39 [0.17, 0.71]
Tumour Stage
Localised (Stage I) 11517 1.00 1.00 — 1.00
Advanced (Stage II, III, IV) 10699 4.23 [3.70, 4.87] 4.23 [3.68, 4.91] [0.798,1.25] 4.22 [3.70, 4.87]
Unknown 1581 14.03 [12.26, 16.77] 14.53 [12.35, 17.20] [0.690,3.00] 14.12 [12.22, 16.46]
BSQ Participant
Yes 9745 1.00 1.00 — 1.00
No 14052 1.91 [1.71, 2.12] 1.96 [1.74, 2.21] [0.927, 1.06] 1.91 [1.72, 2.14]
DIC 34797 34795 34850.7
pD 113 345 130.5
PPC 98.61% 98.64% 98.56%
aAbbreviations: CrI=Credible interval, N=Number of patients, DIC=Deviance information criterion, pD=Effective number of parameters,
PPC=posterior predictive check.
bExponentiated median varying coefficient (VC) values (exp(δi)) of 478 SLA.
cMixing probability of a mixture subgroup (SLA cluster).
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Table 6.2: Model reduction comparison.
Varying coefficient Finite Mixture
Full model
DICa 34795 34850.7
pD 345 130.5
No spatial structured effect
DIC 34814 —
pD 335 —
No spatial structured & unstructured effect
DIC — 34811
pD — 31.2
aAbbreviations: DIC=Deviance information criterion, pD=Effective number of parameters.
SLA−specific RER
< 0.77]
(0.77 , 0.91]
(0.91 , 1.10]
(1.10 , 1.30]
(1.30 +
(a) SLA-specific RER map
Posterior probability 
(relative excess effect > 1)
[0,0.2]
(0.2,0.8]
(0.8,1]
(b) Posterior probability of excess SLA-specific
RER
Figure 6.1: SLA-specific relative excess risk (RER) (exp(ui+vi)) map for the varying
coefficient model.
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(f) RSVC effect for unknown Indigenous
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Figure 6.2: Relative spatially varying coefficient (RSVC=exp(δi + ui + vi)) effect maps for the age at diagnosis and Indigenous
status variables.
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(0.77 , 0.91]
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(d) RSVC effect for advanced tumour
stage
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(f) RSVC effect for non-BSQ participant
Figure 6.3: Relative spatially varying coefficient (RSVC=exp(δi + ui + vi)) effect maps for the marital, tumour stage and BSQ
participant variables.
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6.5 Discussion
Using a population-based cohort of Queensland women diagnosed with breast cancer,
this study has demonstrated the use of spatial regression, spatially varying coefficient
regression models and finite mixture of regressions models to quantify how the impact
of patient characteristics and clinical factors on relative survival outcomes varies by
geographical location. This study found that the varying components model provided
similar fit for our data compared to the spatial regression model, but with additional
spatial varying coefficient information, and both models fit the data better than
the finite mixture of regressions model. Allowing the model parameters to change
by geographical location provides a much greater understanding of the impact of
important variables on survival. These reduced the overall spatial variation in the
SLA-specific RER map of combined spatially structured (ui) and unstructured (vi)
random effects in Fig. 6.1, compared to the spatial regression model and finite mixture
of regressions model maps (see Supplementary Fig. 6.6). The different spatial patterns
can be mapped, as illustrated in in Figs. 6.2 and 6.3; see also Supplementary Figs.
6.4 and 6.5. To the best of our knowledge, this is the first study to use varying
coefficient models to explore the spatial impact that multiple patient and clinical
factors have on breast cancer relative survival, especially across the diverse geographic
and demographic regions of Queensland, Australia.
The spatial regression model quantified overall spatial inequalities through spatially
structured and unstructured random effects by assuming that they were constant
across all cohort subgroups. This model found that, on average, younger women,
those with non-Indigenous ethnicity, were married, were diagnosed with localised
stage tumour or participated in the BSQ program had better survival outcomes.
However, a similar fit to the data was provided by the varying coefficient model,
which removed this assumption of constant spatial coefficients. These models and
the corresponding maps of the relative spatially varying coefficient and posterior
probabilities suggest that there is a different pattern of spatial variation by age, with
better survival for women less than 40 years of age at diagnosis in remote areas
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compared with urban areas, whereas for women diagnosed over 40 years of age the
spatial survival differential is reversed.
It is unclear what unobserved spatial variable would account for a changing effect of
age on survival by spatial location. However, previous studies, including in Queens-
land, have reported that younger women were more likely to be diagnosed with ad-
vanced breast cancer, with their tumours tending to be larger, metastasised and less
well differentiated compared with older women (Anders et al, 2008; Axelrod et al,
2008; Baade et al, 2011b). These characteristics are consistent with breast cancers
among younger women being diagnosed as a result of symptoms rather than through
participation in mammography screening. However our results are adjusted for a
broad measure of spread of disease at diagnosis, so apart from the possibility of resid-
ual confounding, it is unlikely that differences in diagnostic patterns can explain this
result. A recent paper (Cramb et al, 2012) quantified that around 7% of breast cancer
deaths within 5 years of diagnosis could be attributed to non-diagnostic factors such
as treatment, rehabilitation, environmental factors such as area disadvantage, and
other patient characteristics including comorbidities, so it is possible that at least
some of these also vary by age and location. While only a relatively small proportion
of breast cancers are diagnosed in women under 40 years of age, the impact of a di-
agnosis of breast cancer on these younger women in terms of loss of life expectancy is
much greater than for older women (Baade et al, 2015). Clearly, further investigation
is required to better understand the possible mechanisms which are driving this age
differential in spatial patterns.
Confusing the picture, however, was the lack of evidence for multiple clusters, or
aggregations of SLAs, when applying the finite mixture of regressions model. Within
our study cohort, the posterior distributions of the covariate effects and the predicted
RER were statistically indistinguishable in all of the modelled mixture components,
and the estimated mixing probabilities in the mixture model placed almost all the
weight on a single component. Therefore, the spatially-varying coefficients identified
through the varying coefficient model could not be represented as geographically
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contiguous spatial clusters of SLA. Possible explanations could include a different
contiguous pattern in the covariate space at the SLA level, or unmeasured spatial
effects at the individual level that are reflected in a more complex manner at the SLA
level. This is possible given the relatively crude measure of socio-economic status
at an aggregate level, for example. An alternative explanation is that the use of
identical model structures for each of the mixture components impeded our ability to
capture any real unmeasured spatial covariate. The better fit provided by the spatially
varying model compared to the other alternatives in this study, combined with the
posterior probability maps, add to the evidence of there being genuine differences in
spatial patterns in survival across age for women diagnosed with breast cancer, but
no evidence of geographically contiguous clustering in survival outcomes.
Several advantages may result from using the complex spatially varying model. This
model has the advantage over the more commonly used spatial model by providing
more insight in to the spatial variation of all the relevant variables of interest, which
would be able to show how the factor effects vary by spatial location (i.e. spatially
varying coefficient), instead of assuming they are constant. In addition, it can also
help to identify the change of spatial variation pattern between categories of covariate
(i.e. between younger and older age groups). As such, these findings have the potential
to provide greater clarity for allocating health care resources, in that they recognise
that spatial inequalities may have different characteristics for different subgroups of
the population.
One of the limitations of this study is the model complexity which has the drawback
of the increasing needs of computational resources, especially for the finite mixture
of regressions model. Another limitation is the lack of information about the tumour
characteristics that would have reduced the potential for residual confounding when
adjusting for spread of disease at diagnosis.
The methods applied in this paper, and insights that can be derived from the cor-
responding analyses, can be applied across a wide range of studies in the spatial
epidemiology and other spatial fields. Overall, we found that the impact of patient
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demographics on breast cancer survival did vary by age, but that there was no evi-
dence that the spatial inequalities could be represented as geographically contiguous
spatial clusters of SLAs. It remains a priority to better understand the reasons for
these differences in spatial patterns to enable appropriate interventions and strate-
gies to be developed to help ensure equitable and improved outcomes for all women
diagnosed with breast cancer, regardless of where they live.
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6.6 Supplementary materials
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Figure 6.4: Spatially varying coefficient (SVC=exp(δi)) effect maps for the age at diagnosis and Indigenous status variables.
6
.6
.
S
u
p
p
le
m
e
n
ta
ry
m
a
te
ria
ls
1
6
1
SVC
< 0.77]
(0.77 , 0.91]
(0.91 , 1.10]
(1.10 , 1.30]
(1.30 +
(a) SVC effect for never married
SVC
< 0.77]
(0.77 , 0.91]
(0.91 , 1.10]
(1.10 , 1.30]
(1.30 +
(b) SVC effect for wid-
owed/divorced/separated
SVC
< 0.77]
(0.77 , 0.91]
(0.91 , 1.10]
(1.10 , 1.30]
(1.30 +
(c) SVC effect for unknown marital status
SVC
< 0.77]
(0.77 , 0.91]
(0.91 , 1.10]
(1.10 , 1.30]
(1.30 +
(d) SVC effect for advanced tumour stage
SVC
< 0.77]
(0.77 , 0.91]
(0.91 , 1.10]
(1.10 , 1.30]
(1.30 +
(e) SVC effect for unknown tumour stage
SVC
< 0.77]
(0.77 , 0.91]
(0.91 , 1.10]
(1.10 , 1.30]
(1.30 +
(f) SVC effect for non-BSQ participant
Figure 6.5: Spatially varying coefficient (SVC=exp(δi)) effect maps for the marital, tumour stage and BSQ participant variables.
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Figure 6.6: SLA-specific relative excess risk (RER) (exp(ui + vi)) maps.
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Figure 6.7: Maps of posterior probability of excess relative spatially varying coefficient (RSVC) effect for the age at diagnosis
and Indigenous status variables.
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(f) Non-BSQ participant
Figure 6.8: Maps of posterior probability of excess relative spatially varying coefficient (RSVC) effect for the marital, tumour
stage and BSQ participant variables.
CHAPTER 7
General Discussion and Future Work
This research aimed to advance public health knowledge about the mammographic
screening program for female breast cancer in Queensland, Australia, by understand-
ing the complex associations between socioeconomic status, geographic remoteness
and health outcomes with the use of mammographic screening. The project was car-
ried out with the implementation of Bayesian hierarchical models and Markov chain
Monte Carlo simulation algorithms to describe and analyse population-based breast
cancer data. A series of research studies was developed and followed through Chap-
ters 3–6 to meet the objectives outlined in Section 1.2. This chapter summarizes and
outlines the findings and contributions of this project and proposes possible future
research goals.
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7.1 Research Summary and Contribution
In Chapter 3, the influence of all three breast cancer detection methods, that is
screen, interval and non-screen/symptomatic detection, on patient health outcomes
were examined. The study used relative excess risk to measure the relative influence
of demographic and geographic characteristics, as well as the detection method, on
patients’ relative survival. This addresses Objectives 1 and 3. The relative survival
model included spatial structure and unstructured random effects via a Besag, York
and Mollie´ (BYM) approach. The inclusion of a spatial effect allowed the use of addi-
tional information from neighbouring regions for smooth estimation and predictions
as well as accounting for any unrecognized spatial inequalities within the data. This
addresses Objective 2. Disease maps were generated for the spatial random effects as
a visualization aid to reveal spatial inequalities. The study showed that the influences
of demographic, clinical and geographic factors on relative survival are generally con-
sistent with previous breast cancer studies (Condon et al, 2005; Cramb et al, 2011a,
2012; Dasgupta et al, 2012; Shen et al, 2005, 2007; Wishart et al, 2008). In addition,
participation in mammographic screening was associated with better breast cancer
survival (Berry et al, 2005, 2006; Bordas et al, 2007; Mook et al, 2011; Nagtegaal
et al, 2011; Nickson et al, 2012; Roder and Olver, 2012; Shen et al, 2005; Wishart
et al, 2008; Wu et al, 2010). There was no discernible evidence that the impact of
screening on survival varied by geographic location of residence. Furthermore, the
study demonstrated that unexplained spatial variation in relative survival could be
captured by including geographic information and detection methods into the model.
These results have been used in a media release by Cancer Council Queensland and
received media coverage to raise women’s awareness about the risk of breast cancer,
the benefits of attending mammographic screening, and to encourage women to par-
ticipate in a screening program to reduce breast cancer mortality risk (NewsMail,
2014). These findings can be used by BreastScreen Queensland to promote screening
among eligible women to increase the participation rate which could further reduce
breast cancer survival risk and offset the barrier of geographic differences, such as
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area disadvantage and remoteness.
Following the study of breast cancer detection methods in Chapter 3, a study that
tested the hypothesis that the impact of being diagnosed with an interval detected
compared to a screen detected breast cancer varied by geographic location was con-
ducted in Chapter 4. This addressed Objectives 1, 2 and 3 listed in Section 1.2. The
hypothesis was tested using BreastScreen Queensland program participants by first
applying the Bayesian spatial relative survival model from Chapter 3 to find evidence
of interaction between detection method and patient demographic, clinical and geo-
graphic characteristics. The study further modified the statistical model from Chap-
ter 3 to test the proposed hypothesis by examining the difference in survival between
screen and interval detected breast cancer as a random effect across each geographic
location to observe the consistency or change of relative excess risk by spatial location.
Better relative survival was identified among screen detected patients compared to
interval detected patients (Bordas et al, 2007; Brekelmans et al, 1995; Eriksson et al,
2013; McKenzie et al, 2012; Mook et al, 2011; Nagtegaal et al, 2011; Rayson et al,
2011; Shen et al, 2005), but more importantly the difference was consistent across dif-
ferent geographic locations. These results support the consistent effectiveness of the
population-based breast screening program across all geographic areas and suggests
that the composition of interval detected cancer, such as the proportion of ‘missed’
and ‘new fast growing’ tumours (Brekelmans et al, 1996; Gilliland et al, 2000; Hofvind
et al, 2008; Porter et al, 1999), was similar across Queensland. The lack of geographic
variation in survival differential is suggestive evidence supporting minimal health in-
equalities, but the consistent high risk among interval cancer patients highlights the
need for any awareness programs to be geographically widespread. The results have
been released in the media by the Cancer Council Queensland to distribute knowledge
about interval cancer and to urge women to be self breast aware in order to detect any
change and seek early medical attention (Cancer Council Queensland, 2015). These
positive findings provide supporting evidence that organisations such as BreastScreen
Queensland are needed to reduce spatial survival inequalities and raise self-awareness
among women of the various breast cancer symptoms to increase survival chances
168 Chapter 7. General Discussion and Future Work
equally across the state.
Chapter 5 presented a study of the unmeasured shared effect that could potentially
influence women’s intention to choose particular adjuvant therapies after a diagnosis
of breast cancer by mammographic screening. The intended choice of radiotherapy,
chemotherapy or hormonal therapy for BreastScreen Queensland mammographic de-
tected breast cancer patients was examined (Objective 4). The study investigated
the potential existence of common underlying factors that may influence a woman’s
decision to have adjuvant therapy with the hypothesis that the shared factor was spa-
tially structured across the state. This addressed Objectives 2 and 4. Bayesian shared
spatial component models were adopted with the intended use of the three stated ad-
juvant therapies as the primary outcome variable to quantify and examine the spatial
variation of the unmeasured shared component across the state, after adjusting for
demographic, geographic and clinical factors. The choice of adjuvant therapy was
found to vary by geographical location, with women living in areas with shorter trav-
elling time to a cancer treatment facility being more likely to intend to use adjuvant
therapy than those who lived further away (Athas et al, 2000; Martinez et al, 2012a;
Nattinger et al, 2001; Schootman and Aft, 2001). Moreover, the presence of residual
shared spatial effects suggested that the shared component acts as a surrogate for
some unobserved spatially structured factors that may explain the geographical vari-
ation of the usage of the three adjuvant therapies. These findings suggest that women
may be making decisions regarding their treatment strategy based on perceived bar-
riers to treatment, and highlights the need to identify the additional barriers that
impact on treatment intentions among screen-detected breast cancer patients that
live further away from cancer treatment facilities. These results also imply that tu-
mour stage has an influence on a patient’s choice of treatment and thus diagnosing
tumours earlier by attending the BreastScreen Queensland screening program has an
advantage in increasing treatment strategy options that could potentially reduce or
avoid spatial barriers in the choice of intended treatment. This study is going to be
used in a media release by Cancer Council Queensland to encourage all Queensland
women with breast cancer to discuss their treatment options with a GP.
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The findings of spatial heterogeneity within breast cancer data that are collected over
space motivated taking a further step to analyse the spatial association between risk
factors and health outcomes in order to better understand and describe the varying
survival rates among female patients in Queensland. This was pursued in Chapter
6. Bayesian relative survival models were fitted using various model structures, in-
cluding a spatial regression model, a varying coefficient model and a finite mixture of
regressions model to evaluate the relative excess risk of breast cancer. The varying co-
efficients model was used to examine the potentially spatially varying effects of breast
cancer risk factors. The finite mixture of regressions model has similar capability and
was used to examine the changing influence of covariates on the response. Different
trends of spatially varying coefficient effects were identified within predictive variable
categories and some with contrasting patterns, which provides suggestive evidence
of varying covariate effects across the state. However, with further investigation of
such spatial inequalities, no evidence has been found for geographic aggregations
or clusters of spatial locations for which there may be differential health outcomes.
Therefore, to ensure equitable and improved outcomes for all women diagnosed with
breast cancer, regardless of where they live, it remains a priority in public health
to better understand the reasons behind these covariate effect differences in spatial
patterns to enable appropriate interventions and strategies to be developed.
This project has contributed to the understanding of spatial effects on breast cancer
outcomes associated with screening, with a focus on women in Queensland, Australia.
The breast cancer survival benefit in participating in a screening program was consis-
tent over the state after adjusting for spread of disease and diagnosis, demonstrating
that earlier diagnosis (lead-time bias) did not explain the better survival. The ef-
fectiveness of the population-based BSQ screening program has offset the barrier of
distance by providing mobile screening vans, relocatable and satellite screening ser-
vices to over 200 locations across the state, in addition to the statewide network of
Screening and Assessment Services covering the catchment areas. The project find-
ings have been used in media releases by Cancer Council Queensland to encourage
women to participate in a screening program to reduce breast cancer mortality as well
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as be self breast aware in order to detect any breast change and seek early medical
attention. Additional common spatial inequality across the state was identified for
the intended use of adjuvant therapies (radio-, chemo- and hormonal) among screen-
detected breast cancer patients in Queensland, Australia. Identification of different
spatial survival patterns within predictive variable categories of breast cancer demon-
strated evidence of inconsistent predictor effects across the spatial domain.
The statistical modelling contributions of this project include the use of a Bayesian hi-
erarchical spatial model as the baseline model, and investigated and compared model
formulations to examine the influence of various model parameters on the outcome
measure. Model alternatives that were investigated and compared to assess breast
cancer outcomes included a relative survival model, shared spatial component model,
varying coefficient model and finite mixture of regressions model. Different hierarchi-
cal structures were investigated including different sub-model structures or different
levels of hierarchical structures. Various models were applied to a challenging dataset
that is large, unselected and population-based with sparse spatial structure and hence
is computationally challenging. This project also contributed to the process of dis-
seminating stochastic spatial modelling techniques used in the epidemiological field
to an interdisciplinary audience.
7.2 Strengths and Limitations
Strengths of this project include the use of a large, unselected, population-based co-
hort of Queensland females diagnosed with breast cancer, with corresponding infor-
mation about screening practices obtained from prospectively collected administrative
data, the collection of which was designed independently of the study, thus removing
information bias. The Bayesian spatial models were able to accommodate the sparse
area-specific data by borrowing information from neighbouring regions to smooth the
estimated spatial random effects and directly quantify the estimate of spatial vari-
ation. Smoothing the estimated spatial random effects enables better estimation of
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risk in spatial locations with rare outcomes and improves model fit. The survival
analyses of breast cancer were not constrained by any potential inaccuracies in the
cause of death information, with the use of a relative survival model. The lead-time
bias within the survival analysis was greatly reduced by adjusting for tumour stage at
diagnosis. The use of maps facilitated the visualization of spatial inequalities across
the study region.
Some limitations of the project include the lack of information about mammography
screening offered by private hospitals and practices. The inability to completely
adjust for the effect of length bias due to the lack of clinical information on the
aggressiveness of the cancer may lead to a propensity to disproportionally detect slow
growing tumours in a screening program. There was also an inability to differentiate
between various types of interval breast cancers (fast growing tumours or those missed
in the previous screening episode). The possibility of some lead-time bias remains
unaccounted for by not having more detailed stage information. The project is also
limited by lack of data on actual treatment received and/or completed.
The proposed models generally have complex structures which has the drawback of
increasing the needs of computational resources, longer simulation time and careful
assessment of MCMC convergence. The computational challenges also include the
use of large numbers of multiple categorical covariates and the need to assess their
interactions. The use of maps to present spatial variation for each SLA across the
state has a visual disadvantage for the small geographic regions that are difficult to
see on the map. The relative survival model required additional mortality data to
calculate the expected number of deaths in the equation. The varying coefficient
model has almost double the amount of coefficients that required estimation for the
same number of model covariates as the relative survival model. The finite mixture
of regressions model incurred a very long simulation time and, as the total number
of model subgroups increased, more time is required.
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7.3 Future Research
Relatively few studies have focused on regular repeat mammography screening (re-
screen) over time (Pruitt et al, 2009; Schueler et al, 2008). To the best of our knowl-
edge, there is a lack of published studies that focus on the influence of a clear ge-
ographic area classification (rural–urban) on mammography use as well as repeat
mammography screening behaviour (Bobo et al, 2004; Sabogal et al, 2001). The
BreastScreen Australia monitoring report over the years has reported the rescreen
percentage in each state for different numbers of previous screens. However, no re-
screen percentage has been reported for detailed geographic areas (rural–urban). A
future research project could aim to anlayse the rescreen percentage by Queensland
geographic areas (rural–urban) as well as quantify the importance of geographic area
on mammography use and regular repeat mammography screening.
Other research aims could involve the estimation of premature breast cancer deaths by
detection method or evaluate possible environmental factors for the identified spatial
inequalities on breast cancer outcomes.
This project has fitted several models to a large dataset, all of which have required
substantial computational resources. Because of the complexity of the models and
the size of the dataset, some of the simulation times have been especially long. Hence,
another area for future research could aim to develop techniques to reduce the simula-
tion time. Approaches could include using different MCMC algorithms or statistical
software, or modifying the model structure.
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